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Abstract 
Prostate cancer is the leading form of male cancer in western countries. 
However, despite a great deal of interest from the scientific community, the 
cause still remains elusive. What is clear, is that androgenic signalling is 
important within prostate cancer progression, with early cancer under 
androgenic control and androgen regulated genes, such as PSA, commonly used 
for patient prognosis and progression.  
3’,5’- cyclic adenosine monophosphate (cAMP) is an important second messenger 
signalling molecule, which has been extensively studied within the field of 
oncogenesis. cAMP signalling effects are transduced via its effector molecules, 
PKA and EPAC, and the temporal and spatial control of cAMP dynamics are 
orchestrated by phosphodiesterase enzymes (PDEs). This signalling pathway has 
been implicated in a wide range of cellular processors such as, cellular 
differentiation, transcription, proliferation, apoptosis and learning and memory. 
In addition, it has also been linked to steroid receptor signalling such as 
oestrogen, progesterone, and androgen receptors. 
PKA can be expressed as 2 forms (PKA-I and PKA-II) depending on the regulatory 
unit isoform content of the enzyme. In the field of cancer research, PKA-I and 
PKA-II expression profiles have been shown to be linked to the phenotype of the 
cancer, i.e. overexpression of PKA-I is linked to a more proliferative cancer. 
Furthermore, other protein intermediates within the cAMP signalling pathway, 
including PKAC isoforms (PKA catalytic unit) and PDEs, change with respect to 
isoform expression and regulation during cancer progression.  
In this thesis, I have described my original research in which I endeavoured to 
understand the role of several components of the cAMP signalling axis in human 
prostate cancer. I have profiled the isoforms of PKA in androgen sensitive and 
insensitive prostate cancer, identifying isoforms that are dysregulated in the 
androgen independent disease stage. In particular, I found a down regulation of 
PKARIIβ and PKACβ isoforms in AI prostate cancer compared to AS. The function 
of these isoforms are not well categorised in prostate cancer. Due to the higher 
expression of these isoforms in AS cells, I went on to scrutinise these isoforms in 
relation to their interaction with androgenic signalling. Here, I have uncovered 
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previously undiscovered aspects of PKA signalling, including the direct 
interaction of PKARIIβ and PKACβ isoforms with the androgen receptor (AR), and 
that PKA can phosphorylate the AR at site S791. Further analysis of this putative 
phosphorylation site would be beneficial to isolate a functional output. 
In addition, following previous work in the laboratory that identified PDE4D7 as a 
potential biomarker in prostate cancer, I have investigated novel-PDE4D7 
controlled signalling pathways using cutting edge techniques. This data allows a 
better understanding of the mechanism behind the alteration of PDE4D7 driven 
signals and their significance during prostate cancer progression. Given more 
time and scrutiny, changes in these identified novel-PDE4D7 controlled signalling 
pathways, such as N-MYC, could show sites for exciting study into prostate 
cancer progression.  
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1 Introduction- cAMP signalling and Prostate 
Cancer 
1.1 Cyclic Nucleotide Signalling 
Eukaryotes have an elaborate signal transduction system by which information 
from external, extracellular sources, can be converted to intracellular 
information that regulates the interworking of the cell [1]. While some 
molecules can diffuse across the membrane and activate cytoplasmic receptors 
directly, many rely on messenger systems. Here, first messenger molecules such 
as hormones, neurotransmitters or signalling peptides, activate plasma 
membrane receptors, which in turn activate intracellular proteins and secondary 
messengers, thus allowing the transduction of extracellular signals across the 
membrane.  One such secondary messenger is 3’, 5’ cyclic adenosine 
monophosphate (also known as cyclic AMP (cAMP)).  
Cyclic AMP (cAMP) was the first second messenger molecule discovered in signal 
transduction [2], and since its discovery it has been linked to a multitude of 
cellular processes . The cAMP signalling pathway is a paradigm in signal 
transduction and a key pathway in the conversion of information from external 
signalling molecules. Binding of ligands to their specific receptors (GPCR) 
located at the plasma membrane of the cells activates GTP-binding proteins (G- 
proteins) that are coupled to the membrane receptors. Certain G-proteins called 
Gs-proteins, activate predominantly membrane bound adenylyl cyclase (AC), to 
convert ATP to cAMP [3, 4]. This, in turn, activates effector proteins like cAMP-
dependent protein kinase (also known as protein kinase A (PKA)) [5]. This 
intracellular pathway is diminished by the degradation of cAMP by cyclic 
nucleotide phosphodiesterases (PDEs) (see figure 1). Within this pathway, 
different GPCR and AC isoforms can be activated within different regions of the 
cell. The location of the point source of cAMP and the discrete localization of 
PDEs underpin the spatial complexity of these signals. Indeed, it is now thought 
that the compartmentalisation of the cAMP signalling system, in this manner, 
underpins the specificity of receptor action [6], especially amongst different 
receptor types that all use cAMP as their signalling molecule of choice. PDEs are 
crucial for creating cAMP gradients within cells and these are activated via PKA 
when the threshold for activation is reached [4, 7].  
Chapter 1: cAMP signalling and Prostate Cancer 
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Figure 1.1 Example of cAMP signalling cascade 
An example cAMP signalling through PKA activation. Classical Gs-coupled GPCR is 
activated, leading to subsequent activation of adenylyl cyclase. This leads to cAMP 
generation (orange gradient) and attenuation by PDEs. PKA activation by cAMP results in 
phosphorylation of the protein of interest (POI) downstream signalling events e.g. 
transcription. 
PKA and PDE families are made up of multiple isoform variants that exhibit 
tissue and cellular specific localisation patterns. Furthermore, many different 
isoforms of these enzyme families can be expressed within a cell and localised to 
isoform specific signalling complexes and intracellular positions [10-13]. The 
outcome of this dynamic isoform expression is a number of compartmentalized 
cyclic nucleotide gradients that modulates the response to extra-cellular 
signalling molecules. Compartmentalization of cyclic nucleotide gradients and 
thus downstream signalling cascades allows multiple signalling events to occur 
simultaneously, controlling molecular interactions and signalling within the 
intracellular space [12]. 
Chapter 1: cAMP signalling and Prostate Cancer 
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1.2 Protein Kinase A 
Approximately 2% of the mammalian genome encodes for protein kinases, 
making this one of the largest gene families. Protein kinases regulate a wide 
array of cellular processes e.g., they are an integral part of learning and 
memory, growth, development and differentiation and are essential in the 
orchestration of cell death and activated in the response to stress signals [8-11]. 
This means that protein kinase functions are directly related to many diseases 
and hence represent attractive targets for drug discovery. One of the first 
discovered proteins from the kinase family was cAMP-dependent protein kinase 
(PKA), the classical effector molecule of the cAMP signalling cascade.[12, 13]. 
PKA, like other kinases, carries out its function via binding to its substrate and 
transferring one γ-phosphate group from ATP to its protein substrate. PKA 
activity is specific to the phosphorylation of serine/threonine residues located 
within an RxxS/T motif [1, 9]. 
1.2.1 Structure 
When PKA is in its inactive state, the PKA molecule is a tetrameric holoenzyme, 
made up of 2 regulatory subunits (R), and 2 catalytic (C) subunits. Variation of 
PKA subunit composition allows for a degree of signalling complexity and is 
denoted via transcription of four isoforms of the R units: RIα, RIβ, RIIα, RIIβ. 
Additionally there are 3 isoforms of the C subunit: Cα, Cβ, Cγ, and mRNA spliced 
variant of Cβ have been reported [9, 11]. PKA is often referred to as PKA I or PKA 
II denoting the R unit composition of the holoenzyme. The differential 
transcription of the holoenzyme variants allows the regulation of different 
signalling cascades, in differing cellular locales, leading to diverse outcomes of 
cAMP compartmentalising dynamics.  
The R units contain two, tandem cAMP binding domains at the carboxyl terminus 
and a dimerization/docking (D/D) domain at the N-terminal. The D/D domain is 
comprised of four anti-parallel α-helices, which creates a high affinity binding 
site for A kinase anchoring protein (AKAP) binding and also helps with R-unit 
dimerization [14, 15]. In addition, a flexible linker region, which joins the D/D 
and C-terminus, acts as a pseudo-substrate site for the active site of the 
catalytic subunit [15]. 
Chapter 1: cAMP signalling and Prostate Cancer 
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PKA R subunits are highly versatile proteins that exhibit multiple functions. Their 
main purpose is to inhibit the activity of the catalytic subunit via binding to the 
pseudo-substrate site within the linker region. When cAMP concentrations 
increase above activation threshold levels, cAMP binds to the C-terminal of the R 
subunits causing a conformational change in this hinge region, resulting in 
dissociation and release of the active C subunit into two monomeric units, 
leaving the R unit as a dimer (See figure1.2) [11].  
1
R R
C C
R R
C C
cAMP cAMP
cAMP cAMP
cAMP
+
Inactive Holoenzyme
Regulator unit dimer +
Active catalytic unit monomer
 
Figure 1.2 PKA activation  
A diagram depicting PKA activation. PKA inactive holomenzyme is disbanded when cAMP 
concentrations increase above threshold levels and bind to the C-terminal of the R 
subunits. This results in the release of the active C subunits, leaving a R unit dimer. 
The C and R units primarily interact via the pseudo-substrate site, however, 
there is a peripheral docking site that consists of the residues of the cAMP 
binding site A and allows higher affinity binding [16]. While the R units share a 
highly conserved carboxyl terminus, the amino terminus can vary between 
isoforms. One of the key variations between the RI and RII subunits is within the 
C subunit binding site. RII subunits contain an auto-phosphorylation site in the 
inhibitor region, where the RI units contain a high affinity ATP binding site [15, 
Chapter 1: cAMP signalling and Prostate Cancer 
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17]. This change has been shown to be important in holoenzyme conformation as 
well as R and C unit dissociation. In addition, the molecular shape of the 
tetramer differs depending on the R units present in the holoenzyme. The RII 
units, in dimer formation, form an elongated rod-like shape whereas RI units are 
more Y shaped [15, 18].    
Although the R units show some structural homology, they can differ in function 
and cellular expression. It has been shown in mouse knockout models that RIα is 
embryonically lethal, however RIIβ knockouts have resistance to obesity and 
diet-induced diabetes. Furthermore, RIβ knockout resulted in a compensatory 
increase in RIα expression and an associated decrease in neural plasticity. This 
balance between type I and type II PKA expression also plays an important role 
in cell growth and differentiation and has been implicated in several disease 
mechanisms including breast and prostate cancers [19-22]. 
Another notable feature of R subunit architecture include the R subunit D/D 
domain, which allows binding of scaffold proteins known as A kinase anchoring 
proteins (AKAPs). This protein family adds another degree of 
compartmentalisation and PKA specificity of action through the targeting of R 
units of the PKA tetramer to different cellular sites, which are in close proximity 
to a specific protein substrate [9]. Furthermore, AKAP anchoring can also cause 
localisation with enzymes that can degrade cAMP (PDEs), leading to deactivation 
of PKA [1]. This negative feedback loop can be used to produce transient cellular 
signals within the cell. In order to bind the regulatory subunits, AKAPs contain an 
amphipathic helix. Initially, it was thought that R subunit/ AKAPs interactions 
were RII specific, however it has been shown that RI can also bind AKAPs but 
with lower affinity [1, 10, 23].  
The C subunits of PKA contain a small ATP binding site at the amino terminal and 
a larger C- terminal docking site to bind the protein substrate. Within the C 
subunits, residues 40-300 of the unit makes up the conserved kinase core, in 
addition, 40 residues at the amino terminal and 50 at the carboxyl wind around 
the lobes of the protein and dock with the hydrophobic pocket on the surface of 
the smaller amino terminal lobe; this acts to stabilize the catalytic subunit [24, 
25].   
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PKA subunit isoforms have shown differences in their expression profiles and 
tissue distribution, implying specificity of function. For example, mice models 
lacking splice variant Cβ1, while still viable, have deficiencies in cAMP 
dependent processes which result in long-term depression, even though other 
splice variants and isoforms are still expressed [1, 26].  
Protein Kinase Inhibitors (PKI) are a family of small proteins that are able to 
inhibit the catalytic subunit of PKA and are encoded for by 3 genes, giving rise to 
3 isoforms α, β, and γ. These isoforms show different tissue distribution. PKI 
association with C units results in the deactivation of the C subunit and 
promotion of nuclear exportation [27]. 
1.3 Phosphodiesterases: Overview 
In the early 1980s, Brunton and colleagues [28] proposed the concept of cAMP 
compartmentalisation. At the time this concept was met with scepticism, 
however, it has stood the test of time, with new supporting data, resulting from 
novel technically advanced experimental procedures, like FRET probes, which 
detect real time, spatial and temporal changes in intracellular cAMP 
concentrations [29]. One major finding from these studies was that the 
compartmentalization of cAMP responses are underpinned by the action of the 
only known enzymes to degrade cAMP, phosphodiesterases (PDEs). 
Phosphodiesterases (PDEs) are a superfamily of enzymes that are encoded by 20 
human genes and divided into eleven families [30]. These 11 families are 
characterised by their specific structural elements, sequence homology, 
inhibitor sensitivity and their ability to hydrolyse cyclic nucleotides. PDE4, PDE7 
and PDE8 are cAMP specific, PDE5, PDE6 and PDE9 are cGMP specific and the 
other 5 families (PDE1, PDE2, PDE3, PDE10 and PDE11) have dual specificity with 
differing affinities for both types of cyclic nucleotide. Most of these families 
contain various isoforms or splice variants and exhibit tissue specific localisation 
patterns [31]. In addition to this, multiple isoforms of the PDE family can be 
expressed within the same cell, leading to a differential compartmentalisation 
of cyclic nucleotide gradients, enabling independent but simultaneous signalling 
events to occur [32, 33]. This paradigm of compartmentalised cyclic nucleotide 
signalling is altered in many disease states. This has led to interest in the 
regulation and function of cyclic nucleotide signalling pathways. Recently, there 
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has been much interest in the PDE4 family, as a PDE4 inhibitor (roflumilast) has 
been licensed in Europe and the USA for the treatment of severe chronic 
obstructive pulmonary disease (COPD) [34].  
1.3.1 PDE4  
PDE4s are one of the most important enzyme families for the degradation of 
cAMP in cells, and they have been associated with many disease states such as 
schizophrenia, stroke and cancer [7, 35, 36]. They are encoded by 4 genes 
(A,B,C,D) and these give rise to at least 25 different proteins (6 PDE4A forms, 5 
PDE4B forms, 3 PDE4C forms and 11 PDE4D forms) via mRNA splicing and 
promoter diversity. Each isoform is distinguishable via its unique N-terminal, 
which is involved in targeting the PDE4 to specific intracellular signalling 
complexes and it is this consensus sequence that is thought to be one of the 
major factors that promotes compartmentalisation of cAMP signalling [7, 37]. 
The study of the PDE4 family has been key for the understanding of intracellular 
targeting of cAMP hydrolysis. As all the PDE4 isoforms display similar Kms and 
Vmax for cAMP hydrolysis [6], PDE4 research has resulted in the concept that 
PDE function depends on the cellular location, interaction with other signalling 
proteins and post-translational modifications of the PDE.  
1.3.1.1 Structure 
Like all other PDE families, PDE4s have a complex modular structure, consisting 
of a conserved catalytic domain, sub-family specific C-terminal domain, dual 
regulatory domains called upstream conserved region 1 (UCR1) and upstream  
conserved region 2 (UCR2) and an isoform specific N-terminal region [37]. The 
tailoring of compartmentalised cAMP signals by individual PDE4 isoforms are 
conferred by the unique localization sequences that are contained within 
isoform-specific N-terminal regions. This unique binding region allows the direct 
association of PDE4 family members with a variety of inert scaffolds, lipids or 
active proteins, resulting in specific PDE4 isoform localised signalling. Signalling 
scaffold proteins associated with PDE4 binding include, but are not limited to; 
AKAP18, RACK1, disrupted in schizophrenia 1 (DISC1), heatshock protein 20 
(HSP20) and the scaffold protein β-arrestin [29, 36, 38-41].  
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The PDE4 isoforms can be further categorised with the presence of the UCR 
domains, which are located N-terminally to the catalytic domain. With respect 
to the UCR domains, these isoforms can be divided into 3 basic classes (Figure 
1.3). Long forms have UCR1 and UCR2 regions; short isoforms lack the URC1 
region but retain the UCR2 region; and super-short forms lack the UCR1 region 
and contain a truncated UCR2 region [42]. 
UCR1 UCR2 Catalytic
Long Form 
PDE4D3/5/7/8/9; 4B1/3/4; 
4A4/5/8/10/11; 4C1/2/3
Short Form 
PDE4D1; 4B2 
Super- Short Form 
PDE4D2/6; 4B5; 4A1
  
Figure 1.3 PDE4 Family Structures 
The domain structure of PDE4 isoforms, showing the differences in UCR region expression 
(Figure adapted from [7]) 
PDE4s can coordinate enzymatic changes upon regulatory phosphorylation by 
kinases like PKA and ERK. The UCR regions dictate the type of activity change 
that result from such phosphorylations and thus are a contributor in PDE4 
enzymatic regulation. UCR1 includes a PKA phosphorylation site and is connected 
to UCR2 by linker region 1 (LR1) [43]. UCR2 has a hydrophilic N-terminal region, 
which interacts with the hydrophobic C-terminal portion of UCR1 and is 
connected to the catalytic domain via linker region 2 (LR2) [42, 44]. In long form 
PDE4s the interactions between UCR1, UCR2 and their phosphorylation status is 
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important in understanding PDE4 enzymatic activity. Phosphorylation of UCR1 by 
PKA causes an alteration between UCR1 and UCR2 interactions [43]. Alone the 
UCR2 is thought to act as an auto-inhibitory domain of the catalytic unit, the 
change in interaction between UCR1 and UCR2 caused by the phosphorylation is 
proposed to remove this auto-inhibitory effect. Furthermore, PDE4s are 
phosphorylated by extracellular signal-regulated kinase 2 (ERK2) upon the C 
terminus. This phosphorylation has been shown to differ in its effect depending 
on UCR presence, for example the enzyme activity of long form PDE4s 
(containing both UCR regions) was inhibited via this phosphorylation, whereas 
short forms lacking UCR1 exhibited activation by the same phosphorylation [44, 
45]. Long form PDE4s have also been shown to undergo dimerization through the 
intermolecular interactions of the UCR1 regions, thus short and super-short 
forms only exist as monomers [44, 45]. 
1.4 PKA, PDE and Disease 
Michael Gottesman, in 1986, predicted that ‘…sustained expression of the PKA 
catalytic subunit, either because of high cAMP levels from an altered adenylyl 
cyclase or phosphodiesterase system, or because of mutations in R or C, could 
act like an oncogene product in certain cell types’. He had also said that cAMP 
had reappeared in the study of tumorigenesis ‘like a Halley's comet’ [46]. At a 
time when the importance of cAMP as a messenger in many hormonal systems 
was established and the complexity of its functions was becoming apparent, 
human diseases that were linked to abnormal cAMP responses, such as irregular 
cell growth and proliferation, were beginning to be elucidated. 
Recently, mutations in PRKAR1A, the gene encoding RIα, the regulatory subunit 
type 1A of cAMP-dependent protein kinase A (PKA), has been shown to be linked 
to carney complex (CNC), which is a multiple endocrine neoplasia (MEN) 
syndrome and thus has a major effect on the endocrine system [47]. This was 
the first time that cAMP-dependent PKA was found to be directly involved in 
oncogenesis in an inherited disease.  
Furthermore, RIα has been shown to associate with transcription factor, RIAZ. 
Members of the family of BTB/POZ domain zinc finger proteins, including PLZF 
and BCL6, are associated with oncogenesis and RIAZ is shown to be aberrantly 
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expressed in breast cancer cell lines. Co-transfecting GFP–RIAZ with RIα results 
in cytoplasmic localization. The presence of cAMP causes GFP–RIAZ to 
translocate from the cytoplasm into the nucleus. Deletion of the C-terminus of 
RIAZ abolishes its interactions with RIα and GFP–RIAZ localizes in the nucleus 
thus suggesting that the RIα subunit (and potentially the other subunits) of PKA 
may have functions independent of the normal kinase activity [48]. In addition, 
it has also been demonstrated that mutation in the RIα, but not the C subunit, is 
associated with increased resistance to the DNA-damaging anticancer drug 
cisplatin [49]. 
 In mammalian cells, two types of PKA are expressed, type I and type II, 
distinguishable by the expression of different R subunits. During development, 
differentiation and transformation, ratios of PKA I and PKA II can change 
dramatically and this change in expression has been shown to be a feature of 
carcinogenesis. Cho et al [50] showed that PKA-I was over expressed in various 
cancer cells and cells with high RI:RII are associated with poor prognosis in terms 
of early disease recurrence and death. In breast cancer cell lines, increased 
expression of PKA could change sensitivity to estrogens and antiestrogens in 
cancer cells. In a model system of breast cancers, exposure to antisense RIα 
oligonucleotides slows cell proliferation and tumour growth, linking of PKA with 
cancer. This evidence of PKA mutation and links to cancer, make this 
holoenzyme a clear target for novel cancer therapies. 
In addition to PKA signalling, data suggest that cyclic nucleotide 
phosphodiesterases (PDEs) are relevant in various cancer pathologies [51]. Many 
tumour cells interestingly have PDE4, as the major regulator of cAMP-hydrolysing 
activity. PDE4 inhibitors have been shown to inhibit growth and to increase 
differentiation and/or apoptosis in pancreatic cancer cells, colon cancer cells 
and malignant melanoma cells [52-54] Inhibition of PDE4 by the selective 
inhibitor rolipram is also shown to suppress tumour growth and augments the 
anti-tumour effects of chemotherapy and radiation therapy in medulloblastoma, 
glioblastoma [55] and in several hematological malignancies [56]. Why PDE4 
isoforms are overexpressed in so many different tumour types remains elusive. 
However, like PKA, with major links to carcinogenesis, it is a clear target for 
exploitation in the fight against cancer. 
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1.5 Human Prostate Gland 
The prostate gland is a small gland located in the lower pelvis. It sits below the 
bladder and encompasses the proximal part of the urethra as it leaves the 
bladder. The prostate gland weighs approximately 20g and is 10-20cm3 in volume 
[57].  
1.5.1 Function 
The prostate gland is an integral part of the male reproductive system. Its 
primary function is production and secretion of prostatic fluid. This fluid makes 
up 20-30% of semen, which protects and carries the spermatozoa after 
expulsion. It is an alkali solution to counteract the acidic environment of the 
urethra and the vagina, and thus ensuring the gametes stay viable. Electrolytes 
that are important for the function of the spermatozoa while en-capsuled in the 
seminal fluid, originate from the prostatic fluid. The prostatic secretions also 
contain important proteins such as seminal plasmin, which is an antibiotic that 
helps prevent urinary tract infections, as well as kallikrein-related peptidase 3 
(KLK3 (also known as Prostate specific antigen (PSA)) and prostatic acid 
phosphatase (PAP), which are important secretory enzymes [58, 59]. PSA 
participates in the lysing of seminal proteins in order to maintain seminal fluidity 
[60]. PAP is a member of the small protease family and degrades acidic 
molecules like lysophosphatidic acid (LPA) [61]. LPA is present in the seminal 
fluid and is also linked with aberrant cellular proliferation and tumourigenesis in 
many contexts, including prostate cancer [62, 63].  
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Figure 1.4 Anatomical view of the prostate gland 
Image shows the regional anatomy of the Prostate gland (Image taken from 
www.cancer.gov) 
1.5.2 Structure 
The prostate gland is a small capsule about 4cm in diameter. It is a lobular 
capsule subdivided into 3 glandular zones: peripheral, central, and pre-
prostatic, which is encapsulated by a thin fibroelastic, non-glandular layer, 
known as the fibromuscular stroma [57, 64].  
Within the prostate gland there are two basic cell types, epithelial and stromal. 
The glandular zones are comprised of two major types of epithelial cells; luminal 
secretory and basal cells, but also contain a small amount of neuroendocrine 
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cells. In all the glandular zones, there is a layer of basal cells beneath the 
secretory lining, which surrounds the ducts and acini of the zone [65]. The 
fibromuscular stoma surrounding the glandular sections of the prostate is 
comprised of fibroblasts and smooth muscle cells [66].  
 
Bladder
a Central Zone
b Fibromuscular Stoma/Zone
c Pre-Prostatic Zone
d Peripheral Zone
e Preurethral Gland Region
 
 
Figure 1.5 Prostatic Structure (zone model) 
Diagram depicting the zonal structure of the prostate gland (Figure adapted from [67]) 
1.5.2.1 Peripheral Zone 
The peripheral zone makes up over 70% of the glandular part of the prostate and 
is the part of the prostate from which most cancers originate. Nearly 80% of all 
adenocarcinomas arise in this zone [64], which is located towards the rectal side 
of the prostate. The peripheral zone is also the main contributor to the 
secretory epithelial of the prostate, which synthesises the prostatic fluid. 
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1.5.2.2 Central Zone 
The central zone makes up approximately 25% of the glandular prostate in young 
male adults. It is a cone shaped region and is located close to the ejaculatory 
ducts and borders the peripheral zone. It should be noted that, although in close 
proximity, the peripheral and central zones display histologic differences that 
suggest these zones have important biological differences [64]. The central zone 
is less likely to develop carcinomas compared with other zones of the prostate. 
In fact, only approximately 1-5% of carcinomas originate from this area [65]. 
Although the incidence of cancer in this area is reduced, cancers in this region 
often have poorer outcomes than cancers derived from other prostate zones 
[68]. 
1.5.2.3 Pre-Prostatic/Transition Zone 
The preprostatic zone is located proximally to the urethra. It composes about 5-
10% of prostate volume.  In this zone, major ducts do not feature, though there 
is small transition region, and several tiny ducts in which benign prostate 
hyperplasia (BPH) often originates [64]. Approximately 20% of adenocarcinomas 
arise from this zone, however, the morphologic and growth pattern of the 
cancer suggests that it is less aggressive than cancers derived from other zones.  
1.5.2.4 Fibromuscular Stoma 
Surrounding the glandular prostate is a fibromuscular stromal layer. This 
comprises mainly of fibroblasts, smooth muscle, nerves, and lymphatic cells. 
This zone is responsible for the functional contractions of the prostate gland. 
Prostate growth and development is associated with cell-cell communication, 
notably stromal-epithelial interactions [60] and the production of growth 
factors. However these interactions are still poorly understood. 
1.6 Hormone Signalling 
Steroid hormones are diverse class of molecules derived from cholesterol and 
include androgen, oestrogens, progesterone and corticosteroids. Androgens, also 
known as the male sex hormones, are important in a large amount of biological 
Chapter 1: cAMP signalling and Prostate Cancer 
29 
 
processes throughout the body including the maintenance and function of the 
sexual tissues in an adult and differentiation and development in male 
adolescents. They exert this action through the activation of the androgen 
receptor (AR), which is part of the steroid receptor family of transcription 
factors.  These androgens and their action on the androgen receptor can also 
affects the development and progression of male pathologies such as BPH and PC 
[60]. 
1.6.1 Testosterone and Dihydrotestoterone  
The primary sex hormone in an adult male is testosterone. It is secreted via the 
leydig cells of the testes in response to luteinising hormone from the pituitary 
gland [69].It is the most abundant androgen in the serum of males. 97% is bound 
to sex-hormone binding globulins and albumin, leaving 3% as free and 
biologically active, circulating testosterone [70]. Testosterone is the precursor 
molecule for locally metabolised effector molecules at peripheral tissues. The 
mechanism of this uptake into tissues is still poorly understood [71]. The most 
bioactive of the ‘effector’ molecule for AR activation is dihydrotestosterone 
(DHT) which has a 2-5 time higher binding affinity for the AR than testosterone 
itself [72]. DHT is important in the differentiation and growth of the prostate 
gland, male external genitalia and growth of facial and body hair at puberty.   
Conversion of testosterone into DHT requires the action of the 5α-reductase 
enzyme, which is expressed in high amounts within the prostate gland [70, 73]. 
Three forms of 5α-reductase are described in the literature. Type 1 and 2 are 
expressed differentially in liver, genitals and nongenital skin, prostate, 
epididymis, seminal vesicle, testis, ovary, uterus, kidney, exocrine pancreas, 
and brain. Type 1 is usually located within the nucleus, whereas type 2 is 
located within the cytoplasm of the cells. In the prostate gland, type 2 has an 
increased expression within epithelium (especially basal cells) compared to type 
1. Type 3 is ubiquitously expressed in all tissues [71].  
During normal development, DHT promotes the differentiation of the foetal 
prostate and the development of the male genitals. In adults, DHT is the main 
modulator of prostatic function and contributes to the homeostatic effects of 
the AR [69].  
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1.6.2 AR 
The androgen receptor belongs to a superfamily of nuclear receptors that 
mediate the action of steroid hormones. The androgen receptor has a molecular 
weight of 110kDa and is a member of the NR3 subfamily of the nuclear hormone 
receptor family. It is encoded by a gene located on the X chromosome (xq11-12) 
and contains 8 exons which encode 3 protein domains [74]. 
1.6.2.1 Function  
The function of the androgen receptor is to mediate the effects of androgens via 
the regulation and transcription of specific genes. The unliganded androgen 
receptor resides in the cytoplasm, associated with heat-shock proteins through 
interactions with the ligand binding domain of the receptor (Figure 1.6). The 
HSP/AR complex acts to induce a high-affinity conformation in the AR for ligand 
binding. Upon ligand binding, the AR undergoes several conformational changes 
that allows, dissociation from heat-shock proteins, phosphorylation and 
dimerization, and also exposure of the AR nuclear localisation signal and 
translocation to the nucleus [70, 73]. In the nucleus, the AR associates with 
nuclear androgen receptor elements (AREs) on the DNA of various androgen 
receptor target genes [75, 76]. Transactivation of these AR-regulated genes 
often requires the recruitment of cofactors and transcriptional machinery as 
well as the binding of the AR [77]. The most studied of these genes is PSA, a 
component of seminal fluid and currently the main biomarker used for 
monitoring PC development and progression [58, 73]. 
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Figure 1.6 Schematic of basic androgen receptor signalling 
 
1.6.2.2 Structure 
The receptor family to which the androgen receptor belongs, have distinct 
functional domains; a ligand binding domain (LBD) located at the carboxyl 
terminus, a conserved DNA binding domain (DBD) which contains 2 zinc finger 
motifs and an amino-terminal domain (NTD) that is poorly conserved within the 
receptor family and contains the transcriptional activation sequences [76, 78]. 
The androgen receptor fits nicely into this family (see Figure 1.7) as it contains; 
an amino terminal domain (NTD) that modulates transcription activity via its 
transcriptional activation function sequence (AF-1), a conserved DNA-binding 
domain (DBD) that recognises the (androgen) response elements (ARE) in the 
target sequence and C-terminal containing a ligand-binding domain (LBD), which 
modulates ligand recognition, and binding of the co-activator binding sequence 
(AF-2) [70, 79, 80]. 3D structures of the LBD, hinge region and DBD have 
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currently been determined via X-ray crystallography. However, NTD, the most 
unique region of the receptor, still has an undetermined 3D structure [59]. 
Surprisingly, most of the posttranslational modifications of the AR, determined 
via mutation studies, have been reported to lie in this region [81].   
 
 
Figure 1.7 Predicted structural model of the AR. Adapted from [82, 83] 
 
 AF-1 and NTD  1.6.2.2.1
The NTD is the most unique domain in the androgen receptor structure, with 
approximately 15% of homology with other steroid receptors [82, 84]. Unlike 
other domains of the receptor, the NTD has no published crystallographic or 
NMR-based structure. However, the transcription transactivation of the AR has 
been shown to be dependent on contributions from this domain, despite LBD 
activation [82].  
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The NTD of the AR contain the FQNLF motif that is important for the interaction 
with the LBD. This motif is located in the first 25 amino acids of the domain and 
is involved in a ‘charge clamp’ that forms between the LBD and the NTD [85].  
The AF-1 region is located within the NTD. This domain is thought to have 
limited structure and be highly disordered. It is made up of amino acids 142-485 
of the androgen receptor. Within the NTD AF-1 region, several transactivation 
domains have been defined; Most notably, the TAU-1 (amino acids 101-370) and 
TAU-5 (amino acids 360-528) domains.  
A ‘core’ of the TAU-1 domain between amino acids 173 and 203 in the AR was 
described during mutational analysis of the α-helices. The hydrophobic side 
chains and the negative charges of the amphipathic helix are suggested to be 
important in the trans-activating capacity of the AR [86]. The region around this 
core has also been shown to change in confirmation when interacting with co-
factors. This change in structure has been suggested to be the natural active 
confirmation of the AF-1 region, as mutations of these helical structures 
decreases the activity of the AR [82, 84]. Another motif (amino acids 234-247) 
which is located towards the carboxyl-terminal end of the TAU-1 core sequence, 
is highly conserved within the species and is the interaction site for the Hsp70-
interacting protein E3 ligase CHIP [85], and so overexpression leads to a down-
regulation to the steady state of AR. It is also noteworthy that both TAU-1 and 
CHIP-interacting motifs have been shown to have mutations, which increase the 
AR activity. 
TAU-5 domain was first described by Jenster et al in 1995 [87], and has been 
suggested to allow the AR to retain its activation potential in the absence of the 
LBD. It is an autonomous activation domain that is targeted by many co-activator 
proteins [84, 86]. The TAU-5 domain also contains two SUMO-1 modification sites 
at positions 385 and 511 respectively. This SUMOylation has been suggested to be 
in response to agonists and mutation studies of K385, these show an effect on 
the co-operatively of the receptor when forming a complex at the ARE [86]. 
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 DBD and the hinge region 1.6.2.2.2
The DBD is the region responsible for DNA interactions. This domain is highly 
conserved between steroid receptors, with the receptors sharing the same DNA 
recognition sequence (CGSCKVF) [88]. Despite the conservation of the DNA 
binding sequence between steroid hormone receptors, different steroid 
hormones can elicit different biological responses. The mechanism of exactly 
how this occurs is largely unclear, however, differential receptor and cofactor 
expression, cell-type- specific chromatin organization or hormone metabolism 
may account for many physiological situations where a gene is specifically 
regulated by steroid hormones. The DBD region is approximately 80 amino acids 
in length, and is composed of two zinc motifs, which contain three helices each. 
The first helix extends from the C-terminal of the first zinc-finger and contains 
amino acids responsible for the specific recognition of the DNA.  The second 
helix lies in the tip of the second zinc-finger and borders the receptor 
dimerization surface. The third helix is important for the overall three 
dimensional structure of the DBD. Each of the zinc motifs are composed of a zinc 
ion which is surrounded by four cysteine residues [88, 89]. 
The region located between the LBD and the DBD is known as the hinge region. It 
is composed of amino acids 625-670 and is poorly conserved. This region of the 
AR contains a nuclear localisation signal motif (amino acids 617-634) which 
overlaps with the DBD [90]. This localisation signal motif binds importin- α at 
residues 629-634 [84]. The nuclear import of the AR is mediated via an importin 
α/β complex [83]. Although this region was initially thought to be a simple linker 
region, it is now linked to many control factors of the AR as well as its import. 
These factors include, nuclear export (as well as import), DNA affinity and 
selectivity, co-factor interaction and the ARs transactivation abilities. The 
mechanisms of action for these factors still remain to be described fully [83, 84]. 
 AF-2 and LBD 1.6.2.2.3
The C-terminal contains the LBD and the AF-2 sequences and unlike the NTD its 
structure (when in a complex with a variety of ligands) has been solved. The 
mechanistic function of the LBD is to bind androgens (ligand) in the ligand 
binding pocket, causing a conformational change which induces the formation of 
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the AF-2 co-activator binding surface. This is the function which is exploited 
during PC treatment.  
The LBD domain has a very similar structure to other members of the nuclear 
receptor family. However, the LBD of the AR is comprised for 11 α-helices 
instead of the usual 12. These 11 α-helices make up the binding pocket of the 
LDB in a 3 layer, antiparallel sandwich structure (Figure 1.8). 18 amino acids, 
within 10 of the α-helices, directly interact with the ligand and the final helix 
stabilises the ligand in the binding pocket by acting as a flexible lid [91, 92]. 
This conformational change of the helices results in the formation of a 
hydrophobic region on the surface of the LBD known as AF-2. 
 
Figure 1.8 Crystal structure of DHT-bound androgen receptor LBD in complex with the first 
motif of steroid receptor coactivator 3 
Protein bank database ID 3L3X. Graphical represented using visual molecular dynamics 
(VMD) software.  
The AF-2 surface is a hydrophobic region, with areas of positive and negative 
charge. As suggested the AF-2 region acts as a docking site for co-regulators via 
a conserved LxxLL motif. Studies into the recruitment of co-activators has shown 
that residues within the helices of the LBD act as clamps to stabilizes the co-
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activator interaction with the AF-2 region, however the exact role of co-
regulation recruitment by the AF-2 surface is still unclear [78, 93]. The 
boundaries of the AF-2 domain in the androgen receptor ligand-binding domain 
have not been determined as yet, but it is known to contain a defined core 
region. This AF-2 activation domain (AD) core region, contains a conserved 
sequence aa 884-888. Mutations in this region result in a decrease in activation 
without affecting the ligand-binding capability. This indicates that the amino 
acid residues of the AF-2 AD core region are not directly involved in ligand-
binding, but are part of, or are determinates of the interaction surface [94]. 
In several of the nuclear receptor families, a communication between the LBD 
and the NTD has been shown. For the AR receptor, this interaction is very strong 
and thus, its physiological importance has been called into question. This 
communication is conducted via the binding of the LxxLL binding motifs in the 
LBD and the FQNLF motif in the NTD. The NTD/FQNLF motif is of great 
importance for this interaction as illustrated by mutation or deletion studies 
that have resulted in ablation of the NTD-LBD interaction. Ablation of this 
interaction subsequently affects AR trans-activation and kinetics of ligand 
binding [85].  
 
1.7 Prostate Diseases 
1.7.1 Benign Prostatic Hyperplasia 
Benign Prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate 
gland, is a common prostatic disease in men. It affects over 50% of men over 50 
years of age, and 80% of men over the age of 70 [95]. It is an age related, 
regional prostate disorder that normally develops in the peripheral and 
transition zones of the prostate gland. BPH develops from a simple micronodular 
hyperplasia to a macroscopic volume enlargement of the prostate gland and 
progression to clinical symptoms [96, 97]. As BPH progresses, it is associated 
with symptoms such as decreased urinary flow, due to the enlarged gland 
causing a constriction to the urethra. This leads to lower urinary tract symptoms 
(LUTS), which include symptoms such as urinary hesitancy, frequent urination, 
thin urine flow and urinary retention. In severe cases, delayed treatment could 
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lead to worsening symptoms and complications that may result in surgery [98, 
99].  
The causes and mechanism behind BPH occurrence is generally not understood. 
The current theory is that there is a general unbalancing of the factors that are 
associated with cell growth and apoptosis, and so the importance of androgens 
in BPH has been well established [99, 100].  
1.7.2 Prostatitis 
Prostatitis is the inflammation of the prostate gland which can be separated into 
4 clinical categories; acute and chronic bacterial prostatitis, rare infectious 
diseases of the prostate gland, chronic prostatitis/chronic pelvic pain syndrome 
(CP/CPPS) and asymptomatic inflammatory prostatitis. The majority of 
prostatitis relates to the CP/CPPS category.  
Diagnosis of prostatitis is increasingly being linked with the later development of 
BPH and also prostate cancer. In a study on approximately 2500 men in the USA, 
patients that had been diagnosed with prostatitis were associated with a 2.4 fold 
increase in the probability of being diagnosed with BPH at a later date [101, 
102]. Additionally, a meta-analysis  study conducted by Dennis et al, showed 
that the association between prostatitis and PC is significant [103]. Other studies 
have also shown links between these diseases [104, 105]. 
1.7.3 Prostate Cancer 
Prostate Cancer is the leading cause of death among men in Western Europe and 
the United States. In an autopsy study, 64% of men between 60 and 70 years of 
age were shown to have small prostatic carcinomas [106, 107].  
1.7.3.1 Epidemiology 
The specific cause of prostate cancer is unknown but the primary risk factors 
include family history, diet, age and weight. The incidence of prostate cancer 
varies significantly with ethnicity, with African-Americans having the highest 
incidence rates in the world, followed by Caucasian-Americans and Asians 
exhibiting the lowest incidence [108]. <0.1% of cancer cases occur before the 
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age of 50 and risk then, rapidly increases with age [109]. However, in the US 
only one in six men diagnosed with prostate cancer with eventually die from it. 
The number of patients that are diagnosed with the disease has increased 
dramatically in the past few decades due to an ageing population and the 
introduction of new screening methods, leading to earlier diagnosis [110]. 
Another major risk factor is diet. Increased fat intake has been strongly 
correlated to the incidence of prostate cancer, with the main risk foods being, 
animal and saturated fats, and red and processed meats, with the consumption 
of oily fish been associated with reduced risk [111]. Although the causes of 
prostate cancer still remain mostly elusive, epidemiological studies have 
provided important insights into the potential risk factors of prostate disease.  
 Prostatic Intraepithelial Neoplasia 1.7.3.1.1
Prostatic Intraepithelia Neoplasia (PIN) is a suggested precursor of prostatic 
adenocarcinoma. A study by Bostwick et al has also suggested this close 
relationship, indicating that the occurrence of PIN seems to run in parallel with 
the occurrence of prostate cancer, with prostate cancer lagging about 10 to 20 
years behind the appearance of PIN [112]. PIN is detected via biopsy, as it 
doesn’t often affect PSA levels and cannot be detected with ultrasound. The 
incidence of PIN detection in the US averages at approximately 9% of all biopsies 
carried out and like prostate cancer, the possibility of occurrence increases with 
the age of the patient [113].  
PIN is characterised by cellular proliferation within pre-existing ducts and glands 
with cytological changes that mimic cancer [112]. Like cancer, PIN is mostly 
located within the peripheral zone of the prostate, but unlike cancer, retains an 
intact or fragmented basal layer which becomes increasingly disrupted into 
higher grades and finally into carcinoma. Early stromal invasion, which is 
indicative of early progression into carcinoma, occurs at sites of glandular 
outpouching and basal cell disruption [113]. Furthermore, PIN is associated with 
progressive abnormalities in phenotype and genotype, which are intermediates 
between normal epithelium and cancerous tissue. As expected, PIN is shown to 
be hormone dependent, with a marked reduction with androgen deprivation 
therapy. However, patients with PIN are not typically treated with hormone 
therapy but are subjected to further studies to search for concurrent invasive 
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carcinoma. In addition, follow-up biopsies are suggested at 3- to 6-month 
intervals for 2 years, and thereafter at 12-month intervals for life [112-114]. 
1.7.3.2 Hormone signalling and Prostate Cancer Progression  
As earlier discussed, androgens and the androgen receptor are fundamental in 
the development and function of the prostate gland. The most significant 
function of this pathway is the regulation of apoptosis vs proliferation. 
Therefore, because of this function, this pathway and related proteins are, 
unsurprisingly, often changed in prostate cancer, and are key to its progression. 
The androgen receptor was first shown to have a role in the pathogenesis of PC 
in 1941, showing that orchiectomy or treatment with oestrogen could effectively 
treat the metastatic disease. Since this pioneering work, androgen ablation is 
still the main systemic treatment for PC [115]. As this study suggests, the cross 
talk between oestrogen and androgen signalling has been shown to be of 
significance in prostate signalling [116, 117]. In addition, the ratio of these 
hormones has also been shown to decrease with age, and this altered ratio 
correlates with the onset of disease, such as BPH and PC [118, 119]. 
Furthermore, up-regulation of the oestrogen receptor related receptor α (ERRα) 
expression in malignant epithelial and stromal cells subsequently increased 
production of oestrogen from testosterone during prostate progression [120, 
121].  
The androgen reducing enzyme, 5-α reductase enzyme, is present in the prostate 
in 3 isoforms. It is generally thought that the expression of type 1 is increased 
and type 2 decreased in malignant cancers, compared to benign prostate and 
BPH [122-124]. In addition, 5-α reductase type 3 was recently shown to increase 
in malignant prostate cancers compared to BPH [125]. Furthermore, a study 
showed that 5-α reductase type 2 expression decrease in PC was a result of 
methylation on its promoter sequence [126]. The change in expression patterns 
of these enzymes means that it is possible for DHT levels to increase, eliciting 
effects on the prostate stroma and secretory epithelium. Increases in DHT 
levels, subsequently lead to an increase in AR transcriptional activity in the 
epithelium of BPH and in early prostate cancer.  
Chapter 1: cAMP signalling and Prostate Cancer 
40 
 
1.7.3.3 Later Stage- Androgen Independence 
One of the major side effects of androgen ablation therapies is that, over time, 
prostate cancer invariably progresses to an androgen independent phenotype 
[127]. The theory is that the removal of androgens from the sensitive cancers 
results in the selection of cells which are no longer androgen reliant [128]. This 
phenotype of PC is a fatal manifestation, which is resistant to all other known 
treatments and further androgen ablation. The cells within the AI phenotype 
show an increase in proliferation, invasiveness and rate of metastasis compared 
to their AS counterparts [129]. Therefore significant effort has been focused on 
understanding this stage of the disease and its progression from androgen 
dependent PC. 
1.8 Current Diagnostics and Procedures 
1.8.1 Diagnosis 
The ARs importance in prostate cancer and other disease states of the prostate 
has long been exploited for the detection of the disease. Currently, the 
detection of prostate-specific antigen (PSA) is used as a biomarker for the 
detection of prostatic diseases, response of cancers after ablation therapy and 
recurrence after treatment [79, 130]. Early detection of the disease is 
paramount to treatment outcome. As clinical symptoms often do not surface 
until late aggressive stages of the disease, the introduction of PSA testing has 
improved survival rates [131]. 
1.8.1.1 PSA  
PSA is a serine protease from the tissue kallikrein family and is produced by 
prostate epithelial cells. PSA is an androgen sensitive gene, and thus is 
upregulated in PC due to the increase in AR activity [132]. This significant 
increase in expression levels leads to the excretion of PSA into the circulatory 
system. Here, PSA can be monitored via a simple blood test [133]. PSA protein is 
synthesized with a leader sequence which is cleaved to produce an inactive form 
of PSA. Further cleavage from the N-terminal of 7 amino acids results in an 
active enzyme [59]. The majority of PSA that enters the peripheral blood stream 
is intact and is complexed with a protease inhibitor[134]. However, some forms 
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do exists as free inactivated PSA, due to internal cleavage of the enzyme, and 
thus has an inability to form the PSA/inhibitor complex. These free, inactive 
forms are decreased in PC cells and consequently can be used to aid the 
discrimination between normal and PC [59]. 
Prior to the routine screening of men with PSA, diagnosis was conducted via 
physical examination and trans-rectal ultrasound coupled with a biopsy. As a 
result, patients weren’t often diagnosed until after the manifestation of clinical 
symptoms, mostly in the later stages of the disease [135]. PSA came into routine 
use in the early 90s and it is the most studied androgen receptor target [136, 
137]. It is also the most widely used cancer marker for diagnosis and follow up 
[79, 130]. It has also revolutionised patient care. Where previously, patients 
were often diagnosed in aggressive late stages of the disease, testing via PSA has 
given the opportunity for treatment with hormone and radiotherapy, extending 
survival times and decreasing mortality rates [138, 139]. However, it is not 
without is controversy, as it can frequently produce false positives, causing un-
necessary treatment and often inducing\ accelerating cancer growth. In the 
latest report for the U.S. Preventive Services Task Force, its co-chair Michael 
LeFevre stated “Prostate cancer is a serious health problem that affects 
thousands of men and their families. But before getting a PSA test, all men 
deserve to know what the science tells us about PSA screening: there is a very 
small potential benefit and significant potential harms” 
(www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm). Thus, in 
recent years it has become advantageous to find a new, more reliable biomarker 
for this disease [140]. The regulation of the PSA transcription is initially 
androgen-related and thus declines after castration or ablation therapy. 
However, in the case of androgen independent PC, PSA levels are continually 
increased through a currently undefined mechanism [141]. Once the disease 
regresses to the castration resistant, androgen independent form, patients 
usually succumb to the disease in 2 years [142]. 
1.8.1.2 Gleason Scoring 
Gleason scoring was first created in 1966 and is a unique grading system for 
prostate cancer based solely on the tissue architectural pattern in the tumour 
[143, 144]. Gleason originally described this system based on 270 US verterans, 
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later this study was expanded to include 1032 men, with further refinements to 
the system shown even today [144-147]. This scoring system was designed to 
give clinicians a system on which to relate prognostic symptoms and is based 
upon the level of differentiation observed at biopsy. All tumours were classified 
into a 5-grade system representing the progressive complex morphologies. 
Tumours are assigned grades based on a two-step process. The tumours are first 
assigned a primary grading between 1-5 based on the most prevalent tissue 
pattern (i.e. the majority of the tumour contains this type of architectural 
pattern), then they are assigned a secondary grading between 1-5 based on the 
second most common tissue pattern. These 2 scores are added together to give a 
‘Gleason score’. Patients with low Gleason scores (<6) often undergo ‘watchful 
waiting’ and active surveillance treatments, where patients have an increase in 
PSA monitoring and symptom progression. This is to monitor potential cancer 
progression and facilitate early intervention for progressive disease [145, 148]. 
Patients with a score higher than 7, receive active therapy. Gleason scores 8-10 
are associated with treatment with radiation and androgen therapy [145]. The 
table shows a brief overview of the Gleason scoring system (see table 1.1) [143]. 
Gleason 
Grade 
Description of Observed Tissue 
1 Simple round glands, close-packed in rounded 
masses with well-defined edges. 
Closely resembles normal tissue. 
2 Simple rounded glands, loosely packed in vague, 
rounded masses with loosely defined edges 
3A Medium sized single glands of irregular shape and 
irregular spacing with ill-defined infiltrating edges 
3B Very similar to 3A, but small to very small glands, 
which must not form significant chains or cords 
3C Papillary and cribriform epithelium in smooth, 
rounded cylinders and masses; no necrosis 
4A Small, medium, or large glands fused into cords, 
chains, or ragged, infiltrating masses 
4B Very similar to 4A, but with many large clear 
cells, sometimes resembling “hypernephroma” 
5A Papillary and cribriform epithelium in smooth, 
rounded masses, more solid than 3C and with 
central necrosis 
5B Anaplastic adenocarcinoma in ragged sheets 
Table 1.1 Overview of the Gleason scoring system for prostate tumours 
Adapted from [143] 
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1.8.2 Treatments 
1.8.2.1 Hormone therapy 
Prostate tumours are initially under hormonal control, and so respond well to 
androgen ablation therapies and physical and medical castration. Androgen 
ablation is often achieved by using a combination of AR antagonists and 5α- 
reductase inhibitors [149]. For most AR antagonists, the target sequence is the 
LBD. This prevents nuclear translocation and the conformational changes that 
causes the exposure of the AF-2 surface [150]. This in-turn causes the AR to 
promote co-repressor molecules to AR-regulated gene promoters, overall 
decreasing AR activity [77, 151]. Furthermore, suppression of luteinizing 
hormone releasing hormone (LHRH) in the hypothalamus also acts to decrease 
androgen levels [152]. LHRH activation mediates the production of testosterone 
in the testes. Therefore, by suppressing expression of LHRH, medical castration 
can be imposed [152, 153]. 
However, as discussed, androgen withdrawal treatment regimens invariably 
result in the regression of AS cancers into a more aggressive AI phenotype [129]. 
1.8.2.2 Prostatectomy 
Prostatectomy is the removal of the prostate gland (either partial or complete). 
Due to the invasive nature of these procedures, prostatectomy of the prostate is 
usually only conducted in younger patients. Prostatectomies can be carried out 
via 3 procedures. 
 Laparoscopic radical prostatectomy is used for the complete removal of the 
prostate gland, to decrease the invasiveness of open prostatectomy surgery by 
using small incisions and robotics aids [154]. Open prostatectomy, in contrast, is 
a highly invasive procedure.  
Trans-urethral resection of the prostate or TURP, is the least invasive of the 3 
procedures and as such can be employed in high-grade BPH. Here, a cytoscope is 
inserted into the urethra and removal of prostatic tissue is carried out to 
alleviate pressure on the urethra [155].  
Chapter 1: cAMP signalling and Prostate Cancer 
44 
 
1.8.2.3 Radiotherapy 
Radiotherapy has long since been used in the treatment of prostate cancers and 
is thought to be paramount in the treatment of high grade tumour control [156]. 
Treatment of prostate cancer with radiotherapy can be administered via 2 
methods; External beam radio therapy and brachytherapy [157]. External beam 
radiotherapy is based upon directed beams of targeted radiation generated 
outside the body, whilst brachytherapy involves the implantation of radioactive 
isotopes into the tumour mass [156]. Radiotherapy combined with androgen 
ablation therapy is usually used to treat patients with high Gleason scores, as 
warranted by the fact that dual treatment of androgen therapy with 
radiotherapy improves survival of patients compared to single treatments [158]. 
In light of the information above, the main scientific thrust of my thesis was 
directed towards two major cAMP signalling molecules in the context of prostate 
cancer development. Hence the main aims of my thesis were divided into two 
sections: 1) the profiling of PKA isoform expression in prostate progression and 
subsequent characterisation of the direct effects on AR; 2) the isolation of 
interacting pathways with PDE4D7 in advancing prostate cancer, to establish how 
changes in PDE4D7 regulation can effect prostate cancer signalling.  
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2 Materials and Methods 
2.1 Cells Culture 
All cells were grown at 37oC in 5% CO2. All sub-culture of cells was conducted in 
a sterile environment using laminar flow hoods and 70% ethanol to sterile hands 
and working surfaces just prior to use. All culture media and additives were 
source from Sigma- Aldrich and all plastics were sourced from Corning unless 
stated below. Growth media was changed every 48 hours unless otherwise 
stated. All cells were sourced from ATCC, with the exception of PC133 which 
was a kind gift from Dr. Guido Jenster of the Erasmus Medical Centre in 
Rotterdam. 
2.1.1 Culture  
HEK293 cells (Human Embryonic Kidney Cells) were cultured in Dulbecco’s 
modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum, 
2mM L-glutamine and penicillin-streptomycin. Cells were received with a 
passage number between 5-11.  
DU145 cells were cultured the same as HEK293 cells. Cells were received with a 
passage number between 53-62. 
LNCaP cells were cultured in RPMI1640 medium and supplemented the same as 
DMEM. Cells were received with a passage number between 21-28.  
VCaPs and PNT1a cells were all cultured the same as LNCaP cells. Cells were 
received with a passage number between; VCaPs (35-39), PNT1a (19). PC-3 cells 
were cultured as LNCaP cells but with only 5% foetal bovine serum supplemented 
into the medium. Cells were received with a passage number between 9-13.  
2.1.1.1 Sub-culture of cell lines  
Cells lines were sub-cultured when they reached the confluence of 
approximately 70-80%. Cells were washed twice in warm (37oC) PBS. 
Subsequently, cells were incubated with 4ml of 1% trypsin-EDTA (for a 75cm3 
flask) to cleave the extracellular anchoring proteins attaching the cells to the 
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plastic. Once all cells had been dislodged from the tissue culture plastic, 8mls of 
appropriate growth media was added to the flask. The resulting 12ml cell 
suspension was transferred to a 15ml tube. 
Cell suspensions were then centrifuged at 800 x g for 3 minutes to pellet the 
suspended cells. The trypsin/growth media mixture was then removed from the 
tube and the cell pellet was re-suspended in 10mls of growth media. Cells 
required to be precisely seeded were counted using a Millipore® Scepter. For 
sub-culture cells were re-seeded at a density of approximately 30%.  
2.1.1.2 Storage of Cell Lines  
Samples of the cell lines used within this study were prepared for liquid nitrogen 
storage for future use.  All samples were prepared for storage by suspending 
cells in 10% DMSO in appropriate growth media and transferring the suspension 
to a cyro-vial suitable for liquid nitrogen storage. Cells were frozen at -80oC 
prior to transfer to liquid nitrogen storage.  
Cells were retrieved from storage by incubation of the frozen sample at room 
temperature prior to the addition of 5ml of growth media, also at room 
temperature. Cells were centrifuged at 800 x g for 3 minutes and the 
supernatant removed. Cells were then re-suspended in 12mls of growth media 
and plated out in a 75cm3 culture flask.  
2.1.2 Transfection 
2.1.2.1 Lipofectamine 2000 ® 
All prostate cell lines (ATCC) were transfected with DNA constructs using 
Lipofectamine 2000® (Invitrogen ®) transfection reagent, as per the 
manufacturer’s instructions (with the exception of during the high-through-put 
screens in chapter 3). Transfections were typically performed when cell cultures 
were 80% confluent. Outlined below is the procedure for a single well of a 6-well 
plate, which was scaled up or down depending culture vessel surface area.  
Growth media was replaced with Opti-MEM® (Invitrogen®) 2 hours prior to 
transfection. Transfection complexes were formed in 15ml polypropylene tubes. 
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250μl of Opti-MEM was added to each of two separate tubes. 4μg of plasmid DNA 
was then added to one tube whilst 10μl of Lipofectamine 2000® reagent was 
added to the other. Both tubes were gently agitated to ensure mixing. Tubes 
were then incubated at room temperature for 5 minutes before the 
Lipofectamine 2000® mixture was added to the diluted plasmid DNA. 
Transfection complexes were allowed to form for 25 minutes. During this time 
the cell culture media was replaced with 1.5ml of fresh Opti-MEM®. Transfection 
complexes were gently added to the culture vessel by pipetting directly into the 
Opti-MEM® culture media. Transfection complexes were incubated with cells for 
4 hours and then normal growth media was added. Cells were harvested 24- 48 
hours after transfection according to the experimental design. A typical 
transfection efficiency of 30-40% was achieved for the VCaP cell line whilst all 
other prostate cell lines exhibited an efficiency of 50-60%. 
2.1.2.2 X-treme GENE HP ® 
For all the high-through-put screens in chapter 3 the following protocol was 
followed, with the exception of luciferase reporter arrays for which the protocol 
is outlined in section 2.1.3. The X-treme GENE reagent was used after a 
screening of transfection reagents was carried out in a hope to increase the 
transfection efficiently in the VCaP cell line (Appendix 7.1). Lipofectamine 2000 
® was used as outlined in the protocol above, the other transfection reagents 
were used as outlined in the ‘X-treme’ GENE HP’ protocol. 
VCaP cells were transfected with DNA constructs using X-treme GENE HP® 
(Roche ®) transfection reagent, as per the manufacturer’s instructions. 
Transfections were typically performed when cell cultures were 80% confluent. 
Outlined below is the procedure for a single well of a 6-well plate, which was 
scaled up or down depending culture vessel surface area.  
Growth media was replaced with Opti-MEM® (Invitrogen®) 2 hours prior to 
transfection. Transfection complexes were formed in 15ml polypropylene tubes. 
X-treme GENE HP® transfection reagent was heated to room temperature prior 
to use. 500μl of Opti-MEM was added to the tube followed by 4μg of plasmid DNA 
and 12μl of X-treme GENE HP® reagent. The tube were gently agitated to ensure 
mixing and incubated at room temperature for 25 minutes to allow the 
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transfection complexes to form. During this time the cell culture media was 
replaced with 2ml of fresh Opti-MEM®. Transfection complexes were gently 
added to the culture vessel by pipetting directly into the Opti-MEM® culture 
media. Transfection complexes were incubated with cells for 4 hours and then 
normal growth media was added. Cells were harvested 24- 48 hours after 
transfection according to the experimental design. A typical transfection 
efficiency of 40-50% was achieved for the VCaP cell line. 
2.1.2.3 Polyfect ® 
For HEK293 cells were transfected with DNA constructs using PolyFect® 
(Qiagen®) transfection reagent, as per the manufacturer’s instructions. 
Transfections were typically performed when cell cultures were 80% confluent. 
Outlined below is the procedure for a single well of a 6-well plate, which was 
scaled up or down depending culture vessel surface area.  
Transfection complexes were formed in 15ml polypropylene tubes. 100μl of Opti-
MEM was added to the tube followed by 2μg of plasmid DNA and 20μl of 
PolyFect® reagent. The tube were gently agitated to ensure mixing and 
incubated at room temperature for 10 minutes to allow the transfection 
complexes to form. During this time the cell culture media was replaced with 
1.5ml of fresh full growth medium. 1ml of full media was added to the 
transfection complexes and was gently added to the culture vessel by pipetting 
directly into the growth media. Transfection complexes were incubated with 
cells until ready to harvest, 24- 48 hours after transfection according to the 
experimental design. A typical transfection efficiency of 70-80% was often 
achieved. 
2.1.3 Lysate Harvesting 
Cell lysates were harvested using 3T3 lysis buffer (25mM HEPES, 10% w/v 
glycerol, 50mM NaCl, 1% w/v Triton x100, 50mM NaF, 30mM NaPP, 5mM EDTA 
pH7.4). Complete, EDTA-free Protease Inhibitor Cocktail Tablets were added to 
the lysis buffer prior to use and PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets® (both Roche®) were added to the lysis buffer where indicated.  Cells 
were detached from the tissue culture vessel by scraping with a rubber 
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policeman. Lysates were then pipetted immediately into a 1.5ml Eppendorf® 
tube and kept on ice. After, lysates were centrifuged at 13000 x g for 5 minutes 
to remove insoluble material. Concentrations were immediately assessed 
(Section 2.2.1) and lysates were either used the same day, or snap frozen on dry 
ice and stored at -80oC for future use. 
Lysates used in PDE assays were harvested using KHEM lysis buffer (50mM KCl, 
50mM Hepes, 10mM EGTA, 1.92mM MgCl2, pH 7.4). Protein lysates were passed 
through a needle several times. As KHEM buffer contains no detergents, physical 
breaking of the cells was achieved by this process. 
2.1.4 Luciferase reporter arrays 
Luciferase Cignal pathway reporter arrays were purchased from SABioscience® 
(Qiagen®). Each well of the reporter array contained dried constructs of a 
pathway-focused transcription factor responsive Firefly luciferase and ‘control’ 
constitutively transcriptionally active Renilla luciferase constructs in a 1:1 ratio. 
These plasmids were reconstituted and cells reverse transfected as laid out 
below. 
All arrays were transfected using X-treme gene HP® (Roche).  5ml of Opti-MEM® 
per plate was added to a 15ml polypropylene tube. To each tube 20µg of plasmid 
DNA was added and 25µl of Opti-MEM® was added to each well of the 96well 
array to re-constitute the plasmid DNA, these were then incubated for 5 min at 
room temperature. 120µl of X-treme gene® transfection reagent was then added 
to the polypropylene tube and instantly, with a multi-channel pipette, added to 
the 96 well arrays (for control plates only 60µl of transfection reagent was 
used). Transfection complexes were formed over 25 minutes at 37oC. During this 
time VCaP cells were trysonised, added to new Opti-MEM® media and counted as 
previously described. After 25 minutes 30,000 cells added to each well. Cells and 
transfection complexes were incubated together for 4 hours, after which 100µl 
of normal media was added to each well. Cells were incubated for a further 48 
hours. After48 hours, media was removed from the cells and washed with 100µl 
of ice cold PBS. Quantification of luciferase activity was carried out using a dual 
luciferase assay kit from Promega®. Cells were lysed by added 20µl of 1x Passive 
Lysis Buffer (PLB, from the Promega ® kit)) and incubated by rocking for 1 hour. 
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The catalytic activities of the luciferase enzymes was measure for 1 second per 
well using a Mithras® multiplate reader from Berthold® industries as a 
luminometer. The results were described as a ratio of Firefly luciferase/Renilla 
luciferase activity. 
2.1.4.1 Luciferase Assay Calculation  
Results for the dual luciferase assays were expressed as a ratio of Firefly 
luciferase activity / Renilla luciferase activity, where Firefly activity is the ‘test’ 
and Renilla activity is used as a ‘control’. This is due to the Renilla plasmid, 
being constitutively transcriptionally active. This therefore gives a constant 
baseline expression to which the firefly luciferase can be referenced. This acts 
to minimize experimental variability between different transfections, and 
control for factors which can affect the absolute luminescence.  
2.2 Western Blotting Procedures 
2.2.1 Bradford Assay 
Bradford assays were conducted to determine the protein concentration of 
harvested lysates. Assays were carried out using Bio-Rad® reagents, following the 
manufacturers instruction and [159]. The absorbance at A590 nm was assessed 
for each 50μl of a 1/50 dilution of cell lysate. This was compared against a 
standard curve of absorbance spectra from known amounts of BSA. 0-5μg of BSA 
in 50μl dH2O were used to calculate the standard curve and samples were run in 
triplicate wells using 200μl of the protein assay solution.  
2.2.2 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is the 
standard method used for protein separation by molecular weight. SDS-PAGE was 
conducted using the Novex® NuPAGE® SDS-PAGE Gel System from Invitrogen®. 
Protein samples were separated by electrophoresis in XCell SureLock® XCell II® 
Blot Module Kits.  
Protein samples of 20-100ug were denatured and reduced by diluting in 5x SDS 
sample buffer (10% SDS, 300mM Tris-HCl; pH 6.8, 0.05% bromophenolblue, 50% 
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glycerol and 10% β-mercaptoethanol). The samples were boiled for 5 minutes 
and the loaded directly to a well of a NuPAGE® 4-12% Bis-Tris polyacrylamide gel 
from Invitrogen® and immersed in Invitrogen® NuPAGE® MOPS SDS running buffer. 
5µl of Bio-Rad® pre-stained molecular weight protein marker was also loaded to 
an appropriate well of the gel to allow the molecular weight of the proteins 
within the sample to be estimated. The gels were run at 160V for 1 hour.  
2.2.3 Western Blotting 
Western blotting is used to detect proteins, separated via SDS-PAGE, with 
specifically raised antibodies. These proteins were transferred from SDS-PAGE to 
nitrocellulose membrane using the XCell® blotting apparatus and NuPAGE® 
transfer buffer containing 20% methanol. To achieve this, a voltage was applied 
through the blotting apparatus at 20V for 2 hours. Following the transfer of 
proteins onto the nitrocellulose membrane, this membrane was then blocked 
with 5% milk powder (Marvel ®) or 5% PhosphoBLOCKERTM (Cell Biolabs Inc. ®) in 
1x TBST (20mM Tris-Cl pH 7.6, 150mM, NaCl and 0.1% Tween20) as indicated, for 
1 hour on an orbital shaker. The primary antibody, at the appropriate dilution, 
was added to a solution of 1% milk powder/phosphoBLOCKER TM in 1xTBST. The 
blocked nitrocellulose membrane was then heat-sealed in an airtight bag with 
the primary antibody solution. This was incubated overnight at 4oC on an orbital 
shaker. The appropriately raised anti-immunoglobuin secondary antibody 
conjugated with either horseradish peroxidase (HRP)(Sigma®) or LI-COR 
Biosystems® fluorophor was added to a solution of 1% milk 
powder/phosphoBLOCKER TM in 1xTBST at a dilution of 1:10,000. The membrane 
was washed 3 times with 1x TBST for 5 minutes before being heat sealed in an 
airtight bag with the primary antibody bound membrane and secondary antibody 
solution for 1 hour at room temperature on an orbital shaker. Again, the 
membranes were washed 3 times in 1xTBST. For visualisation of HRP conjugated 
secondary antibodies, Amersham Biosciences® chemiluminescence (ECL) western 
blotting kit was used, in collaboration with blue-light sensitive X-ray film 
(Kodak®) and developed using the Kodak® X-Omat model 2000 processor. To 
visualise antibodies conjugated with LI-COR Biosystems® fluorophor, membranes 
were placed face down on the LI-COR Biosystems® Odyssey infrared scanner. 
Membranes were scanned at either 680 or 800nm wavelength, according to the 
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secondary fluorophore. The scans were saved as TIF files and were analysed 
using LI-COR Biosystems® Odyssey® software. 
2.2.4 Immuno-precipitation  
Co-immunoprecipitation is a method for the confirmation of interactions. Cell 
extracts (Section 2.1.3) underwent protein determination via Bradford assay 
(Section 2.2.1) and then adjusted to equal protein amount (1 μg/μl) using 3T3 
lysis buffer. After preclearing, the AR (Santa cruz ®) antibody was used to 
immunoprecipitate (IP) over-expressed AR. The resulting immunocomplexes 
were captured using Protein G beads (Invitrogen) at 4 oC overnight. The 
immunocomplexes/beads were centrifugation at 13 000 rpm for 3 min and 
washed three times with 3T3 lysis buffer. The immunocomplexes/beads pellet 
was re-suspended in SDS-PAGE sample buffer and boiled in order to elute the 
bound proteins in the sample buffer. After, centrifugation the supernatant was 
subjected to SDS-PAGE and Western blotting as described previously (Section 
2.2.2, 2.2.3). Negative controls using isotype-matched IgG (Millipore ®) from the 
same species as the antibody was included to screen for non-specific binding. 
2.2.5 Peptide Kinase Assay 
The peptide kinase assay was undertaken with a peptide array containing 
immobilised peptide libraries that encompass the entire sequence of the AR. The 
array contains 25mer segments of the androgen receptor sequence, each shifted 
by 5 amino acids at a time (produced in house by Ruth McLeod). This was 
blocked with 5% BSA in 1xTBST for 1 hour at room temperature on an orbital 
shaker. 3µg of active catalytic unit of PKA (Millipore®) was added to 
phosphorylation buffer (20 mM MgCl2 in TBS [20 mM Tris-HCl pH 7.5, 150 mM 
NaCl]) plus 10µM of ATP (Cell Signaling®), and overlaid on the slide for 30 
minutes at 37oC on an orbital shaker. A negative control was carried out under 
same conditions but without the addition of the PKA enzyme. PKA consensus site 
phospho-Serine primary antibody (Sigma®) was added to a 1% BSA in 1xTBST 
solution at a dilution of 1:1000. The slides were washed 3 times with 1x TBST for 
5 minutes before being added to a slide tray containing the primary solution and 
was then incubated overnight at 4oC on an orbital shaker. Again the slides were 
washed 3 times in 1xTBST for 5 minutes. Immunoglobin secondary antibody 
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conjugated with HRP (Sigma®) was added to a solution of 1% BSA powder in 
1xTBST at a dilution of 1:10,000. This secondary antibody solution was added to 
the slides and incubated for 1 hour at room temperature on an orbital shaker. 
Again, the membranes were washed 3 times in 1xTBST. For visualisation, 
Amersham Biosciences® chemiluminescence (ECL) western blotting kit was used 
as described in Section 2.2.3. 
2.3 PCR  
2.3.1 Extraction and Purification of RNA 
Due to the delicate nature of RNA samples, surfaces were cleaned with 10% 
chlorinated dH2O to remove any residual nucleic acids, RNase ZAP (Ambion ®) 
was then used to treat gloves, plastic and metal surfaces in order to deactivate 
environmental RNase enzymes. Where pipetting was required nuclease free 
filter-tips (Rannin®) were used and nuclease free water was purchased from 
Ambion ®. Prior to the harvesting of RNA, cells were seeded and grown over 48 
hours to 60% confluency in cell culture plates purchased from Corning. Cells 
were washed with 10mls warm PBS (137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 
2 mM KH2PO4) before direct lysis. RNA was extracted using RNeasy® Mini kit 
(Qiagen ®), according to the manufactures instructions.  
In brief, RLT buffer is added directly to cells for lysis, and homogenised by 
passing through a needle several times. 70% nuclease free ethanol is then added 
to the lysate. This mixture is applied to the RNeasy Mini spin column and 
centrifuged for 15s at 8000 x g. The ethanol creates conditions that cause 
selective binding of RNA to the RNeasy membrane and the flow through is 
discarded.  The membrane is washed twice with 500µl of RPE buffer and 
centrifuged for 15s at 8000 x g, removing any contaminants. The RNeasy Mini 
spin column is then placed into a new collection tube and 30-50µl of nuclease 
free water is applied to the column. This is centrifuged for 1 minute at 8000 x g 
eluting the RNA. All bind, wash, and elution steps were performed at room 
temperature to minimise salt precipitation. 
Total RNA sample was then subjected to DNase digestion to ensure no genomic 
DNA contamination using DNA-free™ Kit (Ambion®). Briefly, if the nucleic acid 
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concentrations were above 200μg nucleic acid per ml, 10μl of 10X DNase I Buffer 
and 2μl of rDNase I was added to 50μl of un-treated RNA sample. This was 
incubated at 37oC for 30 minutes. 10μl of re-suspended DNase inactivation 
reagent was then added to the sample and incubated at room temperature for 2 
minutes, mixing occasionally. The sample was centrifuge at 10,000 × g for 1.5 
minutes to pellet the DNase inactivation reagent and the supernatant, which 
contains the DNA free RNA, was carefully transferred into a fresh tube. 
2.3.2 Nucleic Acid Quantification 
Purified RNA was assessed for quantity and purity using the Nanodrop 
spectrophotometer from Thermofisher Scientific®. 2μl of sample was applied to 
the pedestal on the Nanodrop and RNA concentration was measured by 
absorbance at A260, where an absorbance of 1 is equal to 40µg/ml of RNA. 
Purity of the sample was assessed by the A260/A280 nm ratio method. A value of 
1.8-2.1 was considered optimal for protein/nucleic acid ratio. 
2.3.3 cDNA Synthesis 
First strand cDNA synthesis was carried out using Precision nanoScriptTM reverse 
transcription kit (Primerdesign®). In brief, 1μg of total RNA was added to 1µl of 
random primers and nucleotide free water, to make 10µl total volume. To 
anneal the RNA and primers the sample was heated to 65oC for 5 minutes in a 
thermostatically controlled heat block. After 5 minutes the samples was applied 
straight to ice. To amplify the sample and synthesise cDNA for the RNA, the 10µl 
sample was added to the following components: 
Component 1 reaction 
nanoScript 10X Buffer 2.0 μl 
dNTP mix 10mM of each 1.0 μl 
DTT 100mM 2.0 μl 
RNAse/DNAse free water 4.0 μl 
nanoScript enzyme 1.0 μl 
Final volume 10 μl 
 
After vortexing, samples were incubated at 25oC for 5 minutes. Amplification of 
cDNA was carried out at 55oC for 20 minutes followed by a heat inactivation step 
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at 75oC for 15 minutes. Subsequent dilutions of this preparation were performed 
in nuclease free water and stored at -20oC until further use. 
 
2.3.4 Quantitative Real Time PCR  
2.3.4.1 Primer Design (TaqMan ®)  
Primers were designed to amplify an 80-120 base region of target cDNA within 
the gene of interest (GOI). Melting temperature of probe sets were optimally 
between 55-60oC. Dual labelled probes with TAMRA and FAM labels, 3‘ and 5’ 
respectively, were used throughout this study. To ensure specificity all 
oligonucleotides were BLAST searched against the NCBI mRNA database. Where 
an oligonucleotide showed possible affinity (e.g. 70%) for an off target transcript 
cDNA it was ensured that cognate two oligonucleotides forming the probe-set 
showed no homology to the same off-target transcript.  
Primer and probe sets were synthesised by Eurofins MWG Operon® and purified 
using HPLC.  
2.3.4.2 RT-qPCR Protocol (Taqman®) 
RT-qPCR was carried out using Applied Biosystems® Prism® 7900HT cycler. 
Reactions were carried out in 15µl volumes with the following reaction mixture 
composition: 
Reagent  Final Concentration / Volume  
qRT-PCR Mastermix(Quanta®)  7.5μl  
Nuclease free dH20  2.2μl  
Forward Primer  500nM  
Reverse Primer  500nM  
Probe 500nM 
cDNA 5.0μl 
 
Reactions were carried out in 96-well optical plates from Applied Biosystems ® 
using the following reaction protocol: 
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Segment  Cycles  Temperature  Time  
1  1  60oC  30 Seconds  
 95oC 2 Minutes 
2  40  95oC  15 Seconds  
 60oC 1 Minute 
 
Where not indicated, Taqman® probe sets were used throughout this study. Auto 
adjustment of threshold level means that it was optimally placed within the 
exponential region of the RT-qPCR amplification curves. Cycle number (Ct) 
values were taken for each gene of interest (GOI) where the amplification 
curved intersected the threshold level. The Ct values were then used in the 
calculations described in 2.3.6. 
2.3.5 SybrGreen cDNA Synthesis 
For the experiments in which SYBR green is used, cDNA synthesis was carried out 
using RT2 First stand kit (Qiagen ®). In brief, 1μg of total RNA was added to 
nucleotide free water, to make 10µl total volume. To amplify the sample and 
synthesise cDNA for the RNA, the 10µl sample was added to the following 
components: 
Component 1 reaction 
5x Buffer BC3 4.0 μl 
Control P2 1.0 μl 
RE3 Reverse Transcriptase Mix 2.0 μl 
Nuclease free dH20 3.0 μl 
Final volume 10 μl 
 
After gentle mixing, amplification of cDNA was carried out at 42oC for 15 
minutes followed by a heat inactivation step at 95oC for 5 minutes. Subsequent 
dilutions of this preparation were performed in nuclease free water and stored 
at -20oC until further use. 
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2.3.5.1 RT-qPCR Protocol (SybrGreen ®) 
RT-qPCR was carried out using Applied Biosystems® Prism® 7900HT cycler. 
Reactions were carried out in 25µl volumes with the following reaction mixture 
composition: 
Reagent  Final Concentration / Volume  
2x RT2 STBR Green Mastermix 12.5μl  
Nuclease free dH20  11.5μl  
cDNA 1.0μl 
 
Reactions were carried out in 96-well optical plates from Applied Biosystems ® 
using the following reaction protocol: 
Segment  Cycles  Temperature  Time  
1  1  95oC  10 Minutes  
2 40 95oC 15 Seconds  
 60oC 1 Minute 
 
The Sybr green protocol was used in chapter 5. Auto adjustment of threshold 
level means that it was optimally placed within the exponential region of the 
RT-qPCR amplification curves. Cycle number (Ct) values were taken for each 
gene of interest (GOI) where the amplification curved intersected the threshold 
level. The Ct values were then used in the calculations described in 2.3.4.3. 
2.3.6 Calculating Relative Expression  
Transcript abundance was calculated via the comparative method, where GAPDH 
was used as internal housekeeping genes to which all genes of interest (GOI) 
were compared against.  
The following mathematical transformation was required to take into account 
the optimal doubling of PCR product with every round of the PCR.  
ΔCt= CtGOI- CtHKG 
 
To express GOI relative to HKG 
Relative quantification (RQ) = (2-ΔCt) 
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Error bars were calculated from the standard deviation of a triplicate. This 
triplicate repeats were combined with the variance from the HKG in order to 
properly account for Ct variance. The standard deviation, of the triplicate, of 
the HKG and the GOI were integrated together using this formulation. The 
integrated standard deviations were then used within the original expression 
calculation in order to calculate the maximum and minimum potential values, which 
when compared to the relative expression would give the error bars: 
Upper error bar  = RQ-(2-(xΔCt
 +σ
ΔCt
)) 
Lower error bar  = RQ-(2-(xΔCt
 -σ
ΔCt
)) 
Where: x= mean of samples 
  σ = Standard Deviation 
2.3.6.1 The ΔΔCt Method to Calculate Comparative Expression  
When comparing two or more samples to assess changes in expression, the ΔΔCt 
method was used to quantify the degree of differential regulation between the 
samples. The ΔΔCt calculation is based on the ΔCt method of calculating relative 
expression to the HKG, but expands this calculation to assess fold changes in 
relative expression between samples. This method requires the use of a control 
sample. All experimental samples are then compared to this control sample.  
 
ΔΔCt = xΔCtReference Sample – xΔCtExperimental Sample 
Relative quantification and error bars can be calculated as above substituting 
ΔCt for ΔΔCt.  
Using this method the reference sample will have a value of 1, and the 
experimental samples will be compared as a fold change in this value i.e. a 
doubling in expression will have a value of 2. 
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2.4 Harvesting of Plasmid DNA 
2.4.1 Transformation  
All transformations performed within this study were performed using competent 
DH5α E.coli cells from Invitrogen®. Competent cells were aliquoted into 30μl 
samples in pre-chilled Falcon polypropylene tubes. 10ng of plasmid DNA was 
gently added to 30μl of competent cells. The mixture was incubated on ice for 
15 minutes before a 90 second heat shock treatment at 45oC and a return to 
incubation on ice for 2 minutes. 300μl of SOC medium (Invitrogen®) was then 
added to the transformed cells which were then incubated for 1 hour at 37oC. 
150μl of the transformed cell suspension was then added to a 10cm3 agar plate 
containing 100μg/ml of the appropriate antibiotic. Plates were incubated for 16 
hours at 37oC before colonies were selected using a sterile loop and grown in 
10ml LB containing 100μl/ml of the antibiotic required for selection. Several 
colonies were selected per transformation. 10ml cultures were incubated in a 
shaking incubator for 16 hours before a glycerol stock was created for each 
colony (Section 2.4.2). 
2.4.2 Glycerol Stocks  
Glycerol stocks were created from bacterial cultures by mixing 500μl of the 
bacterial cell suspension with 500μl of sterile 40% glycerol in dH2O in a 2ml cryo-
tube. The mixtures were then snap-frozen on dry ice before transfer to -80oC 
storage. When creating new cultures from glycerol stocks, the glycerol was kept 
on dry ice at all times.  
A scrape from the top of the glycerol using a sterile 10μl pipette tip was then 
added to a 10ml sample of LB containing 100μg/ml of the required antibiotic, 
and incubated at 37oC for 16 hours in a shaking incubator.  
2.4.3 Plasmid DNA Purification  
400ml samples of LB containing 100μg/ml of the required antibiotic were 
inoculated with 10ml suspensions derived from glycerol stocks as described in 
2.4.2. The culture was then incubated at 37oC in a shaking incubator overnight. 
Samples were subsequently centrifuged at 6,000 x g for 15 minutes. The 
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resulting pellet was lysed, and plasmid DNA purified using the Qiagen® QIfilter 
Plasmid Maxiprep kit® as per the manufacturer’s instruction.  
2.5 CelluSpotTM Peptide Arrays 
VCaP cells were transfected with the specified constructs and cellular lysates 
were made after 48hrs. Slides were blocked in blocking buffer (50 mM HEPES, pH 
7.4, 150 mM NaCl, 0.05% TX100) and 5% BSA at room temperature for 2 hours. 
After, the kinase reaction was carried out by incubating the slides with kinase 
buffer (for Ser/Thr slides; 25 mM Tris-HCl (pH 7.5), 2 mM dithiothreitol (DTT), 1 
phosphoStop tablet/10ml, 10 mM MgCl2, 10µM ATP: For Tyr Slides; 60 mM HEPES, 
5 mM MgCl2, 2.5mM DTT, 5 mM MnCl2, 1 phosphoStop tablet/10ml, 10µM ATP) 
which was supplemented with 1% BSA, 400μCi/ml [γ-32P]ATP and 1 μg/ml of 
cellular lysate. Peptide array slides were incubated with 1ml of the kinase 
reaction mixture for 2 hours at room temperature. After incubation the slides 
were washed 2x 5 minutes with 1xTBST, followed by 3x 5 minutes in dH2O. The 
arrays were dried on blotting paper and dried slides were incubated with X-ray 
film at -80oC and developed via the x-omat 2000 processor. 
2.6 Pure Protein Kinase Assay 
1µg of pure AR protein (Millipore ®) was incubated with phosphorylation buffer 
(20 mM MgCl2 in TBS ([20 mM Tris-HCl pH 7.5, 150 mM NaCl]), 0.5mM DTT and 
1mM ATP and pre-heated to 30oC. After, 1µl of PKACβ (Millipore ®) was added 
along with 4µCi of (γ-32P)ATP (PerkinElmer ®) and incubated at 30oC for 30 
minutes. 5x SDS buffer was added to the solution and the samples were boiled 
for 5 minutes and then loaded directly to a well of a NuPAGE® 4-12% Bis-Tris 
polyacrylamide gel from Invitrogen® and immersed in Invitrogen® NuPAGE® MOPS 
SDS running buffer. 5µl of Bio-Rad® pre-stained molecular weight protein marker 
was also loaded to an appropriate well of the gel to allow the molecular weight 
of the proteins within the sample to be estimated. The gels were run at 160V for 
1 hour. The gel was then dried for 2 hours and overlaid with blue-light sensitive 
X-ray film (Kodak®) in a development box. This was place at -80oC for 2 weeks 
and then developed using the Kodak® X-Omat model 2000 processor. 
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2.7 Protein Isolation and Overlay 
R unit proteins were isolated from a donated mini-preparation (Dr Frank 
Christian). A scrape from the top of the glycerol using a sterile 10μl pipette tip 
was then added to a 1L sample of LB containing 100μg/ml of the ampicillin 
antibiotic, and incubated at 37oC for 16 hours in a shaking incubator. After, 15ml 
of this solution was added to a new 1L LB flask containing 100μg/ml of the 
ampicillin antibiotic and the OD of the sample was monitored until 0.6A was 
reached. 0.5mM IPTG was then added to the solution and incubated at 25oC 
overnight. Samples were spun at 5000g for 10 minutes, supernatant discarded 
and the pellet re-dissolved in 10ml of MOPS buffer (Sigma ®). To this solution, 
1mM PMSF, 1mg/ml lysozyme, 5mM DTT was added and supplemented with 
protease inhibitor tablet (Roche ®) and then incubated for 20 minutes at room 
temperature. After, the solution was soinicated for 10 minutes and centrifuged 
at 35000g for 1hr, after which the supernatant was removed. 400ul of cAMP 
agrose beads were washed in MOPS buffer and added to the supernatant. This 
solution was incubated on the ‘end over end’ for 2 hours. R units within the 
solution bind to the cAMP and thus binding to the beads. The solution was 
centrifuged at 500g for 3 minutes, the supernatant removed and the pellet 
washed with MOPS buffer. The pellet was then re-dissolved into 2.5ml 
(3.7mg/ml) of cGMP and incubated at 4oC on the ‘end over end’ for 1 hour. This 
excess amount of cGMP causes a displacement of the R units, resulting in the 
units moving into solution. After centrifugation at 500g for 3 minutes, the 
supernatant was added to washed salt columns. The R units were eluted by 
adding 3.5 ml of MOPS solution to the columns. This eluent was added to 
hydrated dialysis cassettes (pirece ®) and incubated in MOPS buffer overnight at 
4oC. The pure protein was then removed from the cassettes. A sample was taken 
from each protein to determining concentration and to test for purity using SDS-
PAGE and western blot procedure (2.2.2, 2.2.3). 
After isolation the R unit pure protein was utilised in peptide array overlay 
experiments. A peptide array containing immobilised peptide libraries that 
encompass the entire sequence of the AR were used. The array contains 25mer 
segments of the androgen receptor sequence, each shifted by 5 amino acids at a 
time (produced in house by Ruth McLeod). The array was blocked with 5% BSA in 
1xTBST for 1 hour at room temperature on an orbital shaker. The array was 
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overlaid with 1 µg/ml of protein diluted in 1% BSA in 1xTBST, overnight at 4oC. 
After the array was washed 3x in 1xTBST and antibody probed with the 
appropriate regulatory unit antibody (BD Biosciences ®) as outlined in the 
western blotting protocol (Section 2.2.3). 
2.8 PDE assay 
Eppendoff tubes were incubated on ice and protein lysates were added, with or 
without the PDE4 selective inhibitor, rolipram (4-[3-(Cyclopentyloxy)-4-
methoxyphenyl]-2-pyrrolidinone). If rolipram was to be used the protein lysate 
sample was adjusted to a volume of 40µl and 10µl of the inhibitor was added as 
a 10 x stock, if no inhibitor was used the protein sample was adjusted to a 
volume of 50µl by the addition of KHEM lysis buffer. Two control tubes 
containing only KHEM buffer were prepared for each substrate concentration. A 
2 x stock solution of substrate was prepared by adding 3‟,5‟-cyclic adenosine 
(Sigma®) from a stock solution to the desired concentration in buffer A (20 mM 
Tris-HCl, 10 mM MgCl2 pH 7.4). Tritiated cAMP (Sigma®) was then added at 
3µCi/ml and mixed thoroughly. 50 µl of substrate was added to the protein 
samples on ice and mixed briefly by flicking the tubes. The PDE reaction was 
started by incubating the samples at 30oC for 20 min. Here, 3H-cAMP is linearized 
to 3H-AMP via the activity of the PDE within the protein lysate sample. The 
reactions were stopped by transferring tubes immediately to a boiling water 
bath and incubating for 2 min. Samples were allowed to cool on ice and 25µl of 1 
mg/ml snake venom (Sigma®) (diluted 1:10 from a 10 mg/ml stock solution) was 
added and tubes were mixed thoroughly by flicking. Snake venom is added as it 
contains a 5’ nucleotidase which converts the 3H-5’AMP into 3H- adenosine, thus 
with a further 10 minutes incubation at 30oC allowed phosphate groups to be 
removed from AMP. Dowex ion exchange resin (Sigma®) prepared as a 1:1 
Dowex: water stock was thoroughly resuspended, diluted 1:2 with ethanol and 
0.4 ml added to each tube. This exchange resin allows the displacement of the 
3H from the 3H-adenosine within the sample. Tubes were vortexed to mix and 
incubated on ice for at least 15 minutes before a final vortex. The Dowex resin 
was pelleted by centrifugation at 13,000g at 4oC for 2 minutes and 150µl of the 
supernatant (which contains the 3H) was removed to an Eppendorf tube 
containing 1 ml of Ecoscint® scintillation fluid. 50 µl of substrate was also added 
to two tubes to enable calculation of specific PDE activities. Tubes were 
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vortexed thoroughly to mix and counted for 1 minute in a β scintillation counter 
calibrated for [3H]. 
 
2.9 Microscopy 
2.9.1 Confocal Microscopy 
Cells were plated onto collagen-coated glass coverslips in 6-well cell culture 
plates and treated as indicated. Cells were analysed 24-48 hours after plating. 
Cells were fixed with TBS (20mM Tris-Cl pH 7.6, 150mM, NaCl) containing 4% 
paraformaldehyde for 5 minutes and then permeabilised with 0.1% Triton X-100 
in TBS for 10 min at room temperature. The cells were blocked with 10% donkey 
serum and 2% BSA (w/v) in TBS by a blocking step comprising three 5-minute 
incubations. Primary antibodies were diluted to the required concentration in 
dilutant buffer (blocking buffer diluted 1:1 with TBS) and added to the cells for 
2 hours followed by three wash steps with TBS. This step was then repeated for 
the other primary antibody. After the second primary antibody incubation, cells 
were incubated with 1:400 diluted secondary antibodies Alexa Fluor 488 donkey 
anti-mouse IgG and Alexa Fluor 594 donkey anti-rabbit IgG (Molecular Probes) for 
1 hour. Following several extensive washes with TBS, the coverslips were 
mounted onto glass slides with ProLong Gold anti-fade reagent with 4’,6-
diamidino-2-phenylindole (DAPI) nuclear stain (Invitrogen®). Staining was 
visualized using a Zeiss Pascal laser-scanning confocal microscope (LSM) 510 
Meta and an Axiovert 100 microscope (Carl Zeiss, UK) equipped with an oil 
immersion objective (63x/1.4 NA plan apochromat lens). Images were captured 
and processed on Zeiss LSM Image Examiner. 
2.10 Statistical Analysis 
2.10.1  Students T-test  
Where data distribution followed a Gaussian distribution the student’s two-tailed 
t-test was used. Graphpad Prism® (Graphpad® software) was used for two-tailed 
student’s t-tests.  
Chapter 2: Materials and Methods 
64 
 
2.10.2 Mann-Whitely Test  
Where the distribution of data was observed to be skewed (as observed in box-
whisker plots) the Mann-Whitney statistical test was used. A P value of less than 
0.05 was considered to be statistically significant. 
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3 PKA Subunits and Prostate Cancer 
3.1 Introduction 
3.1.1 PKA subunits in hormone related cancers 
As discussed earlier, PKA is the classical effector molecule of the cAMP signalling 
cascade and, as such, has been implicated in a variety of diseases. This is 
particularly true in the context of carcinogenesis, where cAMP/PKA is known to 
modulate cellular growth and proliferation.  
In mammalian cells, two types of PKA are expressed, type I and type II, 
distinguishable by the expression of different R subunits. During development, 
differentiation and transformation, ratios of PKA I and PKA II can change 
dramatically and this change in expression has been shown to be a feature of 
carcinogenesis. Cho et al [50] showed that PKA-I was over expressed in various 
cancer cells. They went on to show that switching the dominant form of PKA 
(PKA-I) by over-expressing the RII subunit of PKA, resulted in reversion of the 
phenotype in these cells. This change in cancer phenotype depending on R unit 
expression has also been linked to hormone related cancers and is thought to be 
predictive of patient outcome. 
In breast cancer studies, significant increases in epithelial proliferation in breast 
tissue were correlated to a high RI expression. Furthermore, measurements of 
regulatory subunits in paired samples of normal and malignant tissues from the 
breasts of 13 women with breast cancer, displayed a higher expression of RI and 
RII PKA regulatory subunits in malignant tissues, with the degree of RI subunit 
overexpression greater than that of the RII subunit [160]. In addition, similar 
findings have been reported when comparing regulatory subunits in colorectal 
cancer [161]. In a study of breast cancer patients, it was shown that there were 
no significant relationships between R subunits and tumour histological grade 
and patient lymph node positivity, although levels of R subunits were higher in 
oestrogen receptor-negative tumours. However, in patients presenting with 
early-stage disease,  high levels of R unit expression could be associated with 
poor prognosis in terms of both disease recurrence and overall survival, and 
allowed the identification of a small subgroup of patients whose poor outlook 
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warranted implementation of aggressive systemic therapy [162]. Similar effects 
were shown in ovarian cancer cell lines. In a microarray study using  transfected 
OVCAR8 cells, RIα transfection resulted in changes in genes for pathways 
involved in cell growth, whereas the RIIβ up-regulation lead to changes in 
pathways involved in cellular differentiation [163].   
In light of these findings, it is worth noting that increased expression of the PKA 
catalytic unit, Cα, has not only been linked to an increase in PKA I expression, 
but has also shown to be expressed externally by a various cancer cell types. In 
breast cancer, hormone independent cancers display an increase in internal and 
external PKA activity compared to the hormone dependant cancer [50]. 
Furthermore, the increase activation of PKA in breast cancer has been linked to 
drug resistance, through the increased phosphorylation of the ER leading to 
reduced drug induced degradation [164]. Due to the discovery of increased 
extracellular PKA in cancer, it too has been suggested as a potential diagnostic 
marker for cancer [50].   
3.1.2 PKA subunits in Prostate Cancer 
Several reports have linked prostate cancer with the action of PKA. Reports 
suggest that PKA action can modulate androgen dependency of prostate cancer 
cells [165, 166]. There are numerous papers and reviews [166-169] that focus on 
the PKA isoform\subunit expression (i.e. PKA I vs II) within prostate cancer. It is 
clear that changes in PKA I affects cancer cell proliferation and that the 
increased expression of PKA II is found to correlate with less proliferative cells. 
This is due to the change in expression of the R subunits. Neary et al [167] 
showed that up-regulation of RIIβ in prostate cancer cells (PC3M) caused a 
decreased RIα expression and tumour growth. However, they also found that 
upon up-regulation of RIα, they could not induce the same repression of the RIIβ 
subunit but instead found that it induced increased protein levels of the 
catalytic unit. It was later found that cells overexpressing RIα can produce 
extracellular active catalytic subunit [170].  
A study conducted by Kvissel et al [169] found that RIIβ was up-regulated in 
clinical samples of prostate tissue vs normal, and this expression pattern was 
mirrored in the LNCaP cell line. Furthermore, they showed a significant increase 
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of PKACβ2 protein levels in clinical samples, and also an increase in both PKACβ2 
protein and mRNA in the LNCaP wild type (WT) cell line compared to LNCaP cells 
subjected to an androgen free environment. This was not evident in androgen 
insensitive cell lines and when cells were incubated in an anti-androgen 
environment.  
Following on from these studies, investigations into PKA expression in prostate 
cancer for diagnostic purposes have been undertaken. In 2008, the 
overexpression of RIα was examined as a biomarker for predicting the outcome 
of patients in clinical trials [171].  
Here, I endeavoured to profile the PKA expression patterns of frequently used 
prostate cancer cell lines in order to elucidate changes in the regulation of PKA 
signalling during prostate cancer progression.  
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3.2 Results 
3.2.1 RT-qPCR Profiling vs Western blotting 
In this study, I employed both western blotting and RT-qPCR techniques in order 
to construct a full profile of the PKA subunit expression in advancing prostate 
cancer. RT-qPCR and western blotting are 2 major biochemical techniques with 
their own drawbacks and positives. Both were used in this study, where possible, 
to gain insight into the full profile of PKA subunits in prostate cancer. 
3.2.1.1 Western blotting 
Western blotting is a standard biochemical technique, which involves antibody 
probing for the detection of specific proteins. This technique, compared to RT-
PCR, has the advantage of displaying the functional levels of a specific protein 
within a sample. The technique does not involve ‘sensitive’ RNA and one 
membrane can be used for concomitantly detecting different sized proteins 
[172]. However, the production and testing of antibody antisera for this 
technique can be time consuming and costly. To achieve the optimal sensitivity 
for each antibody, incubation conditions and working dilutions of the antibody 
have to be optimised before each experiment to reduce background signals. 
Western blotting also lacks the sensitivity of PCR techniques, especially with 
proteins of high or low-molecular mass.  
3.2.1.2 Antibody selection 
Antibody selection is very important in western blot analysis. The sensitivity of 
the antibody for its epitope can severely affect the sensitivity of the western 
blot procedure, as promiscuity of the antibody can markedly increase the false 
positives within the experiment. Thus, all antibodies used in this procedure 
should be fully tested before use in the study. 
For this screening, PKA regulatory unit isoform antibodies (RIα, RIIβ, RIIα) were 
selected from BD bio laboratory® as they are readily available and conditions 
have been optimised previously within our laboratory (as well as [169, 173]). All 
these antibodies are mono-clonal and so have increased isotope specificity, 
reducing interaction within isoforms. RIβ has been reported not to be expressed 
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in LNCaP cells [169], and accordingly, we tested RIβ antibodies and detected no 
protein expression in the cell lines used. PKA catalytic units were detected with 
a ‘pan’ monoclonal antibody. This was selected after varying results with 
isoform specific antibodies. The antibody is also from BD Biolaboratories and has 
been previously used in the Baillie group. 
3.2.1.3 RT-qPCR 
Reverse transcription polymerase chain reaction (RT-PCR) is a molecular biology 
technique for amplifying a specific piece of mRNA. The mRNA molecule is first 
reverse transcribed into complementary DNA (cDNA), followed by amplification 
of the resulting DNA by polymerase chain reaction (PCR). RT-qPCR uses primers 
to amplify a short segment of cDNA usually approximately 100bp in length. These 
primers are specific to the transcript of interest and it is important that they are 
validated for ‘off target’ binding affinity to reduce non-specific amplifications. 
RT-PCR is widely and increasingly used because of its high sensitivity, good 
reproducibility, and wide dynamic quantification range [174]. While it is 
generally accepted that RNA levels correlate to protein expression, it is shown 
that is not always the case. Post-transcriptional regulation of proteins can cause 
differences between RNA and protein concentration [175, 176]. 
3.2.1.4 TaqMan Probes 
Taqman® probe-sets were used during this study due to previous testing and 
validation within the Baillie group. These probe sets are composed of forward 
and reverse primers and a probe that is targeted toward unique sequence 
between the primer binding sites. The probe is an oligonucleotide that is 
labelled with a fluorophore (FAM) and a quencher molecule (TAMRA). When 
bound to the probe, emission from the fluorophore is intercepted by the 
quencher due to the close proximity. However, during PCR amplification the 
probe is broken down by DNA polymerase activity. This separates the 
fluorophore and quencher, leading to an increase in fluorescence level within 
the reaction [177]. As the probe should only anneal and be broken down at a 
specific location, no melting point analysis is required, as any off target binding 
will not be broken down in the amplification process and thus not affect the 
overall change in fluorescence in the PCR reaction.  
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3.2.1.5 Use of Relative Quantification 
There is two major types of quantification for RT-PCR; absolute and relative 
[174].  
Absolute quantification involves the use of calibration curves. In this method, 
PCR amplifications are compared to an established standard curve. While these 
curves are highly reproducible and generate highly specific and sensitive data, 
the calibration curve has to be thoroughly validated, as this technique relies 
entirely on the accuracy of the standard curve. Design and production of this 
standard curve can be highly time consuming and problematic. 
Relative quantification determines the change of mRNA levels of a gene of 
interest and expresses it relative to the levels of an internal control gene. 
Housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) are the most often used internal control genes. This eludes the issues 
of absolute quantification as a standard curve is not required. However, in this 
model, gene of interest expression is normalised by a non-regulated reference 
gene, whose mRNA expression could vary between treatments or individuals. To 
try and circumvent this more than one reference gene is often selected.  
To profile the expression levels of the PKA isoforms by RT-qPCR in this study, we 
have selected to use the TaqMan® approach, coupled with a relative 
quantification method, when compared to GAPDH. As discussed, Taqman probes 
add specificity unavailable in other approaches. Plus use of relative 
quantification means that no standard curve set-up or validation is needed and it 
also decreases pipetting errors associated with this method. 
3.2.1.6 Housekeeping Gene Selection 
GAPDH, was selected as the reference gene used in this study. GAPDH is an 
enzyme that catalyses glyceraldehydes-3-phosphate to D-glycerate1,3-
bisphosphate in the sixth step of the glycolysis pathway. Due to its function it is 
often ubiquitously and stably expressed in most tissues. It is also resistant to 
most cellular manipulations that can cause gene expression changes, but gene 
expression levels have been shown to change between tissue types.  
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Mori et al [178], using prostate cancer and normal tissue from patients, 
investigated the usefulness of beta-actin and GAPDH as housekeeping genes. 
Using AR as the variable gene, expression levels normalised using beta-actin 
significantly correlated with the expression of GAPDH. This suggests that GAPDH 
is a suitable reference gene in prostate cancer studies. Furthermore, work 
carried out by our laboratory on the cell lines used in this study, examined the 
expression level of GAPDH in relation to 18s rRNA (Figure 3.1). 18s rRNA is a part 
of ribosomal RNA and is a component of the small ribosomal subunit. It has been 
often described as a reliable reference gene in PCR. This work showed no 
significant changes in expression between samples of each of the cell line. In 
addition, transcript variance was tested by comparison of the expression of 
genes that vary between cell line samples and each housekeeping gene. In 
plotting this change, they observed a strong correlation between the two 
housekeeping genes suggesting that they didn’t undergo differential regulation 
in the prostate cancer cell lines (Figure 3.2).  
 
Figure 3.1 GAPDH and 18S rRNA expression in prostate cancer samples.  
Taken from [179] 
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Figure 3.2 PDE4D7 was assessed against GAPDH and 18SrRNA.  
An R2 value of 0.94 indicates a good positive correlation using a straight line trend line. 
Taken from [179] 
3.2.2 Selection of Cell Lines 
Studying the molecular changes in cancer and its progression is paramount to the 
identification of novel avenues for the development of effective therapies. 
While animal models can be beneficial to this cause, they have significant 
drawbacks, such as ethical concerns and housing costs. To my knowledge there is 
no animal model that mimics all the aspects of human prostate cancer. To 
overcome this, significant effort has been put into developing cell culture 
models that represent various cancer stages. Cell lines selected in this study are 
well established lines for studying prostate cancer and its progression [180, 181]. 
I have selected 2 well-characterised androgen sensitive (AS) and androgen 
insensitive (AI) cell lines for western blot analysis and 3 of each for RT-qPCR 
analysis, to try and highlight difference in PKA isoform expression as PC 
progresses towards the AI phenotype. A cell line predictive of ‘normal’ epithelial 
prostate cells was also included in the final part of the screening to establish 
changes between “normal” prostate signalling and that during prostate 
carcinogenesis.  
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3.2.2.1 AS cell lines 
AS cell lines selected were VCaP, LNCaP and DUCaP. VCaPs (along with DUCaP) is 
the newest of the selected cell lines and was isolated in 2001 from a 60 year old 
male. It was isolated from a metastatic lesion from the lumbar vertebral region 
of the patient at post-mortem. This cell line expresses wild type AR, PSA, and 
PAP; characteristics usual of clinical prostate carcinoma [182].  
LNCaP cell line was isolated in 1977 from a needle biopsy of a lymph node 
metastasis in a 50 year old male. It has been used extensively used as a AS 
model in prostate cancer, and it can also be grown in the absence of androgens 
to generate an AI type cell line and also to study prostate cancer progression. 
This has led to the large number of sub-lines described in the literature. These 
cells express PSA and AR, however a mutation has been shown in the AR, which 
results in somewhat promiscuous response to steroids [180, 183].  
DUCaPs were isolated from the same patient as the VCaP cell line at autopsy 
from a metastatic lesion in the dura matter. The tissue was first xenographed 
into SCID mice and later harvested and plated to derive this cell line. These cells 
express wild type AR, PSA and PAP [180, 184]. 
3.2.2.2 AI cell lines 
AI cell lines selected were DU145, PC3 (and PC133). DU145 cells were the first 
cell line established in tissue culture. They were isolated at autopsy from a 
metastatic tumour from the brain of a 69 year old male. This cell line is 
described as moderately differentiated and fails to express AR and PSA with low 
levels of PAP. It is also negative for any neuroendocrine markers [180]. 
PC3 is classified as one of the ‘classical’ prostate cancer cell lines and as such is 
one of the mostly used models for AI prostate cancer. It is classified as a poorly-
differentiated cancer cell line and was isolated in 1979 from a 62 year old male 
lumbar vertebral metastasis. It does not express AR or PSA [180, 185]. 
PC133 is an AI xenograft that was isolated from bone metastasis in 1981. It 
doesn’t express AR or PSA and was a kind gift from Dr. Guido Jenster of the 
Erasmus Medical Centre in Rotterdam. 
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3.2.2.3 Normal prostate epithelial 
PNT1a cells are immortalised normal prostatic epithelial cells isolated in 1991 
[186].  They have been shown to lose AR expression after 3 weeks in culture and 
the reduced expression of PAP and PSA is correlated with this loss [187].  
3.2.3 Expression Profile of PKA Subunits in Prostate Cancer Cell 
Lines 
Protein and mRNA expression profiles of PKA isoforms are presented for each cell 
line in sections 3.2.3.1 and 3.2.3.2. The samples have been split into AS and AI, 
depending on their androgen sensitivity, to correlate with the differential 
analysis of the PKA isoforms in prostate cancer progression conducted later in 
this study. For the protein expression analysis RIβ was not profiled due to the 
inability to pick up the protein with the antibodies tested, and previous 
literature stating that RIβ is not present in LNCaP prostate cancer cells. In 
addition, the expression of all the PKAC isoforms with a molecular weight of 
40kDa (Cα, Cβ1/3/4) were presented together. The protein expression of PKACβ2 
(47kDa) was profiled separately. For mRNA profiles, RIα profile is not presented 
owing to validation problems with the RIα TaqMan® probe set. PKAC isoforms are 
split into Cα and Cβ transcripts. 
3.2.3.1 Western Blotting 
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Figure 3.3 PKA isoform protein expression profile of AS LNCaP cell line 
 
 
Figure 3.4 PKA isoform protein expression profile of AS VCaP cell line 
 
 AI 3.2.3.1.2
 
Figure 3.5 PKA isoform protein expression profile of AI DU145 cell line 
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Figure 3.6 PKA isoform protein expression profile of AI PC3 cell line 
 
3.2.3.2 RT-qPCR 
 AS 3.2.3.2.1
 
Figure 3.7 PKA isoform mRNA expression profile of AS LNCaP cell line 
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Figure 3.8 PKA isoform mRNA expression profile of AS VCaP cell line 
 
 
Figure 3.9 PKA isoform mRNA expression profile of AS DUCaP cell line 
 
 AI 3.2.3.2.2
 
Figure 3.10 PKA isoform mRNA expression profile of AI DU145 cell line 
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Figure 3.11 PKA isoform mRNA expression profile of AI PC3 cell line 
 
 
Figure 3.12 PKA isoform mRNA expression profile of AI PC133 xenograph 
 
3.2.4 PKA subunit Expression in Prostate Cancer Samples 
By using RT-qPCR and western blot analysis I have investigated the expression of 
PKA isoforms in prostate cancer cell lines. I found that all PKA isoforms are 
expressed at mRNA level (with the exception of RIα) including RIβ. However, 
upon western blot analysis, the detection of all isoforms but RIβ protein could be 
detected. This correlates with Kvissel et al who indicated that RIβ is not 
expressed in LNCaP prostate cancer cells [169].  
To assess the expression of these PKA isoforms during the transition of prostate 
cancer the sample set was reorganised into AS and AI groupings (Figure 3.13).  
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Figure 3.13 PKA expression of AS vs AI cell lines 
A) Graph shows western blot analysis of AS vs AI. Blots are representative of PKA 
expression in prostate cancer cell lines B) Graph shows RT-qPCR analysis of AS vs AI  
B) 
A) 
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3.2.4.1 Regulatory Subunits 
The change in expression of the regulatory (R) subunits of PKA has been 
described in many cancers and also studied in relation of prostate cancer. As 
discussed, the change in R unit composition of the holoenzyme can determine 
the balance between growth and proliferation and therefore can often change in 
cancer progression. In relation to cancer proliferation, it has been reported that 
PKA-I is over expressed in growth-stimulated cells, as well as in normal cells in 
response to physiological stimulation. Conversely, PKA-II is found in normal non-
proliferation tissues and in growth arrested cells. 
Using student T-test statistics, I showed that PKA RIIβ is significantly down-
regulated in RT-qPCR (P=0.0001) (Figure 3.13B) and western blot analysis (Figure 
3.13A)(P=0.0004) in AI cell lines compared to AS. In addition, using western blot 
analysis I found RIα (P=0.0013) to be significantly up-regulated (Figure 3.13A) 
and mRNA showed that PKA RIβ is significantly decreased (P=0.0066) (Figure 
3.13B). This data correlates with other studies into PKA R unit expression within 
prostate cancer which report an increase in PKA I in prostate tumours. There is 
also evidence that the PKA I and II isoforms exert different functions in prostate 
cancer. These studies have reported that PKA RIα is over expressed in prostate 
cancer and is linked to poor prognosis, and the PKA RII isoform is preferentially 
found in differentiated tissues. I have shown that RIα and RIIβ are regulated 
inversely proportionally with progression from AS to AI prostate cancer 
suggesting that differently expressed isoforms are employed at different stages 
of PC progression. 
In RT-qPCR studies, I showed that RIβ is also significantly decreased in 
expression from AS to AI. However this finding cannot be correlated to protein 
levels. Additionally, Kvissel et al also found no protein expression of RIβ in LNCaP 
cell lines, agreeing with my western blot data. RT-qPCR is more sensitive to low 
level transcription than western blot analysis and thus could show levels of RIβ 
that cannot be isolated via western blotting. However, as post-transcriptional 
regulation of proteins can cause differences between RNA and protein 
concentration [175, 176] and as other literature agrees with my observation that 
RIβ is not present at protein level, the function of this change in RIβ regulation 
in prostate cancer may be hard to characterise into a functional output. 
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3.2.4.2 Catalytic Subunits 
The change in catalytic subunit regulation in prostate cancer has also been 
investigated by Kvissel et al [169]. They investigated the change in PKAC 
expression in LNCaP incubated in CSS medium to induce differentiation. In 
addition, they have shown expression in AI cell lines, DU145 and PC3. Here, they 
found that PKACβ2 isoform was down-regulated into prostate cancer 
differentiation and further decreased in the AI cell lines. My data broadly agrees 
with these findings, as using student T-test statistical analysis showed PKACβ/β2 
are significantly down-regulated in RT-qPCR (P=0.0001) and western blot analysis 
(0.0001) in AI cell lines compared to AS. In western blot analysis PKACβ2 (47kDa) 
shows a statistical decrease in expression while the expression of all other 
isoforms do not vary, thus in RT-qPCR analysis, where all Cβ isoforms were 
examined together, it could be suggested that the change in expression here is 
also due to PKACβ2. However, Kvissel et al has suggested a decrease in Cβ3/4 
isoforms via western blot analysis which were not confirmed by my study.  
  RT-qPCR Western Blot analysis 
PKA 
isoform 
Observed 
change in 
regulation 
T-Test 
P-Value 
Mann-
Whitney 
P-Value 
Significant 
difference 
(P<0.05) 
T-Test 
P-Value 
Mann-
Whitney 
P-Value 
Significant 
difference 
(P<0.05) 
PKA RIα Increase - - - 0.0013 0.0087 Yes 
PKA RIβ Decrease 0.0066 0.0097 Yes - - - 
PKA RIIα None 0.2207 0.3508 No 0.6066 0.7273 No 
PKA RIIβ Decrease 0.0001 0.0001 Yes 0.0004 0.0022 Yes 
PKA Cα None 0.1004 0.1600 No 0.2276 0.3680 No 
PKA 
Cβ/Cβ2 
Decrease 0.0001 0.0001 Yes 0.0001 0.0022 Yes 
Table 3.1 Showing the regulation status of the PKA isoforms from AS to AI phenotype. 
 
Box-and whisker plots are used in statistics to graphically display differences 
between the populations, indicating the spread or skewness of the data without 
making assumptions about the distribution. The data regarding all AS and AI 
samples, in RT-qPCR and western blot analysis were plotted as box and whisker 
plots in Figures 3.14/3.15. In brief, the upper box represents the third quartile. 
The median is represented by the intersection of the upper and lower box and is 
known as the second quartile. The lower box represents the first quartile. The 
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upper and lower ‘whiskers’ represents the minimum (lower) or maximum (upper) 
of all the data.  
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Figure 3.14 Box and whisker plot showing analysis of the PKA isoform protein expression in 
AS and AI prostate cancer samples  
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Figure 3.15 Box and whisker plot showing analysis of PKA isoform mRNA expression in AS 
and AI prostate cancer samples 
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As some of the data sets do not follow Gaussian distribution, the Mann-Whitney 
statistical test was used alongside the student t-test to give two tailed p-values 
(Table 3.1). This shows that the significance of the PKA isoforms differential 
regulation is not affected by the distribution or spread of the data. 
3.2.5 Regulation change of PKA subunits towards androgen 
independence 
I conclude from the data that RIIβ and RIα are expressed in an inversely 
proportional manner in prostate cancer and Cβ/Cβ2 is downregulated in AI cell 
lines compared to AS. In cancer RIIβ has been linked to neuroendocrine 
differentiation, and PKACβ2 has been recently shown to be downregulated in 
differentiating cells [169].  
To explore whether these signalling molecules also change in regulation under 
an androgen ablated environment and thus are important in the ‘switch’ from AS 
to more aggressive AI prostate cancer, LNCaP cells were used as a model system 
to study prostate cancer progression (Figure 3.16). Androgen ablation is 
conducted by charcoal stripping of the fetal calf serum (FCS) in the cellular 
media, which pushes LNCaP cells to trans-differentiate into NE-like cells. 
Morphological characteristics like neurite extensions and soma compaction 
appear after 3–5 days in charcoal-stripped FCS (CSS) as well as induced 
expression of NE-markers like neurotensin and neuron-specific enolase [4]. 
LNCaP cells were incubated in CSS medium for 2 months or differentiated into AI 
cells for 4 months. LNCaPs incubated in FCS and CSS+ 10nM DHT were used as 
controls. Full differentiation of the AI cell line was assessed via RT-qPCR of 
neurone specific enolase and chromogranin A (carried out by Dr. David 
Henderson) 
Results are expressed in relation to LNCaP grown in FCS medium. PKACβ 
decreases 5 fold in CSS treated cells compared to FCS (Figure 3.16). However, 
cells incubated in CSS medium containing DHT, display a similar change in mRNA 
levels compared to CSS only, suggesting the effect may not be due to androgen 
ablation. However the decrease in Cβ correlates with the data from Kvissel’s 
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study, which showed a 70% decrease in expression of Cβ2 when comparing CCS 
incubated cells with FSC. In addition, they also showed restoration of this 
decrease after treatment with R1881 (a synthetic androgen). Interestingly, I 
have also shown a decrease in mRNA levels in LNCaP AI cells when compared to 
FCS-WT LNCaP, which correlates with the decrease in expression shown with 
other AI cell lines. PKARIIβ has similar mRNA levels in CSS and CSS+DHT treated 
cells as FCS WT LNCaPs (Figure 3.16).  However, this has a high-variability within 
the data and so no conclusions can be drawn. Furthermore, RIIβ expression is 
decreased by 16 fold in AI LNCaP cells compared to FSC WT LNCaPs (Figure 
3.16).  
 
Figure 3.16 Androgen dependent regulation of PKA RIIβ and Cβ in CSS incubated LNCaP 
cells. 
LNCaP cells were incubated in a) FCS medium b) CSS medium for approximately 4 months 
until AI proliferation occurred c) CSS medium for 2 months of differentiation and d) CSS 
medium + 10nM DHT for 2 months. RNA was isolated and RT-qPCR was carried out as 
outlined in the ‘material and methods’ section. Results are relatively expressed to GAPDH. 
3.2.6 PKA Subunit Expression in a Normal Prostate Epithelial Cell 
Line  
Thus far, I have shown a decrease in Cβ and RIIβ from AS to AI prostate cancer. 
However, I have not yet addressed the expression of these two isoforms in a 
normal prostatic cell line. Kvissel showed the expression of Cβ isoforms within 
cancer specimens (isolated from localised prostate adenocarcinomas) as 
compared to normal tissue from radical prostatectomies, showing an up-
regulation of PKACβ2 in the cancerous tissue. However, this study failed to 
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elucidate the PKA isoform expression within the differing cell types. In 
particular, PKA expression within the prostate epithelium is of interest as 95 % of 
all prostate cancer cases arise from this cell type.  In addition, while the cellular 
ratio of C subunits to R subunits is fairly constant around 1:1, PKA RI and RII 
subunits show considerable differences in expression between tissues. In order 
to fill this obvious gap in the experimental protocol, we examined the expression 
of PKA RIIβ and Cβ in a normal epithelial cell line, PNT1a cells, using RT-qPCR. 
Here (Figure 3.17), RIIβ expression is significantly down regulated compared to 
AS cells(P=0.0016), but exhibits simiar levels of expression to the AI cell lines 
used in this study. Furthermore, PKACβ was signifacntly down regulated 
compared to both AS and AI cell lines (P=0.0001).  
 
Figure 3.17 PKA isoform mRNA expression profile of PNT1a normal epithelial prostate cell 
line 
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3.3 Discussion 
One aim of my PhD thesis was to discover putative new biomarkers for advancing 
prostate cancer. Within this study, I have concentrated on the regulation of the 
PKA isoforms in prostate cancer and how they change as the cancer develops and 
progresses. These studies were done on the back of a large amount of evidence 
that points to cAMP signalling as a key factor in advancing prostate cancer. In 
several studies, the effects of the differential regulation of the PKA isoforms has 
been discussed [17, 50, 167, 169, 171, 173, 188-191]. 
Composition of the PKA holoenzyme has led to two isozyme descriptions of PKA, 
I and II. As discussed, these R units have high homology in cAMP-binding 
domains, but vary in structure in the D/D and linker domains. These sequence 
diversions are yet to be fully understood, however major differences in 
subcellular localisation and physiological differences have been shown between 
the R-unit isoforms [19, 192-195]. These changes in physiological function have 
also been linked to cancer and cancer progression. Expression of the RI and RII 
isoforms have shown to be high in malignant breast tissues. In addition, the ratio 
of RI/RII seems to favour RI expression, and this is correlated in many cancers 
including colorectal and ovarian [160, 161, 163]. RIα expression has been 
extensively studied in the context of cancer, including prostate cancer. This 
isoform’s constitutive overexpression is associated with increased proliferative 
cancers and poor prognosis in patients. PKA I expression has also been linked to 
hormone levels. PKA I activity was shown to decrease by 50% in ventral prostate 
three days post-castration, whereas PKA II levels did not change, suggesting a 
potential functional link between the PKA I protein levels and hormone 
production  [50, 196]. Additionally, PKARIα has been studied in the context of 
prostate cancer progression as a biomarker and also as a potential cancer 
treatment, e.g.PKA isoform knockdown combined with radiotherapy as a 
treatment for advanced cancer [171, 191].  
Using western blotting and RT-qPCR techniques, I have shown that RIIβ and RIα 
are inversely regulated in prostate cancer cells. This correlates with the R unit 
expression in other cancers [50, 160] and in a study by Kvissel et al [169]. In this 
study Kvissel and co-workers showed that PKA RIIβ was upregulated in LNCaP 
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cells compared to AI cell lines DU145 and PC3. In addition they showed that RIIβ 
decreased in regulation in patient samples compared to normal tissue. 
In the early stages of prostate cancer, the ademocarcinoma is very slow growing, 
contrasting with more advanced cancers. RIIβ (or expression of PKA-II) is found in 
nonproliferating tissues and growth arrested cells. Moreover, over expression of 
RIIβ in RI dominant cells, switches the dominant isoform leading to growth 
arrest, apoptosis and changes in cancer cell morphology. In my study, I have 
shown an overexpression of RIIβ in AS cells compared to AI [50, 167]. AS cancers 
have also been described as slower growing and less aggressive than their AI 
counterpart, suggesting that RIIβ overexpression could be the mechanism behind 
this phenotype.  
However, RIIβ is shown to be mostly associated with differentiating cells [17, 
196]. Differentiation has also been proposed to nucleate the formation of AI 
growth and provide paracrine proliferative signals which signal the advancement 
of prostate cancer. NE differentiation is also an important factor in PC 
progression [197]. Changes linked neuroendocrine differentiation have been 
associated with the transition into the later, more aggressive stage of prostate 
cancer [198]. Neuroendocrine cells are found in the lumen of the healthy 
prostate and secrete a variety of signalling molecules [199]. In cancer, tumours 
have been shown to form around neuroendocrine cells. Furthermore, secretion 
of mitogenic peptides from neuroendocrine cells is thought to contribute to 
cellular proliferation and tumour growth [200]. It is important to note however 
that epithelial cells that undergo neuroendocrine differentiation in cancer still 
retain epithelial markers, and so are potentially hybrid of neuroendocrine and 
epithelial signalling [201]. 
 
Increased intracellular cAMP concentrations can lead to neuroendocrine 
differentiation in some AS prostate cancer models [165]. I have shown that RIIβ 
is significantly up-regulated in LNCaP and VCaP AS cells when compared with AI 
cells. The RIIβ PKA isoform is associated with differentiating cells, and thus could 
be the isoform that initiates this change. This correlates with the study by 
Kvissel which shows overexpression in LNCaPs cells compared to AI. In addition, 
they demonstrate increased RIIβ levels during the differentiation process. I have 
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shown that while RIIβ levels are the same in LNCaP WT cells as CSS treated cells 
during the LNCaP differentiation process. However, I also show that when cells 
are no longer under androgenic control (AI), RIIβ levels diminish. This suggests 
that RIIβ overexpression in AS stage cancers could drive neuroendocrine 
differentiation through AR dependant mechanisms. I have also shown a decrease 
in RIIβ in the normal epithelial prostate cell line. These cells don’t, however, 
express the androgen receptor as it is lost during the immortalisation process. 
Thus I cannot conclude if this decrease of RIIβ is due to normally lower 
expression in the prostate or, as I hypothesise, that RIIβ is down-regulated due 
to the loss of AR. 
In addition to significant RIIβ downregultion, PKACβ is also downregulated in AI 
cells compared to AS. PKA catalytic subunit expression has also been discussed in 
the context of cancer, but not as extensively [50, 169, 170]. PKAC was shown by 
Cvijic et al [170] to be present as a free extracellular kinase in the growth media 
of cultured cancer cells, including prostate cancer. This finding was also linked 
to an increase in PKA activity of plasma samples of prostate cancer patients. 
This increase in extracellular PKA activity has been shown to be inversely 
proportional to hormone-dependency in breast cancer cells e.g. hormone 
independent cancers have an increase in extracellular activity [50].  
Conversely, Kvissel et al [169] showed an increase expression of PKACβ2 isoform 
overexpression in AS LNCaP cells. This isoform decreases quickly upon cellular 
incubation in androgen stripped media (shown by Kvissel and myself (Figure 
3.16)) and is significantly down regulated in AI cell lines (Figure 3.13/3.16 and 
[169]). In addition, Kvissel showed an increase in tumour cells compared to 
normal prostate tissue. This data suggest that regulation of PKACβ could be 
androgen sensitive and that PKACβ is correlated with androgen activity in 
androgen sensitive cancer cells, suggesting that this isoform is potentially 
important in androgen dependant androgen receptor activity in malignant cells.  
In the context of considering PKA RIIβ and Cβ isoforms as biomarkers, we have to 
address how advantageous these markers would be in prostate cancer 
diagnostics. While there is no doubt about the change in expression of these 
isoforms between AS and AI prostate cancer, at present, intracellular proteins or 
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mRNA can only be measured in cases where a prostate biopsy has been taken. If 
I consider this, would there be an advantage of using these isoforms as 
biomarkers if a biopsy is required, as prostate cancer assessments from biopsy 
(or ultrasound) are very accurate in determining the stage and prognosis of the 
cancer. However, if these problems can be overcome, the use of PKA isoforms as 
biomarkers for advancing prostate cancer may be incredibly useful. In addition, 
it may also decrease the reliability on tests currently based on PSA, the use of 
these isoforms as biomarkers may also allow the identity of the androgen 
sensitivity of the tumour and its selectivity for AI growth. 
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4 Study of putative PKA phosphorylation sites on 
the Androgen Receptor 
4.1 Introduction 
4.1.1 AR and posttranslational modifications 
Like all steroid hormone receptors, activation of the androgen receptor is 
triggered by the binding of a steroid hormone, in this case, testosterone and its 
derivatives. In recent years, another level of regulation has come to the fore in 
the form of a number of posttranslational modifications of the AR. As these 
modifications are discovered and as their roles emerge, they have been shown to 
contribute to the regulation of AR activity, stability and structure [75, 202]. 
With such effects on the AR, it is thought that these modifications are important 
in normal prostate function and also in prostatic diseases such as cancer. To 
date there are approximately 23 sites of direct posttranslational modification of 
the AR via acetylation, methylation, SUMOylation, ubiquitination and 
phosphorylation [75, 203-206]. 
4.1.2 AR as a phospho-protein 
16 of the 23 modification sites have been shown to be phosphorylation sites (see 
table 1) [75, 81]. Other steroid hormone receptors have also been shown to be 
extensively phosphorylated, such as the progesterone, oestrogen and 
glucocorticoid receptors [207-209]. Several basal phosphorylation sites have 
been identified on the progesterone receptor, with many of these increasing in 
phosphorylation levels upon ligand binding. Moreover, sites have also been 
identified that even with ligand binding, have a delay in becoming 
phosphorylated [205, 210]. In the case of the glucocorticoid receptor, 
phosphorylation has been shown to have a prominent role in the receptor 
turnover [211]  and with the oestrogen receptor, phosphorylation at Ser167 helps 
regulate the transcriptional activity of the AF-1 region of the receptor. 
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  Summary of AR phosphorylation sites. 
Phosphorylation Site Regulation Function 
Amino 
acid ID 
DHT 
Required Kinases Transcription Stability Localisation Growth 
S16 MS Ab MA Yes - - - - - 
S81 MS Ab MA Yes 
CDK9, 
CDK1 Yes - - Yes 
S94 MS Ab MA No - - - - - 
S213 - Ab MA Yes Akt Yes - - - 
S256 MS Ab MA Yes - - - - - 
Y267 - - MA - Ack Yes - - Yes 
T282 - - MA No Aurora-A Yes - - - 
S293 - - MA No Aurora-A Yes - - - 
S308 MS Ab MA Yes CDK11 Yes - - - 
Y363 - - MA - Ack Yes - - Yes 
S424 MS Ab MA Yes - - - - - 
S515 - - MA - 
MAPK, 
CDK7 Yes Yes - - 
Y534 MS Ab MA Yes Src Yes Yes - Yes 
S578 - Ab MA - PKC Yes - Yes - 
S650 MS Ab MA Yes p38, JNK Yes - Yes - 
S791 - - MA - Akt Yes - - - 
 
Table 4.1 Summary of AR phosphorylation sites 
Adapted from [75] 
The 16 phosphorylation sites on the AR have been identified by mutational 
analysis, with some having additional verification via MS or western blot 
analysis. In several of the mass spectrophormetry (MS) experiments, 
phosphorylation of the androgen receptor was shown to increase upon ligand 
binding [202, 205]. However, several different kinase sites have been identified 
as the reason behind the increase in AR phosphorylation and no clear functional 
output has yet been uncovered [202, 205, 212]. Whats more, the accuracy of 
mutagenesis analysis (MA) has been called into question, with the suggestion 
that mutagenesis can alter the phosphorylation events on sites distinct from the 
ones mutated [205].  
13 of these 16 sites are located in the N-terminal of the protein, which contains 
the ligand independent activation domain (AF-1) [213]. This domain is 
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responsible for target gene transactivation independent of a ligand [70, 202] and 
this phenomenon has been suggested to be important in unpinning the 
understanding of androgen independent cancers. However 5 of the 13 sites in 
the N-terminal have been shown to need ligand binding for induction of 
phosphorylation [75]. The remaining 3 known phosphorylation sites are located 
within the other major domains of the receptor. pS578 is located within the 
DBD, pS650 within the hinge region of the receptor and pS791 within the LBD 
[75, 81, 214].  
4.1.3 The effect of FSK treatment on AR 
Several reports have shown that adenylate cyclase activators (like FSK) can 
activate PKA and serve to increase the phosphorylation of the AR causing its 
activation. It is known that this activation can occur with or without ligand 
binding, depending on PKA signalling effects. For instance Gioeli et al [205] 
reported that treatment of LNCaP cells with FSK, increased the overall 
phosphorylation of the AR, and Sadar et al [76] showed that treatment with FSK 
increased PSA mRNA levels, suggesting AR activation. It is also reported that 
treatment with AR antagonists can block this PKA-dependant activation and 
downstream PSA increase, suggesting that although activation is driven by PKA, 
AR is required for transcription [76, 215]. In addition, Janne [216], using ARE and 
reporter constructs, showed that PKA activating treatments can not only 
simulate the AR, but also sensitise it to low level androgens. It is also worth 
noting that modifications such as phosphorylation could affect AR activity by 
increasing/decreasing protein interactions close to the phosphosite [75].  
It is widely thought that aberrant phosphorylation of the AR could promote 
deleterious mechanisms that underpin certain cases of prostate cancer. 
Additionally, a considerable amount of evidence now indicates that kinase 
cascades can affect AR signalling within PC. Many different kinase cascades have 
been shown to have different effects upon AR signalling at different stages of 
the pathway. This suggests that these kinase signals are important in regulating 
AR signalling, and thus changes in these kinase cascades could drive PC 
progression through their effect on the AR [75, 80, 205].  
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As shown in the previous chapter, I have found a downregulation of PKA RIIβ and 
PKACβ from AS to AI prostate cancer cells. These findings also correlated with 
several studies that have reported an increase in RIIβ in less proliferative 
cancers, and a study by Kvissel et al [169], who found the same expression 
pattern of PKACβ2 in cell lines and clinical samples.  In addition I have discussed 
the possibility that PKA RIIβ and PKACβ could interact with the androgen 
receptor pathway. In correlation with this hypothesis, as outlined above, there 
are many reports about the effects of PKA on AR signalling and potential 
prostate cancer progression, and the direct effect on the AR of other kinase 
signalling cascades. However, very little is known about the phosphorylation 
events that mediate AR signalling. Here, I explore whether PKACβ and PKARIIβ 
can interact directly with the AR and the potential effect on PC signalling.  
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4.2 Results 
4.2.1 Investigations into the phosphorylation of AR by PKA. 
I have hypothesized that PKARIIβ and PKACβ down-regulation could be used as 
biomarkers for advancing prostate cancer due to observed expression changes 
during cancer progression. As discussed, AR is extensively post-translational 
modified but mainly the full function of these modifications remains mostly un-
known. Here I endeavour to tackle these issues by investigating the effects of 
PKACβ and RIIβ overexpression on prostate cancer progression. 
The AR has a pivotal role in prostate cancer, and many studies have shown that 
nearly all prostate cancers express AR in the early stages of the disease. In 
addition, studies have shown a relationship between AR and disease progression 
to AI cancer [217]. The increase in PSA levels in AI prostate cancer also suggests 
a restoration of inappropriate AR signalling during this progression [76]. This 
evolution from a localised hormone-sensitive state to the AI phenotype requires 
the interplay of a complex network of signalling molecules.  Intracellular kinase 
signalling cascades can initiate cellular processes such as proliferation.  The 
dysregulation of cellular growth that is often observed in cancer can therefore 
result from the disrupted signalling cascades with alterations in certain kinases.  
PKA activation, as discussed earlier, has been shown to modulate AR activity in 
the absence of androgens, increase mRNA of PSA and increasing the overall 
phosphorylation levels of the AR [76, 205, 215].  However, no study has 
effectively isolated the potential sites of PKA phosphorylation on the AR and 
established their effects on AR transcription and PC progression. 
Many of the site directed studies of AR phosphorylation by PKA have been 
carried out via MS, however this technique is based on peptide fragments. I 
wanted to examine the ability of PKA to phosphorylate the AR full length 
protein, with native folding. Therefore I carried out an in vitro protein kinase 
assay, with pure full length AR protein, which was incubated with purified 
PKACβ kinase in a kinase assay mixture containing radio-labelled phosphate. 
Gratifyingly, I was able to validate the phosphorylation of the full length AR 
protein by the PKACβ isoform (Figure 4.1) as a band was only visible at the AR 
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molecular weight when active kinase was included. A band was also seen in the 
positive control lane where another verified PKA substrate, PDE4A4 had been 
incubated in a similar fashion to the purified AR.  
 
 
Figure 4.1 PKACβ phosphorylation of AR 
Purified androgen receptor protein was phosphorylated with PKACβ enzyme (both Abcam®) 
using [γ-
32
P] ATP for 30 minutes at 30
o
C. Lane 1: AR protein plus PKACβ enzyme Lane 2: AR 
protein Lane 3: PKACβ enzyme Lane 4: PDE4A4 with MBP tag plus PKACβ enzyme Lane 5:  
PDE4A4 with MBP tag. Data is a representation of 2 independent experiments 
The sequence of the consensus PKA phosphorylation site is RxxS*, where x is any 
amino acid, and S* the target for PKA-mediated phosphorylation. The AR has 4 
potential phosphorylation sites in its sequence, 2 located at the N-terminal and 
2 located in the LBD. We have identified that AR can be directly phosphorylated 
by PKACβ (Figure 4.1). However, this does not tell us which site or sites are 
being modified. As the domains of the AR have different function in AR 
signalling, different sites of phosphorylation may lead to differences in 
downstream function. To isolate the phosphorylation site responsible for the 
PKACβ phosphorylation of AR, novel peptide array technology was employed. 
This technique uses peptide libraries of known sequences that are covalently 
linked to macro-molecular cellulose fibres. 
The sequence of the AR was, broken down into a series of overlapping 25mer 
peptides each shifted by 5 amino acids that covered the entire AR. These 
AR Protein         +              +               - - -
PKACb (active)  +              - +              +             -
PDE4A4 MBP     - - - +             +
pAR
pPDE4A4
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peptide segments are synthesised and presented as distinct spots on the 
cellulose membrane. The membranes can be probed with potential binding 
partner proteins, or proteins that will covalently modify certain sequences (e.g. 
kinases). The array was overlaid with an active PKACβ enzyme in a kinase assay 
mix and subsequently probed for modification with a phospho-serine primary 
antibody and visualised with a secondary HRP conjugate. Distinct regions of 
phosphorylation were seen in experiments that were overlaid with active kinase 
(Figure 4.2), whereas no positive spots were detected in the dead kinase 
control. 
 
 
 
Figure 4.2 Peptide array, overlaid with active PKA catalytic unit 
An androgen receptor peptide array was blocked with 5% BSA prior to over lying with 
activate PKA catalytic subunit, ATP and phosphorylation buffer. This was then subjected to 
immuno-probing with PKA phospho-serine antibody, anti-rabbit secondary antibody 
conjugated with HRP and subsequent development using ECL. Data is a representation of 2 
independent experiments. 
The array exhibited 4 sites of phosphorylation by PKA. Site one, (S16) contained 
a series of proline’s that surround the phosphorylation site, a feature that made 
it a less than ideal PKA site, and so it was believed that this site would likely not 
be phosphorylated in vivo via PKA. In addition, this site had been shown 
previously not to be phosphorylated in MS studies that utilised samples isolated 
1    2     3    4     5 
38  39   40  41  42  43 
151  152  153  154   155  156  157  158 
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from LNCap cells treated with FSK [205]. Hence, this site was discounted for 
further analysis. Site 2 (S213) was also discounted. It would have been 
interesting to study this site due to its location in the NTD, which is shown to 
modulate transcriptional activity [70] of the AR and has been shown to target 
gene activation independent of ligand binding and thus may show a link between 
PKA and androgen free AR activation [70, 202]. However, currently, this domain 
has no crystal structure and so in vivo site surface availability could not be 
verified. 
Peptide array screening can provide a highly efficient way for identifying binding 
sites and sites of post-translational modification and these results can serve as a 
base for modelling predictions at the full protein level. This method is successful 
in the investigation of protein-protein interactions as binding partners  often 
undergo induced fit events upon ligand detection and as a consequence, 
interactions between purified proteins and immobilised peptides can be similar 
to the natural situation [218]. That said one must be mindful that the arrays are 
made up of peptide fragments and thus, cannot form a truly native structure or 
interactions indicative of a full length protein. In addition, amino acids could 
potentially become available for interaction, which are not normally available in 
a fully folded, full length protein. Due to this I utilised modelling VMD software 
to check the availability of the phosphosites on the surface of isolated crystal 
structures. 
Sites 3 and 4 (S782, S791: Fig 2 lowest panel)) look like promising sites for PKA 
phosphorylation and both are located in the ligand binding domain. The LBD 
contains the AF2 sequence that has been shown to mediate transactivation [75, 
219]. These sites were checked for surface availability using VMD modelling 
software alluded to above.  
AR residue, S650, was also considered as a putative PKA phosphorylation site. 
Although this site wasn’t detected on the peptide array assay, there is strong 
evidence that phosphorylation of this site is significantly increased following 
forskolin treatment [205]. S650 is located within the hinge region- linking the 
DBD and LBD. This region has been shown to regulate AR nuclear localization, 
DNA binding and co-activator recruitment, and is increasingly thought to 
potentially be of great importance in prostate signalling [75, 83]. Although this 
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isn’t a PKA consensus sequence, we have included this site to examine the 
effects of FSK treatment and as a potential positive control within the study.  
As sites 3 and 4 (S782, S791) represent novel PKA sites on the AR, I wanted to 
determine if these were physiologically relevant. To this end, I commissioned 
the production of phospho-site specific antibodies to these sites.  
 
4.2.2 Peptide array analysis of novel phospho-antibodies 
6 phospho- site specific antibodies were raised in rabbits against sequences 
corresponding to the phosphorylated forms of the 3 unique phosphorylation sites 
of AR mentioned above (S782, S791, S650). Peptide array technology was used 
again to examine the specificity and avidity of the novel phospho-antibodies.  
Arrays were synthesised where the peptide sets comprised of the 20 amino acid 
antigen for each antibody, with or without phosphorylation of the serine site. In 
addition alanine ‘mutations’ of the phosphorylation consensus sequence was 
included as a negative control. Mutating amino acids to alanine will prevent the 
antibody binding and thus controlling for false positives.  Each of the novel 
phospho-antibodies were incubated with the arrays and detection of positive 
interactions was conducted via HRP conjugated secondary antibodies and ECL 
reagent. 
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Figure 4.3 Peptide arrays overlaid with novel antibodies. 
Peptide arrays displaying spotted phosphorylated and non-phosphorylated peptides of 
novel antibody antigens, plus peptides with alanine substitutions in the PKA consensus 
sequence.  
Antibodies raised in 2 of the 6 rabbits, (numbers 1741, 1742) displayed specific 
recognition of the indicated phosphosites, discriminating between the 
phosphorylated and non-phosphorylated consensus sequence. Both these 
antibodies were raised against a sequence of the AR containing consensus site 
RHLS* (Site 4, S791).  
After, peptide array technology was implemented to examine the specificity of 
the novel phospho-antibodies identified in figure 4.3, to the phosphorylation of 
the PKA phosphorylation site. Here, I used peptide arrays that contained 
‘truncations’ of the antibody consensus sequence. The 20 amino acid antigen 
was truncated by one amino acid (from either the left, right or both) at a time 
and a non-phosphorylated consensus sequence was used as a negative control.  
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Figure 4.4 Truncated peptide arrays overlaid with novel pS791 antibodies. 
Peptide arrays displaying 20 amino acid phospho-antibody antigen that was truncated by 
one amino acid (from either the left, right or both) at a time, overlaid with novel phosphor-
antibodies for pS791.  
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Antibodies (both numbers 1741, 1742) exhibited binding to peptide spots that 
contained the PKA consensus site and upon ablation of this site binding was lost.  
RHLS* (S791) is located within the ligand binding domain of the receptor. One 
other antibody raised in rabbit number 1739, exhibited strong phosphosite 
specific binding with very weak non-specific binding in some experiments. The 
consensus sequence for this antibody is RMYS* (Site 3, S782), and is also located 
in the ligand binding domain.   
The AR ligand binding domain facilitates binding of AR ligands and is recognised 
as the primary control mechanism for androgen signalling. This domain also 
contains the AF-2 region, which forms after androgen binding and is crucial in 
co-factor binding. I hypothesize phosphorylation in this domain could therefore 
have a potential effects on AR transcription. To further validate these 
phosphorylation sites and to better understand their function, I investigated the 
putative phosphosite within a cellular model. 
4.2.3 Detection of putative phosphorylation sites using novel 
phospho-antibodies in cells 
Many studies have endeavoured to categorise cAMP-specific effects in prostate 
cancer. As previously discussed, many studies have used forskolin (FSK) and IBMX 
treatments to elevate cAMP levels. In keeping with other studies, I too used 
forskolin/IBMX treatments to elevate cAMP and activate its effector molecule 
PKA.  
Forskolin is a diterpene that is produced by coleus forskohlii and is often used to 
increase cAMP levels. Forskolin activates adenylyl cyclase inducing an increase in 
intracellular levels of cAMP. This leads to downstream activation of cAMP 
effector molecules such as PKA and Epac. IBMX is a non-selective PDE inhibitor, 
which as a consequence leads to an increase in cAMP intracellular levels. IBMX 
inhibits all PDE isoforms with the exception of PDE8 and 9. In a study using 
fluorescently labelled PKA subunits and PC12 cells, it was shown that 
dissociation of PKA subunits occurs within 2 minutes after cAMP stimulation, and 
nuclear translocation of the catalytic unit begins in 3–5 minutes [1]. 
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4.2.3.1 Androgen Receptor transfected HEK293 model 
Peptide array has identified novel putative phosphorylation sites for PKACβ on 
the AR.  In order to ascertain if PKACβ phosphorylation of the AR can be 
observed in cells, I utilised the human kidney cell line HEK293. HEK293 or Human 
Embryonic Kidney Cells were first isolated in 1977 and are commonly used in 
tissue culture due to a high rate of proliferation and ease of transfection [220]. 
Due to the anatomical origins of this cell line, they are not classed as a paradigm 
for prostate cancer, however as they do not endogenous express AR [221] non- 
transfected cells can act as a good control for antibody testing. In addition, they 
have been used in many studies as a ‘model’ system for testing molecules 
involved in prostate cancer within the literature [221-223]. 
HEK293 cells, while not expressing endogenous androgen receptor, have been 
shown to express other hormone receptors such as the glucocorticoid receptor 
[224]. As the LBD domain, where these phosphosites are located, retains some 
homology between the hormone receptor family, I conducted a BLAST search of 
the antibody epitope. Notably however, no protein sequences showed significant 
homology to residues within the 20 amino acid epitope of the phospho specific 
antibodies (BLAST searched in the NCBI database against the unique region of 
each phospho-specific antibody of the AR).  
HEK293 cells were transfected with the AR and cAMP levels were elevated by 
treatment with FSK/IBMX for 10 minutes. The resulting western blots were 
immuno-blotted with the phospho-specific antibodies for sites pS791 and pS782.  
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Figure 4.5 Testing of novel phospho antibodies in HEK 293 cells 
Testing was carried under normal western blot conditions. HEK 293 cells were transfected 
with AR (lanes 1+2) or transfection agent only (lanes 3+4) 24-48hrs prior to treatment.  Cells 
were then treated with 100µM Forskolin and 100µM IBMX (lanes 1+3) or DMSO (lanes 2+4) 
for 10 minutes and harvested with 3T3 buffer. Western Blots were blocked in 5% milk 
solution and immuno-blotted with the indicated novel phospho-antibodies. 
Unfortunately, no specific phospho-bands were detected by the phospho-
antibodies despite good transfection of the AR. In addition, treatment with 
FSK/IBMX was unable to induce detection of any phospho-bands with the 
phospho-antibodies used.  
To further investigate the phosphorylation of AR in a cellular model, I used 
immuno-precipitation studies, in which the transfected AR is isolated at high 
concentrations on IgG beads and the subsequent western blot was probed with 
pS791 phospho-antibodies.  
FSK/IBMX
AR
(110kDa)
α-tubulin
(50kDa)
pS791
(1741)
pS782
(1739)
+             - +             -
+AR
Chapter 4: Study of putative PKA phosphorylation sites on the Androgen Receptor 
104 
 
pAR
(10kDa) 
AR
DHT
FSK/IBMX
P791
(1741)
pAR
(10kDa) 
+    +   +     +  +   +     +   +    +     +     +   +
+    +   +     +   +   +    - - - - - -
+    +   +     - - - +    +    +     - - -
- - - - - - - - - - - -
+    +   +     +   +   +    - - - - - -
+    +   +     - - - +    +    +     - - -
P791
(1742)
A) B)
C) D)
 
Figure 4.6 Testing of novel phospho antibodies in using AR IP 
HEK 293 cells were transfected with AR (blot A and C) or transfection agent only (blot B and 
D) 24-48hrs prior to treatment.  Cells were then treated with 100µM Forskolin and 100µM 
IBMX (all blots lanes 1-3 and 7-9) or DMSO (all blots lanes 4-6 and 10-12) for 10 minutes and 
harvested with 3T3 buffer. 1µg of protein was used to conduct AR IP, under normal 
conditions. Subsequent western blots were blocked in 5% milk solution and immuno-blotted 
with the indicated novel phospho-antibodies. Data is a representation of 2 independent 
experiments 
 
Figure 4.6 shows successful immunoparticipation of the androgen receptor. 
Unfortunately the antibodies raised against the novel phosphorylation site S791 
was unable detect phosphorylated androgen receptor under these conditions.   
Prostate cancer is a complex array of interacting signalling molecules and as 
previously discussed, the AR receptor is an integral part of many of these 
signalling pathways. Therefore it could be assumed that other signalling 
molecules within the cancers complex of interacting pathways could be 
paramount to evoking the phosphorylation of novel phosphosites. If this is true, 
HEK293 cell, not been derived from prostate, may not contain the required 
signalling molecules to evoke the PKA phosphorylation. I therefore endeavoured 
to test these novel antibodies in transfected prostate cancer cell lines. 
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4.2.3.2 Prostate cancer cell lines 
The LNCaP cell line has long been used to investigate different post-translational 
modifications of the AR including phosphorylation [76, 205, 214, 225]. In 
addition, LNCaP cells have been used as a model for AS prostate cancer since its 
description in 1977 [183]. I have previously shown that PKACβ and PKARIIβ are 
increased in AS prostate cancer cell lines and thus this model of prostate cancer 
could induce the novel phosphorylation shown in the peptide arrays. The PC-3 
cell line has been used as a model for AI prostate cancer since its isolation in 
1979 and it does not express the AR [185]. Both these cell lines were used as a 
transfected model of AR expression. 
As the novel antibodies produced poor and unexplainable results in the HEK293 
transfected ‘model’ system, it could be argued that these transfected cells may 
not possess the required interacting signalling pathways to allow the AR to be 
phosphorylated at these novel sites. Therefore, testing of the antibodies was 
also carried in LNCaP cell lines (Figure 4.8) and transfected PC3 (AR independent 
cell line) model (Figure 4.7). 
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Figure 4.7: Time course of Forskolin\IBMX treatment in transfected PC3 cells 
Testing was carried under normal western blot conditions. PC3 prostate cancer cells were 
transfected with AR (lanes 1-4) or transfection agent only (lanes 5-8) 24-48hrs prior to 
treatment.  Cells were then treated with 100µM Forskolin and 100µM IBMX (lanes 2-4, 6-8) or 
DMSO (lanes 1+4), for 2 min (lanes 2+6), 5 min (lanes 3+7) and 10 min (lanes 4+8) and then 
harvested with 3T3 buffers containing phosphatase and protease inhibitors. Western Blots 
were blocked with 5% PhosphoBlocker, and subjected to immune-probing by novel 
phospho-antibodies (as indicated [B,C, D]), AR [A] and a-tubulin loading control. Data is a 
representation of 2 independent experiments 
A) B) 
C) D) 
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A) B)
C) D)
 
Figure 4.8: Time course of Forskolin\IBMX treatment in transfected LNCaP cells 
Testing was carried under normal western blot conditions. LNCaP prostate cancer cells 
were transfected with AR (lanes 1-6) or transfection agent only (lanes 7-12) 24-48hrs prior to 
treatment.  Cells were then treated with 100µM Forskolin and 100µM IBMX (lanes 2-6, 8-12) 
or DMSO (lanes 1+7) for 1 (Lanes 2+8), 2 (lanes 3+9), 5 (lanes 4+10), 10 (lanes 5+11) and 20 
(lanes 6+12) minutes and harvested with 3T3 buffers containing phosphatase and protease 
inhibitors. Western Blots were blocked with 5% PhosphoBlocker, and subjected to immune-
probing by novel phospho-antibodies (as indicated), and further incubated with a 700nm 
alexa floraphore secondary and developed using odessey. After blots were probed for a-
tubulin loading control and AR, incubated with a 800nm alexa floraphore secondary and 
developed using odessey. Data is a representation of 2 experiment. 
 
These experiments yielded little in the way of informative results as no phospho-
bands were detected with the novel phospho-antibodies in both LNCaP and PC3 
prostate cancer cells lines, despite good transfection of the AR.  
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4.2.3.3 DHT  
As previously discussed, ligand binding to the LBD causes the AR to undergo 
conformational changes.   
The novel phosphorylation sites identified are located in the ligand binding 
domain. There is conflicting evidence whether ligand is needed for PKA to cause 
its effects on the AR [166, 226]. However, other sites of phosphorylation within 
the AR sequence have been identified as requiring ligand binding for 
phosphorylation to occur [75]. It is therefore possible that ligand presence 
maybe needed in order for phosphorylation to occur at the sites identified. If 
these effects are caused via direct phosphorylation, as I hypothesize, then it is 
shrewd to test these antibodies with and without ligand present. Furthermore, it 
has also been suggested that phosphorylation on pS650 occurs or is enhanced in 
the presence of bound ligand [205]. 
To test if the novel phosphorylation of the AR is ligand dependant, HEK 293 
(Figure 4.9A) and LNCaP cells (Figure 4.9B) were transfected with the AR, 
treated with DHT for 16hrs and cAMP levels elevated via FSK/IBMX for 10 
minutes. 
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(A) 
 
(B) 
A) B)
C) D)
 
Figure 4.9: Treatment of transfected HEK 293 and LNCaP cells with both DHT and FSK\IBMX 
(A) Testing was carried under normal western blot conditions. HEK 293 cells were 
transfected with AR (lanes 1+2) or transfection agent only (lanes 3+4) 24-48hrs prior to 
treatment.  Cells were then treated with 10nM DHT for 16hrs and subsequently treated with 
100µM Forskolin and 100µM IBMX (lanes 2+3) or DMSO (lanes 1+4) for 10 minutes and 
harvested with 3T3 buffers containing phosphatase and protease inhibitors. Western Blots 
were blocked with PhosphoBlocker and subjected to immune-probing by novel phospho-
antibodies (as indicated), and α-tubulin loading control. Data is a representation of 2 
experiments 
pS782
+            - +            -
+AR +DHT +DHT
FSK/IBMX
pS791
pS650
α- tubulin
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(B) Testing was carried under normal western blot conditions. LNCaP cells were transfected 
with AR (lanes 1-4) or transfection agent only (lanes 5-8) 24-48hrs prior to treatment.  Cells 
were then treated with 10nM DHT (Lanes 1+2, 5+6) for 16hrs and subsequently treated with 
100µM Forskolin and 100µM IBMX (lanes 1+3, 5+7) or DMSO (lanes 2+4, 5+8) for 10 minutes 
and harvested with 3T3 buffers containing phosphatase and protease inhibitors. Western 
Blots were blocked with PhosphoBlocker and subjected to immune-probing by novel 
phospho-antibodies (as indicated), AR and α-tubulin loading control. Data is a 
representation of 2 experiments 
As seen for figure 8, these experiments also produced little in the way of 
informative results as no phospho-bands were detected with the novel phospho-
antibodies in both LNCaP and HEK cells lines following DHT and FSK/IBMX 
treatment, despite good transfection of the AR.  
While nuclear translocation of the PKA catalytic unit begins 3–5 minutes after 
cAMP elevation, translocation doesn’t peak until 30 minutes and levels do not 
return to basal until after 50 minutes. As it is not determined where in the AR 
activation pathway phosphorylation occurs, it could be possible that 20 minutes 
stimulation of FSK/IBMX may not be sufficient to produce an effect that can be 
detected using our techniques. Phosphorylation of other hormone receptors such 
as the PR, exhibit a delay in the induction of phosphorylation. Moreover, Sadar 
et al [166] showed that mRNA levels of PSA increased with FSK treatments. This 
experiment was carried out over a 48hr period and optimal induction of PSA 
levels was between 8-16hrs of treatment. These again suggest that 10-20 minute 
treatment of cells with cAMP simulating agents maybe insufficient to induce PKA 
phosphorylation. 
With this in mind, I transfected the AR into HEK 293 cells and treated them with 
FSK/IBMX over a 24hr time course. As it is not yet apparent whether the sites I 
have identified require DHT to become phosphorylated, the cells were also 
treated with or without DHT for 24hrs.  
Surprisingly, a robust and repeatable phosphorylation was detected at site S791 
following 24 hours of treatment of FSK/IBMX and DHT (Figure 4.10).  
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C) D)
 
Figure 4.10: 24hr Treatment of transfected HEK 293 cells with both DHT and FSK\IBMX 
Testing was carried under normal western blot conditions. HEK 293 cells were transfected 
with AR (Blots A and C) or transfection agent only (Blots B and D) 24hrs prior to treatment.  
Cells were then treated with 10nM DHT for 24hrs (Blots C and D) and subsequently treated 
with 100µM Forskolin and 100µM IBMX (Blots A-D) or DMSO (lane 1 of all blots) for the time 
indicated and then harvested with 3T3 buffers containing phosphatase and protease 
inhibitors. Western Blots were blocked with 5% PhosphoBlocker and subjected to immune-
probing by novel phospho-antibodies (as indicated), AR, pAKT and α-tubulin loading 
control (as indicated). Data is a representation of 2 experiments. 
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4.2.4 RIIβ AR interaction 
As discussed, it has been shown that several components of the PKA signalling 
pathway are changed at their transcription level in human prostate cancer cells 
compared to normal prostate cells. This, coupled with preliminary evidence that 
increased expression of PKA II is found in less proliferative cells and the 
observation that RIIβ expression is decreased as the prostate cells move towards 
androgen insensitivity, led me to the hypothesis that RIIβ may directly interact 
with the AR [167, 169]. 
To investigate this hypothesis, I implemented peptide array technology in order 
to assess the binding of PKARIIβ to the AR. As before, the sequence of the AR 
was broken down into a series of overlapping 25mer peptides which shifted by 5 
amino acids at a time and covered the entire AR sequence. These peptide 
segments are synthesised and presented as distinct spots on the cellulose 
membrane. This membrane (array) was then overlaid with pure PKARIIβ protein 
(produced in house, see materials and methods) and subsequently probed with 
PKARIIβ antibody to detect sites of PKARIIβ/AR binding. 
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1. M-E-V-Q-L-G-L-G-R-V-Y-P-R-P-P-S-K-T-Y-R-G-A-F-Q-N 
4. S-K-T-Y-R-G-A-F-Q-N-L-F-Q-S-V-R-E-V-I-Q-N-P-G-P-R 
16. Q-Q-E-T-S-P-R-Q-Q-Q-Q-Q-Q-G-E-D-G-S-P-Q-A-H-R-R-G 
17. P-R-Q-Q-Q-Q-Q-Q-G-E-D-G-S-P-Q-A-H-R-R-G-P-T-G-Y-L 
73. Y-Y-N-F-P-L-A-L-A-G-P-P-P-P-P-P-P-P-H-P-H-A-R-I-K 
112. T-C-L-I-C-G-D-E-A-S-G-C-H-Y-G-A-V-T-C-G-S-C-K-V-F 
113. G-D-E-A-S-G-C-H-Y-G-A-V-T-C-G-S-C-K-V-F-F-K-R-A-A 
114. G-C-H-Y-G-A-V-T-C-G-S-C-K-V-F-F-K-R-A-A-E-G-K-Q-K 
115. A-V-T-C-G-S-C-K-V-F-F-K-R-A-A-E-G-K-Q-K-Y-L-C-A-S 
116. S-C-K-V-F-F-K-R-A-A-E-G-K-Q-K-Y-L-C-A-S-R-N-D-C-T 
117. F-K-R-A-A-E-G-K-Q-K-Y-L-C-A-S-R-N-D-C-T-I-D-K-F-R 
118. E-G-K-Q-K-Y-L-C-A-S-R-N-D-C-T-I-D-K-F-R-R-K-N-C-P 
119. Y-L-C-A-S-R-N-D-C-T-I-D-K-F-R-R-K-N-C-P-S-C-R-L-R 
120. R-N-D-C-T-I-D-K-F-R-R-K-N-C-P-S-C-R-L-R-K-C-Y-E-A 
121. I-D-K-F-R-R-K-N-C-P-S-C-R-L-R-K-C-Y-E-A-G-M-T-L-G 
122. R-K-N-C-P-S-C-R-L-R-K-C-Y-E-A-G-M-T-L-G-A-R-K-L-K 
123. S-C-R-L-R-K-C-Y-E-A-G-M-T-L-G-A-R-K-L-K-K-L-G-N-L 
124. K-C-Y-E-A-G-M-T-L-G-A-R-K-L-K-K-L-G-N-L-K-L-Q-E-E 
126. A-R-K-L-K-K-L-G-N-L-K-L-Q-E-E-G-E-A-S-S-T-T-S-P-T
140. A-A-L-L-S-S-L-N-E-L-G-E-R-Q-L-V-H-V-V-K-W-A-K-A-L
141. S-L-N-E-L-G-E-R-Q-L-V-H-V-V-K-W-A-K-A-L-P-G-F-R-N
142. G-E-R-Q-L-V-H-V-V-K-W-A-K-A-L-P-G-F-R-N-L-H-V-D-D 
147. Q-M-A-V-I-Q-Y-S-W-M-G-L-M-V-F-A-M-G-W-R-S-F-T-N-V
148. Q-Y-S-W-M-G-L-M-V-F-A-M-G-W-R-S-F-T-N-V-N-S-R-M-L
149. G-L-M-V-F-A-M-G-W-R-S-F-T-N-V-N-S-R-M-L-Y-F-A-P-D 
151. S-F-T-N-V-N-S-R-M-L-Y-F-A-P-D-L-V-F-N-E-Y-R-M-H-K
152. N-S-R-M-L-Y-F-A-P-D-L-V-F-N-E-Y-R-M-H-K-S-R-M-Y-S
153. Y-F-A-P-D-L-V-F-N-E-Y-R-M-H-K-S-R-M-Y-S-Q-C-V-R-M
154. L-V-F-N-E-Y-R-M-H-K-S-R-M-Y-S-Q-C-V-R-M-R-H-L-S-Q
155. Y-R-M-H-K-S-R-M-Y-S-Q-C-V-R-M-R-H-L-S-Q-E-F-G-W-L 
158. R-H-L-S-Q-E-F-G-W-L-Q-I-T-P-Q-E-F-L-C-M-K-A-L-L-L
159. E-F-G-W-L-Q-I-T-P-Q-E-F-L-C-M-K-A-L-L-L-F-S-I-I-P
160. Q-I-T-P-Q-E-F-L-C-M-K-A-L-L-L-F-S-I-I-P-V-D-G-L-K
161. E-F-L-C-M-K-A-L-L-L-F-S-I-I-P-V-D-G-L-K-N-Q-K-F-F
162. K-A-L-L-L-F-S-I-I-P-V-D-G-L-K-N-Q-K-F-F-D-E-L-R-M 165. N-Q-K-F-F-D-E-L-R-M-N-Y-I-K-E-L-D-R-I-I-A-C-K-R-K
166. D-E-L-R-M-N-Y-I-K-E-L-D-R-I-I-A-C-K-R-K-N-P-T-S-C
167. N-Y-I-K-E-L-D-R-I-I-A-C-K-R-K-N-P-T-S-C-S-R-R-F-Y
168. L-D-R-I-I-A-C-K-R-K-N-P-T-S-C-S-R-R-F-Y-Q-L-T-K-L
169. A-C-K-R-K-N-P-T-S-C-S-R-R-F-Y-Q-L-T-K-L-L-D-S-V-Q
171. S-R-R-F-Y-Q-L-T-K-L-L-D-S-V-Q-P-I-A-R-E-L-H-Q-F-T
172. Q-L-T-K-L-L-D-S-V-Q-P-I-A-R-E-L-H-Q-F-T-F-D-L-L-I
173. L-D-S-V-Q-P-I-A-R-E-L-H-Q-F-T-F-D-L-L-I-K-S-H-M-V
178. S-V-D-F-P-E-M-M-A-E-I-I-S-V-Q-V-P-K-I-L-S-G-K-V-K
179. E-M-M-A-E-I-I-S-V-Q-V-P-K-I-L-S-G-K-V-K-P-I-Y-F-H
180. M-A-E-I-I-S-V-Q-V-P-K-I-L-S-G-K-V-K-P-I-Y-F-H-T-Q 
RIIβ
Negative antibody Control
 
Figure 4.11: Overlay of pure RIIβ protein on a AR peptide array 
PKA RIIβ protein was overlaid onto an immortalised AR peptide array. The array was 
subsequently probed with a PKARIIβ antibody and processed under usual western blot 
conditions. Data is a representation of 1 experiment 
Figure 4.11 shows possible RIIβ interacting sites on the AR. While this peptide 
array study is useful in identifying the binding sites, it is an artificial screening 
tools that requires validation in a more physiological environment. 
4.2.4.1 RIIβ AR IP 
To validate the binding shown using the peptide array technology, I carried out 
immuno-precipitation experiments to detect possible binding between RIIβ and 
AR. LNCaP and VCaPs lysates were immuno-precipitated with AR antibody (Santa 
Cruz®) and subsequently blotted with a RIIβ (BD Bioscience®) primary antibody. 
Detection was achieved via a HRP conjugated light chain only secondary.  
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Figure 4.12: Co-immuno-precipitation of AR and PKA RIIβ subunit in LNCaP cells 
Testing was carried under normal western blot conditions. LNCaP cells were harvested with 
3T3 buffers containing and protease inhibitors. Lysates were incubated with 1µg of AR 
(Santa Cruz®) antibody and Protein G beads. Negative control was conducted in the same 
manner without antibody. Western Blots were blocked with 5% milk protein and subjected 
to immune-probing by the RIIβ and AR as indicated. This was followed by a mouse light-
chain only secondary and subsequent development by ELC.  Data is a representation of 3 
independent experiments 
This experiment shows a reliable and reproducible interaction of the AR with 
RIIβ in LNCaP and VCaP cells lines. Suggesting that RIIβ can interact directly with 
AR.  
4.2.4.2 Confocal analysis of proposed RIIβ and AR interaction 
To confirm the co-immunoprecipitation experiments and assess localisation of 
PKA RIIβ and AR in prostate cancer cells, confocal imagery using LNCaP cells was 
carried out (Figure 4.13). Cells were treated with or without FSK/IBMX for 10 
minutes prior to fixing with 4% formaldehyde and subsequently immunostained 
using the protocol hightlighted in ‘materials and methods’ section. AR (abcam®) 
and RIIβ (BD Bioscience®) antibodies were used.  
  
RIIβ
AR
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B) C) D) E)
FSK/IBMX 
treatment
B) C) D) E)
 
Rabbit 
IgG control
A) B) D)
RIIβ peptide 
blocking control
A) B) C)
Secondary 
only control
A) B) C) D)
 
Figure 4.13: Co-localisation experiments using confocal microscopy 
Cells were plated onto glass cover slips, coated in rat tail collagen, and incubated in normal 
growth medium prior to fixing. Cells were fixed using 4% paraformaldehyde and then 
permibilised. Cells were subjected to immuno-probing by primary PKA RIIβ (BD 
Bioscience® [Green]) and AR (Santa Cruz® [Red]) antibodies, and subsequent Alexa® 
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fluorophore secondary antibodies; anti-mouse- 488 and anti-rabbit- 594 (molecular probe®). 
Slips were mounted onto slides using Gold+Dapi (Invitrogen®) and analysed using 
confocal. A) Cells under light microscope B) Nuclear Dapi C) RIIβ D) AR E) Co-localised 
image of RIIβ and AR. Row 1 shows cells with no treatment. Row 2 shows cells incubated 
with 100µM FSK/IBMX 10 minutes prior to fixing. Row 3 shows Alexa fluorophore secondary 
only control. Row 4 shows Rabbit IgG to identify any none specific binding of the AR 
antibody. Row 5 shows RIIβ incubated with RIIβ purified protein to identify any none 
specific binding of the RIIβ antibody. 
This revealed a lack of endogenous co-localisation of PKA RIIβ and AR in the un-
treated cells (FIG 4.13, row 1). Additionally treatment with FSK/IBMX was unable 
to invoke a change in the localisation pattern of either protein (FIG 4.13, row 2). 
Rigorous negative controls were used in this experiment to control for none-
specific antibody binding. All 3 controls employed (FIG 4.13, rows 3-5) show only 
a background signal, showing antibody specificity for both primary (Figure 4.13, 
rows 4-5) and secondary antibodies (Figure 4.13, rows 3). 
Furthermore, the androgen receptor appears to be mostly translocated to the 
nucleus. When AR is in the nucleus it is thought to be active and carrying out its 
transcriptional function. Surprisingly there doesn’t appear to be an increase in 
AR translocation after FSK/IBMX treatment. As discussed many studies have 
shown that increase FSK/IBMX results in the increase transcription activity of the 
AR [76, 142]. However, with large expression already displayed in the nucleus of 
the cell any additional translocation maybe negligible. In addition, RIIβ is mainly 
located in the cytoplasm and again exhibits very little change when treated with 
FSK/IBMX. RIIβ cellular localisation is mainly controlled via binding to AKAP 
domains and therefore is usually expressed in specific locations in the cell [227, 
228]. I have shown that RIIβ is specifically located within the cytoplasm of the 
cells, with area of increase expression which looks to be localised to the cell 
membrane. While, PKA RIIβ and AR co-localization could be induced via another 
mechanism e.g. DHT; co-localisation via FSK/IBMX treatment alone does not 
occur.  
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4.3 Discussion 
Post-translational modifications, for example acetylation and sumoylation are 
shown to have an influence on the transactivation of the AR [75, 204]. However, 
it is unclear what effects, if any, are orchestrated by PKA mediated AR 
phosphorylation. It has been shown that the AR is a substrate for many different 
kinases and that additional phosphorylation of the AR can be induced when cells 
are exposed to androgens [205, 212]. Phosphorylation occurs predominantly at 
serine residues [205].   
Other members of the steroid superfamily can be activated via phosphorylation. 
It has been shown that the human oestrogen receptor can be activated in the 
absence of steroids after treatment with PKA activators such as FSK or PKA 
specific 8-Bromo-cyclic AMP. In addition, other members of this superfamily, for 
example the human progesterone and glucocorticoid receptors, can be activated 
in a synergistic fashion by steroids and kinase stimulators [229, 230]. These co-
treatment effects can be inhibitory or synergistic. This is no different within the 
AR pathway. In the case of the rat AR, there is a proposed synergism between 
the PKA pathway and the steroid pathway, to stimulate transcriptional 
activation rather than a steroid-independent activation of the AR [215, 231]. In 
addition Gioeli et al [205] reported that upon treatment with FSK in LNCaP cells, 
the overall phosphorylation of the AR was increased. Sadar et al [76] 
demonstrated that treatment with FSK increased the PSA mRNA levels, 
suggesting AR activation. It is also reported that treatment with AR antagonists 
can block this PKA-dependant activation and downstream PSA increase, 
suggesting that although activation is driven by PKA, AR is required for 
transcription [76, 215].  
Some studies have endeavoured to explain these results by looking at PKA 
activating events and their downstream effects on AR function. Despite the 
obvious link between PKA and AR signalling, it is yet to be shown conclusively 
that PKA can directly phosphorylate the AR. In this study, I have endeavoured to 
show the phosphorylation status of AR in relation to activated PKA signal 
transduction pathway, in a step towards understanding PKA’s effect on AR 
transcription/regulation and how this may contribute to prostate cancer 
progression. 
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The AR has been shown to have 16 phosphorylated residues and they have been 
linked to different effects on the receptor. Some sites require ligand binding and 
some do not and most are located in the N-terminal domain. These 16 sites of 
phosphorylation have been linked to dimerization, transactivation, localisation, 
transcriptional activity, degradation and stability of the AR receptor [223] 
confirming that phosphorylation has an important role within AR function. 
Within this study, I have shown that AR is able to become directly 
phosphorylated by PKACβ in vitro. In addition, I have identified S791 as a novel 
phosphorylation site for PKA.  
Currently phosphorylation of S791 is thought to be AKT dependent.  A 
phosphomimetic mutant study (S791D) exhibited reduced binding of ligand, a 
decrease in nuclear translocation, and reduced transcription via lack of AR 
binding to its promoter. In addition, this phosphomimetic mutation at S791 in 
addition to S213 (S213 is an ATK dependent site), resulted in an impaired 
translocation of AR to the nucleus in COS1 cells [232]. These data suggest 
phosphorylation at this site could be important in decreasing the translocation 
and transcription of the AR. Furthermore, AR stability was decreased when S791 
was phosphorylated and this was restored following treatment with the 
proteasome inhibitor MG132. These results suggesting that phosphorylation of AR 
at S791 plays a role in the ubiquitination of AR and modulates its degradation via 
the proteasome. Moreover, S791 is the only modified residue within 50 amino 
acids of the ubiquitinated lysine 845 and 847 [232]. AKT and PKA are structurally 
very similar and studies have shown them to share the same phosphosites [233, 
234]. Thus S791 could also be a phosphosite for both kinases and PKA could also 
play a role in regulating the half-life of the AR. However I was unable to follow 
this area of research due to time contraints. 
My data suggests that the kinetics of phosphorylation at S791 are slow following 
FSK/IBMX treatment. PKA is rapidly dissociated from the R subunits upon cAMP 
binding and nuclear translocation of PKA catalytic unit can begin within 3–5 
minutes. While nuclear translocation doesn’t peak until 30 minutes after cAMP 
elevation, the AKT study discussed above, suggests that phosphorylation of S791 
inhibits AR translocation and thus in theory should occur in the cytoplasm. 
Conversely, Gioeli et al [205] stated that most of the sites phosphorylated on the 
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AR, weren’t maximal until 2hrs after hormone treatment and in the case of S81 
phosphorylation, it was still increasing after 6hours. S791 wasn’t included in this 
study; however delayed overall phosphorylation of the AR was shown. 
Furthermore, these slow kinetics are in parallel to the delayed hormone-
dependent phosphorylations that have been shown on progesterone receptor 
[235].  
AR translocation to the nucleus after ligand binding is rapid, occurring 15 
minutes after treatment. This suggests that AR phosphorylation is likely to play a 
role in a late phase of transcriptional regulation or receptor recycling, which 
correlates with the proposed function of S791 phosphorylation. However, a 
longer time course would be required to further investigate the phosphorylation 
of AR by PKA, as the phosphorylation event described is only weakly bound by 
site-specific antibody and so no conclusions can be made from this data alone. 
PKA phosphorylates and activates AKT. Treatment with FSK/IBMX will lead to the 
hyper-activation of PKA and thus increase phosphorylation of AKT. As AKT has 
been shown to phosphorylate at S791 to play a role in ubiqutation and turnover 
of the AR, late stage activation of AKT may occur via PKA signalling. Future 
studies should consider an increase AKT activation via PKA as a possible 
mechanism for FSK/IBMX induced phosphorylation at S791. 
Finally, I tried to demonstrate a interaction between PKA RIIβ and the AR. PKA 
regulatory units have been investigated as a signalling mechanism in many 
prostate cancer studies [50, 169, 171, 191]. 
R unit isoforms demonstrate distinct subcellular localizations via A-kinase 
anchoring proteins (AKAP) that can specifically bind the N-terminal domain of 
the regulatory subunits. Numerous AKAPs have been identified, and they are 
suggested to facilitate the compartmentalization of PKA isoforms to discrete 
intracellular localizations [227]. The localization of PKA plays a crucial role in 
determining which substrates are phosphorylated. In addition, RI and RII subunits 
show considerable differences in expression between tissues, and changes in the 
ratios of PKA I and PKA II play an important role in processes like cellular 
differentiation and cancer development. The overexpression of PKA II due to the 
up-regulation of the regulatory subunits type II of PKA has shown to have a 
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protective affects in cancers owing to the decrease in proliferation and invasion 
correlating with its expression increase [167]. Whilst RI overexpression has been 
linked to poor patient outcome. In prostate cancer, this is also true. Cho et al 
[50] demonstrated the over-expression of the RII subunit in various cancer cells, 
including prostate adenocarcinoma. This over-expression resulted in a reversion 
of the transformed phenotype. As discussed, the AR has a pivotal role in prostate 
cancer progression and thus I hypothesized that RIIβ up-regulation in the AS cells 
may interact with AR to exert its effects.  
RIIβ and AR co-IPs showed that RIIβ could form a complex with endogenous AR in 
AS cell line. However we couldn’t reproduce these effects with confocal 
microscopy.  RIIβ lays in the vicinity of the heavy chain (50kDa) on a western 
blot. Use of secondary antibodies that recognise the heavy and light chain of the 
primary antibody used to pull down a target protein can therefore affect the 
signal of the protein of interest, in this case RIIβ. In this study, light chain only 
secondary antibodies were implemented. These antibodies should circumvent 
this problem, however it is still possible that antibodies can recognise non-target 
proteins in a non-specific manner. Therefore, it could be argued that the 
positive signal from the IPs is due to specificity problems with the secondary 
antibody. Additionally, upon sequence investigation, no conventional AKAP 
consensus sequence for PKA RII anchoring exists on the AR.  
In conclusion I doubt if PKARIIβ directly binds to the AR, but exerts its effects via 
indirect downstream signalling. 
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5 Exposing the role of PDE4D7 in Prostate Cancer 
Progression 
5.1 Introduction 
5.1.1 PDE4s and links in Prostate Cancer 
PDE families have long been considered as possible therapeutic targets in many 
disease states.  Prostate cancer is no exception [236]. As with most tumour 
microenvironments, prostate cancer is a forever changing environment of 
stimulatory and inhibitory signals that requires the expression and regulation of 
secondary messenger pathways to respond and interpret this environment. As 
PDEs are the only known way to degrade cyclic nucleotides and therefore control 
the spatial and temporal components of these signalling pathways, it was 
suggested that these enzymes maybe differentially regulated in prostate cancer 
[236, 237]. Despite the number of papers that implicate cAMP signals as having 
an effect on prostate cancer progression, the literature is particularly lacking in 
details of a mechanistic role for PDE enzymes in prostate cancer progression.  
Uckert et al have carried out many studies to analyse the distribution and 
effects of phosphodiesterases within the prostate to determine whether PDE 
inhibition could be a potential treatment for urinary tract disease and BPH [238-
242]. Uckert et al confirmed the presence of mRNA specifically encoding for 
PDE4A, PDE4B, PDE4C, and PDE4D  within the distinct anatomical regions of the 
prostate, using PCR [240]. He went on to show the importance of PDE4’s in 
prostate function and the co-localization of PDE4’s and isoforms of PKA in 
smooth and glandular areas of the prostate [238, 239]. However, the potential 
significance of PDE signalling and control of human prostate function wasn’t 
comprehensively investigated. 
Another study by Wheeler et al investigated PDE expression in tissues of the 
urinary tract and describes the presence of all PDE families within the prostate, 
with the exception of PDE6 [243]. Although interesting, this work does not 
describe the PDE complement of the prostate in a cell specific fashion. 
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Work  by Rahrmann and co-workers [244] utilised a transposon based 
mutagenesis screen to implicate PDE4D as a critical factor in the induction of 
epithelial proliferation and hyperplasia in the prostate after mutagenesis. They 
went on to investigate the putative role of PDE4D in prostate cancer. It was 
suggested that PDE4D was overexpressed in prostate cancer samples and cell 
lines and that changes in PDE4D isoform expression was detected in prostate 
cancer progression. Furthermore, they suggested that knock-down of PDE4D by 
shRNA also reduced the proliferation of DU145 prostate cancer xenografts in rats 
and also effected migration by wound healing assays. Once again, these studies 
were relatively descriptive and failed to provide the molecular mechanism that 
was underpinned by PDE4D activity and resulted in the phenotypic changes. 
Further to these studies, a comprehensive analysis of PDE isoform expression in 
prostate cancer has been carried out by our laboratory [179]. Within this study 
19 prostate cancer cell lines and xenographs were used, 10 AS and 9 AI, to 
provide an expression profile for each PDE within prostate cancer and its 
possible fluctuation in abundance in prostate cancer progression. The RT-qPCR 
analysis of these prostate cancer samples identified PDE3B, PDE4B, PDE4D, 
PDE7A, PDE8A, PDE8B and PDE9A as PDE isoforms that are the most abundantly 
expressed within the prostate and that members of the PDE4D family showed the 
highest significant change in regulation from AS to AI cancers. In particular, this 
study identified PDE4D7 as a possible biomarker for prostate cancer progression 
with a significant 40 fold decrease in expression between AS and AI samples (see 
further explanation below). 
5.1.2 PDE4D7 
Since PDE4D7 was first discovered by Wang et al, the understanding of the 
contribution to the control of intracellular cAMP and signalling events have not 
been greatly expanded upon [245]. Wang showed PDE4D7 expression in the 
brain, placenta, lung and kidney. However, one study linked ischemic stroke to 
small nucleotide polymorphisms of PDE4D in the Icelandic population [246]. They 
reported that mutations in the region surrounding the PDE4D7a exon are 
positively correlated with incidence of ischemic stroke. Furthermore, they also 
suggested that these mutations can lead to a reduction in the expression of the 
PDE4D7 isoform. However, this remains to be thoroughly proven. 
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As mentioned above, a study [179] to isolate a prostate cancer biomarkers 
identified PDE4D as being significantly over expressed in AS prostate cells lines 
and xenographs. In addition, the isoform PDE4D7 exhibited the highest degree of 
expression in AS and the largest amount of down-regulation in AI samples than 
any other PDE4D isoform. To further characterise the role of PDE4D7  in prostate 
cancer, the report went on to pinpoint the sub-cellular localisation of the 
isoform at the plasma membrane and utilise FRET-based, targeted cAMP 
reporters to show that PDE4D7 contributes a significant proportion of rolipram 
sensitive PDE4 activity at the plasma membrane of AS cell lines. 
As prostate cancer progresses, there is an increase in the proliferation enhancing 
effects of cAMP signalling, thus I hypothesise that PDE4D7 is important in 
controlling compartmentalisation of cAMP signalling at the sub-plasma 
membrane, where it is in prime position to modulate cAMP generated by plasma 
membrane associated adenylyl cyclases. In addition, it is plausible to 
extrapolate the notion that PDE4D7’s compartmentalisation at this locale may 
require the presence of binding partners and/or induce other signalling 
pathways. While PDE4D7 is a putative biomarker for prostate cancer progression, 
nothing is known about its regulation, binding partners or crosstalk with 
downstream signalling pathways. This may be the key to understanding the 
mechanism by which PDE4D7 exerts it control over the proliferative effects of 
cAMP mediated pathways in prostate cancer. This chapter seeks to investigate 
the role of PDE4D7 in prostate cancer signalling using a range of biochemical, 
molecular biology and proteomics techniques. 
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5.2 Results 
5.2.1 Using VCaP as a model to investigate PDE4D7 function in 
PC. 
For this section of my study, the VCaP cell line was selected to represent PC AS 
phenotype. VCaP cells express the highest level of PDE4D7 mRNA and PDE4D5/7 
protein, out of all the cell lines examined in this study [179]. VCaP cells exhibits 
many of the characteristics of clinical prostate cancer as it expresses a 
functional wild type AR, PAP, and large amounts of PSA [180, 182]. VCaP cells 
grow in distinct colonies on plastic, making them harder to transfect than the 
LNCaPs used earlier in this study (unpublished observation) and also take 50-100 
hours to double [180, 181]. This observation mirrors the situation in vivo where 
AS versus AI growth in xenografts of the cell line exhibit a similarly different 
growth pattern. Since its isolation, the VCaP cell line has increased in use within 
the prostate cancer field, in part due to the fact it is derived from a bone 
metastasis and  PC patients have metastasis primarily or exclusively in bone 
[59]. 
5.2.2 PDE4D7 constructs 
Plasmid constructs used during this study were produced in house[179]. The first 
of which was produced by the sub-cloning of a wild-type PDE4D7 construct in 
order to express the vesicular stomatitis virus (VSV) epitope tag (YTDIEMNRLGK) 
on the C-terminal end of the isoform. The tag was placed on the C-terminal end 
of the protein away from the unique N-terminal region of PDE4D7 , which is 
known to be the unique targeting domain of all PDE4s. The second construct 
produced was a dominant negative (DN) version of the PDE4D7 VSV construct. 
The Houslay/Baillie group has excelled in the use of the dominant negative 
approach to gain insight into unique cellular roles of PDE4 isoforms. This 
approach requires that PDE constructs be mutated at a single position within the 
catalytic site. The catalytic site is essential for the hydrolysis of the 
phosphodiester bond of cAMP, and thus this mutation rendering the enzyme 
catalytically inactive. These constructs are useful in defining the function of a 
particular PDE isoform as it displaces the endogenous, functional protein with 
the inactive, DN form. This has the benefit of only affecting the displaced, 
targeted, isoforms allowing local cAMP levels to rise around the original site of 
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the displaced isoform only, while not affecting global cAMP levels or the 
functioning of untargeted PDE isoforms [7]. A singular D559A mutation within the 
catalytic site of PDE4D7 rendered the enzyme unable to hydrolyse cAMP. 
The PDE4D7 constructs were transfected into HEK293 cells and the resulting cell 
lysates were assayed for PDE activity. This assay was performed in order to 
ensure the inactive nature of the dominant negative PDE4D7 construct and the 
active nature of the VSV fused PDE4D7 construct. This assay showed that the VSV 
tagged construct retained catalytic activity while the dominant negative 
construct exhibited no increase over basal PDE activity.  
 
Figure 5.1 PDE activity of PDE4D7 constructs transfected into HEK293 
A PDE assay was conducted on HEK293 cells transfected with PDE4D7 VSV or Dominant 
Negative PDE4D7 VSV constructs. For activity calculation, see ‘material and methods’ 
section.  
5.2.3 The use of high –through-put screens 
The use of high-through put screens allow for the investigation of multiple 
molecular targets at any one time at either the DNA, RNA or protein level. This 
has multiple advantages over conventional methods; the speed of analysis, the 
relatively low amount of sample used, the consideration of effects on entire 
signalling cascades and the very large amount of molecular targets that can be 
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analysed in a single experiment. By exploiting this approach, we are able to 
investigate the influence of PDE4D7 on many different cellular molecules and 
signalling systems within prostate cancer. 
5.2.4 RT-qPCR 
The RT2 ProfilerTM PCR arrays used for this high-through-put screen were 
purchased from Qiagen®. These arrays use Sybr-green technology instead of the 
Taq-man primer/probe set that were used earlier in this study. 
5.2.4.1 Sybr-green vs Taq-man  
SYBR green is a small cyanine dye which changes its fluorescence spectrum when 
bound to double stranded DNA (dsDNA) [247]. As the amplification of target 
genes increases during the RT-qPCR reaction, initiated via gene-specific primers, 
this change in fluorescence can be monitored [248]. Sybr-green technology is a 
widely used PCR technique due to its ease of use and low running costs. 
However, due to the non-specific fashion in which the SYBR green dye binds to 
dsDNA ,any off-target amplification can lead to a false result. A post-assay 
melting point analysis can be used to ensure that the observed change in 
fluorescence signal is representing only the transcript of interest. During this 
analysis, the PCR reaction product is exposed to a graduated temperature range 
which causes further changes in the fluorescence reading as the double stranded 
amplifications dissociate at specific melting points. The melting point of the 
specific amplifications can be calculated from its sequence, and thus any change 
in fluorescence above or below this temperature indicates off-target 
amplification and a false result. The amount of false positive can be significantly 
reduced by the careful design of primers and full validation of PCR products 
[248, 249]. Therefore, in this study, I have used RT2 ProfilerTM PCR high- 
throughput arrays and associated probe sets from SABioscience (Qiagen ®). 
These arrays contain primers that have been carefully designed and fully 
validated to reduce false positives. I have also run melting curves for the initial 
screen to authenticate the Sybr-green primers.  
PDE4D7 VSV and DN PDE4D7 VSV constructs were transfected into VCaP cells, 
and overexpression was confirmed via RT- qPCR and PDE4D7 Taq-Man ® 
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primer/probe set prior to use of the RT2 ProfilerTM PCR arrays (Figure 5.2). Cells 
were also transfected with empty vector pcDNA3 controls, which as expected, 
showed no PDE4D7 overexpression. 
 
Figure 5.2 Expression of PDE4D7 constructs transfected into VCaP cell 
VCaP cells were transfected with pcDNA3, PDE4D7 VSV and dominant negative PDE4D7 
VSV constructs. Cellular lysates were subjected to RT-qPCR with PDE4D7 and GAPDH Taq-
Man ® probes. Cells transfected with PDE4D7 VSV and dominant negative PDE4D7 VSV 
constructs show an up-regulation in PDE4D7 compared to pcDNA3 construct and un-
transfected cells. Values are plotted as relative quantities to the expression of GAPDH. 
5.2.4.2 RT2 ProfilerTM PCR arrays 
In this study RT2 ProfilerTM PCR arrays were used to provide insight into the 
action of PDE4D7 in PC by identifying novel interacting pathways/proteins. The 3 
arrays that were selected were; Prostate Cancer array, Cancer PathwayFinder 
array and Focal Adhesions array. Four conditions were carried out for each 
array; Cells only, pcDNA3 transfection control, PDE4D7VSV transfected and DN 
PDE4D7 VSV transfected cells.  
Cells PCDNA3 PDE4D7 VSV
Dom Neg
PDE4D7 VSV
PDE4D7
Normalisation
2.9727448 1.417499557 2265.931895 561.6212128
0
500
1000
1500
2000
2500
3000
3500
R
e
la
ti
ve
 Q
u
an
ti
ty
 o
f 
P
D
E4
D
7
 
to
 G
A
P
D
H
 H
K
G
 e
xp
re
ss
io
n
  
PDE4D7 expression normalised with GAPDH
Chapter 5: Exposing the role of PDE4D7 in Prostate Cancer Progression 
129 
 
 
Figure 5.3 Diagram explaining RT
2
 Profiler
TM
 PCR array technique 
 
Cells only control was used to assess fold changes in relative expression between 
samples e.g. all experimental samples were compared to cells only control and 
plotted as relative fold change. Figures 5.4, 5.5, 5.6, show genes that are 
expressed with a fold change above 2. 
The prostate cancer arrays contain Sybr-green primers for key genes that are 
often involved in the development of prostate cancer. These 84 genes include; 
genes involved in AR, AKT and PTEN signalling as well as genes associated with 
metastatic potential, cells cycle and apoptotic pathways. In addition, the array 
included genes that are known to change in methylation profile in PC and genes 
that have been detected routinely in PC samples to be dysregulated. All these 
genes are known to be important in prostate cancer initiation, progression, and 
metastasis. Thus in an attempt to unveil the mechanism by which PDE4D7 exerts 
it control over cAMP mediated pathways in prostate cancer, this study focused 
on the changes in expression of a panel of genes following PDE4D7 
overexpression or displacement via the dominant negative approach.  Figure 5.4 
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displays the fold regulation of these genes in each test condition with relative 
expression to untreated cells alone.  
  
Figure 5.4 Fold regulation of RT
2
 Profiler
TM
 prostate cancer PCR array  
RT
2
 Profiler
TM
 prostate cancer PCR array was conducted under 4 conditions; Cells only, 
pcDNA3 transfection control, PDE4D7VSV transfected and DN PDE4D7 VSV transfected 
cells. Data is expressed relative to VCaP cells only control and is displayed as relative fold 
change greater than 2. 
The Cancer PathwayFinder arrays contain Sybr-green primers for key genes that 
are often involved in transformation and tumourgenesis. 84 genes represent 9 
different biological pathways that regulate specific aspects of cell growth. 
During oncogenesis, dysregulation of these key pathways can occur due to an 
increase in gene mutation and expression changes. A myriad of different genes 
can potentially be affected during tumourgenesis and the profile can sometimes 
be indicative of a specific cancer type. As the mechanisms behind PC are not 
fully understood, I wanted to investigate the possible interaction of all common 
genes involved in oncogenesis with PDE4D7. The 84 genes encompassed within 
this array represent these 9 pathways that are often affected in oncogenesis; 
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apoptosis, cell cycle, DNA damage/repair, cellular senescence, telomere 
maintenance, angiogenesis, epithelial-to-mesenchymal transition, hypoxia and 
metabolism. PDE4D7 interaction with any of these pathways could be the key to 
understanding how PDE4D7 exerts its effects in PC. Figure 5.5 displays the fold 
regulation, with relative expression to cells only, of these 84 genes. 
 
Figure 5.5 Fold regulation of RT
2
 Profiler
TM
 cancer pathway finder PCR array  
RT
2
 Profiler
TM
 cancer pathway finder PCR array was conducted under 4 conditions; Cells 
only, pcDNA3 transfection control, PDE4D7VSV transfected and DN PDE4D7 VSV 
transfected cells. Data is expressed relative to VCaP cells only control and is displayed as 
relative fold change greater than 2. 
The focal adhesions arrays contain Sybr-green primers for key genes that are 
often involved in cellular adhesion to the extracellular matrix (ECM). Focal 
adhesions form around the intracellular domains of integrins that are bound to 
components of the ECM, such as those found in the basal lamina underlying 
epithelial cells. Focal adhesions connect the intracellular domains of integrins to 
actin filaments. These structures regulate several key biological processes 
including angiogenesis, anchorage-dependent cell survival, cell cycle, cell 
migration, and wound healing. Dysregulation of focal adhesion function and 
integrity plays a key role in the pathophysiology of diseases such as fibrosis and 
epithelial-to-mesenchymal transition during tumour metastasis. Within Prostate 
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Cancer, many focal adhesion proteins have been linked to advancing disease. For 
example the overexpression of focal adhesion kinase (FAK), which mediates 
cellular processes like growth, proliferation, adhesion, migration and survival, 
has been implicated in tumour development and maintenance. FAK 
overexpression in androgen insensitive cells increased the survival and 
proliferation of cells, whereas knockdown diminished this effect [250, 251]. 
Furthermore, FAK has been documented to form a complex with RACK1 and 
PDE4D5 to contribute to cell polarisation and directional migration [252]. In the 
study by Serrels et al, disruption of the FAK/RACK/PDE4 complex, by knockdown 
of either RACK1 or FAK or increase of cAMP, resulted in reduced polarisation and 
migration. In addition, FAK and the cAMP signalling pathway have been shown to 
interact in breast cancer studies [253]. This suggests that interactions between 
the cAMP pathway and focal adhesion signalling proteins could represent a 
pivotal point of crosstalk in prostate cancer. Although this is just one example of 
the importance of focal adhesion (FA) proteins in prostate cancer progression, it 
shows how FA molecules can be linked to different signalling pathways and 
cAMP, and how these can be exploited in cancer progression. Therefore, I can 
hypothesize that such proteins may be involved in a signalling axis that impinges 
on the proliferative effects of cAMP in PC and influences PDE4D7’s control over 
these effects. Figure 5.6 displays the fold regulation of these genes. pcDNA3 
control is not displayed for this array series as the genomic DNA negative control 
amplified and was therefore discarded as it was deemed to be contaminated. 
The remaining 3 plates showed no amplification within the negative control 
wells.  
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Figure 5.6 Fold regulation of RT
2
 Profiler
TM
 focal adhesion PCR array  
RT
2
 Profiler
TM
 focal adhesion PCR array was conducted under 4 conditions; Cells only, 
pcDNA3 transfection control, PDE4D7VSV transfected and DN PDE4D7 VSV transfected 
cells. Data is expressed relative to VCaP cells only control and is displayed as relative fold 
change greater than 2. 
The data above suggests that I have managed to isolate some potentially 
interesting genes/signalling pathways that are affected by increased expression 
of PDE4D7 and displacement of endogenous PDE4D7 using dominant negatives.  
Worryingly, some genes showed similar trends towards increased expression 
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PDE4D7. One would expect opposite effects resulting from ectopic expression of 
these two constructs. This could be a transfection effect, where high amounts of 
PDE4 overexpression (both WT and DN) could be affecting the stichiometry of 
protein complexes that are not regulated or affected by PDE4 activity. 
Alternatively, as the DN molecule and the catalytically active PDE4D7 share the 
same unique N-terminal region, I could hypothesize that effects seen are due to 
binding or scaffolding effects. However, one must be mindful that this is a high 
throughput screen with a low number of biological and technical replicates and 
will favour false positives. With this in mind, genes with high fold change when 
transfected with the catalytically active construct were cross referenced with 
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the literature and 6 genes where chosen for further analysis based on their links 
to (prostate) cancer progression, metastasis or survival and possible links to the 
cAMP signalling pathway. 
5.2.4.3 CAV 
The caveolin family is made up of caveolin 1, 2 and 3. They are predominantly 
found at the plasma membrane as part of caveolae structures (invaginations in 
the plasma membrane), however they are also expressed in the golgi, 
endoplasmic reticulum, vesicles and cytosolic locations. Caveolins are 
ubiquitously expressed but levels vary depending on tissue type. Caveolin 2 is co-
expressed with caveolin 1 and requires it for membrane targeting. These are 
found mainly in differentiated cell types, such as endothelia and smooth muscle 
cells, whereas caveolin 3 is mainly expressed in muscle cells, such as skeletal 
and cardiac myocytes [254, 255]. Caveolin 1 has been linked to tumour 
suppression in early stage cancers. However, it has also been implicated in the 
regulation of endothelial cell proliferation and angiogenesis, and evidence 
suggests that caveolin 1 is upregulated in many drug-resistant and metastatic 
cell lines and tumours, positively correlating with tumour stage and grade [256]. 
Both Caveolin 1 and 2 have shown links to prostate cancer progression. 
Expression of caveolin 1 has been associated, in prostate cancer, with high 
Gleason score, metastases and disease recurrence [255, 257, 258]. Caveolin 1 
exhibited a proportional increase from primary tumour to lymph metastasis [257] 
and overexpression has been predictive of progression and poor clinical outcome 
[255]. Unlike caveolin 1, caveolin 2’s role is less clear. Nevertheless, it has been 
shown to be essential for the assembly of caveolae and acts as a positive 
regulator of caveolin 1 in human prostate cancer cell lines. In addition, a study 
by Sowa et al demonstrated that Cav 2 was shown to be expressed at very low 
levels in LNCaP cells, but the expression levels were distinctly elevated in 
androgen-independent PC3 cells, as compared to normal prostate epithelial 
cells. Overall, this data suggest that changes in the plasma membrane involving 
caveolin could be imperative to prostate cancer progression [259, 260]. In 
addition, caveolin 1 has also been linked to G-coupled receptors and 
serine/threonine kinases which interact with caveolin through the cav-1 
scaffolding domain. Interaction with this domain then mediates the generation 
of platforms for compartmententalisation of downstream signalling events [261]. 
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Furthermore, caveolin has been shown to decrease endogenous cAMP 
concentrations, and treatment of cells with FSK or IBMX leads to an dose-
dependent decrease in caveolin mRNA levels [262].  
5.2.4.4 CASP3 
Caspase 3 is a protease that is activated during programmed cell death. Caspases 
are members of the cysteine protease family and 14 different caspases have 
been identified in humans. Caspase 3 is initially expressed as a pro-inactive 
enzyme, which is activated via selective cleavage of the amino bond following a 
certain aspartate residues to form an active heterotetrameric enzyme [263, 
264]. Caspase 3 is responsible for the execution of apoptosis (along with caspase 
6 & 7) by cleavage of the downstream end of the DNA repair enzyme poly(ADP-
ribose) polymerase, which is essential for the initiation of apoptosis [264]. 
Activation of caspase 3 in prostate cancer cells leads to the execution of 
apoptosis in the cells and blockage of caspase activity within LNCaP cells leads 
to the reduced effectiveness of androgen-ablation inducted apoptosis [265]. 
Thus it is not a surprise that immunoreactivity of caspase 3 is significantly 
decreased in prostate cancer [264]. Loss of expression of this key caspase could 
protect the prostate cancer cells against programmed apoptosis. cAMP activation 
has also been linked to caspase activity. In vascular cells it was shown that 
activation of adenylate cyclase via FSK treatment resulted in a decrease in 
caspase 3 activation [266]. Furthermore, cAMP elevation also protected against 
apoptosis and promoted growth in colorectal cancer. Here the elevation of cAMP 
levels decreased the activity, but not the production of caspase 3 [267].  
5.2.4.5 BCL2 
The main function of BCL-2 or B-cell lymphoma-2 is to decrease apoptosis in 
cells. BCL-2 acts to inhibit pro-apoptotic family members, which induce 
permeabilisation of the outer mitochondrial membrane and cause the 
subsequent release of apoptogenic molecules and caspase activation [268]. BCL 
2 has been found to be involved in a wide range of cancers including prostate 
cancer. BLC-2 has been extensively linked to prostate cancer progression, with 
studies showing that BCL-2 is considerably increased in androgen independent vs 
androgen dependent cancers. In addition, an increased level of BCL-2 is linked to 
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metastasis and poor response to radiotherapy [269]. BCL-2 and the cAMP 
pathways are known to have points of crosstalk in prostate cancer signalling 
mechanisms. For example, a decrease in PKA RIα subunit results in an increase in 
pro-apoptotic BCL family members and that this reduction in PKA subunit also 
inhibited tumour growth in nude mice. As BCL-2 acts to inhibit these pro-
apoptotic BCL members, it could be suggested that a link could exists between 
the cAMP pathway and BCL-2 [188]. 
 ETV1 5.2.4.5.1
ETV1 is a member of the ETS transcription factor family. There are 28 ETS genes 
that have been isolated in humans and these are separated into 12 groups. One 
of the defining characteristic of the encoded proteins is the ETS domain, which 
binds to DNA sequences with a 5’-GGA(A/T)-3’ core. ETS proteins assemble 
distinct sets of coactivators or corepressors, and so the ETS protein bound to the 
DNA will influence and modulate gene transcription in different ways. In 
prostate cancer, the majority of tumours display a chromosomal translocation 
involving ETS (frequently the ERG gene, but here we will discuss the less 
frequent but still established, ETV1 gene) and TMPRSS2 gene (a trans-membrane 
protease serine enzyme). This translocation results in the generation of a 
TMPRSS2-ETS fusion gene. In this case, the ETV1 protein is controlled by the 
TMPRSS2 gene promoter/enhancer, which is under androgenic control and is 
highly expressed in prostate tissue. As a result of this control point, ETV1 
undergoes androgen dependent expression in prostate cells and subsequent ETV1 
overexpression in prostate cancer. All fusion proteins created in this way, retain 
the ETV1 DNA binding domain and thus cause dysregulation of gene 
transcription. Furthermore, cells with this translocation that are subjected to 
ETV1 down-regulation, display impaired cell proliferation, invasion and tumour 
formation in nude mice. The counter is also true, that overexpression of ETV1 in 
immortalized, non-transformed prostate epithelial cells can lead to enhanced 
proliferation and invasion [270]. 
It is also noteworthy that PKA has been shown to phosphorylate ETV1 on several 
sites, including serine 334, during in vivo studies. Phosphorylation on this site 
severely reduces the DNA-binding ability of ETV1 [271, 272]. 
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5.2.4.6 IL6 
IL-6 is a pleiotropic cytokine that regulates a wide range of biological actions 
within immune regulation, inflammation and oncogenesis. IL-6 ‘s primary 
function is in acute state response and inflammation, and is secreted by 
monocytes. It has also been shown to interact with activated B-cells to induce 
terminal differentiation into anti-body secreting cells [273]. However, it does 
have other functions and can also be secreted by osteoblasts and skeletal muscle 
cells [274]. In prostate cancer, IL-6 levels are elevated in cancer tissues and PIN, 
and increased in circulating levels have been shown in metastatic prostate 
cancers. In the prostate cancer cell line, LNCaP, IL-6 has been suggested to have 
both growth promoting and inhibiting activities. Studies have indicated that IL-6 
can mediate growth arrest in cells, as well as acquisition of NE characteristics, 
however these studies are contradicted by reports that IL-6 can increase 
androgen-induced growth rates by either autocrine or paracrine mechanisms 
[275, 276]. In vivo, cytokine signalling occurs in the context of other interacting 
pathways. One study showed that the co-treatment of LNCaP cells with agents 
that increase the activity of PKA and IL-6 expression caused a promotion of the 
NE phenotype above that seen with single agents. The author suggested that this 
indicates that PKA and IL-6 signals cooperate to produce gene transcriptional 
alterations that result in the acquisition of NE changes in LNCaP cells [275].  
5.2.4.7 Validation of candidates using RT-qPCR 
The genes described above were pulled from a high throughput screen and hence 
I wanted to validate them by using individual Sybr-green primers (SA Bioscience 
®) and VCaP cells transfected as before with three constructs, pcDNA3 
transfection control, PDE4D7VSV and DN PDE4D7 VSV. The pcDNA3 transfection 
control was used to assess fold changes in relative expression between samples. 
RNA purity, integrity and RIN were assessed via Agilent 2100 bioanalyzer and 
NanoDrop ® prior to use. cDNA expression of PDE4D7 was confirmed via RT- qPCR 
and PDE4D7 Taq-Man ® primer/probe set prior to use. This was repeated for 
each biological replicate. 
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Figure 5.7 Validation of the genes isolated for potential interaction with PDE4D7 
VCaP cells were transfected with pcDNA3, PDE4D7VSV and DN PDE4D7 VSV constructs. 
RT-qPCR was carried out with Sybr ® green primers towards the indicated genes. Results 
are expressed as relative expression to GAPDH and pcDNA3 
Candidate genes that had previously been selected from the of RT2 ProfilerTM 
screen were reprobed using RT-qPCR  in order to confirm differential regulation 
following overexpression of WT and DN PDE4D7 constructs.. Unfortunately, none 
of the genes pinpointed during the high-through-put study, showed significant 
differences between over-expressed PDE4D7 and controls during the secondary 
assay. A trend towards ETV-1 down regulation is seen, however, due to 
variability of the experimental data, this change was not deemed significant. To 
control for potential housekeeping gene variability, 3 housekeeping genes were 
used in this validation study (see appendix).  
Due to a highly disappointing failure of any of my candidates to repeat in the 
secondary assay, none of the “hits” were taken forward for further analysis. In a 
way to try and explain the failure to repeat results in the validation assay shown 
in the initial screening, one has to consider that while high through-put 
screening assays are a useful tool, they do concede a low number of biological 
and technical replicates and will favour false positives. Therefore, although care 
was taken by cross referencing results with the literature to reduce the risk of 
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selecting a falsely positive result, it is plausible that the proteins selected could 
not be effected by PDE4D7 overexpression or the effect could be less than in the 
initial screening and so is lost in the experimental noise. In addition, as 
previously suggested in the initial high through-put screen, the transfection of 
DN and active PDE4D7 constructs exhibited similar changes in protein expression 
insinuating that these effects were caused by binding or scaffolding effects. I 
could theorise that this scaffolding effects could be shown due to an over 
saturation with the transfected constructs. Therefore with multi-biological 
replicates and slightly changing transfection efficiency, this scaffolding “noise” 
maybe reduced. 
5.2.5  Luciferase reporter arrays 
In an attempt to circumvent problems associated with the lack of reliable data 
from the RT-qPCR experiment, we decided to use a different but complementary 
technique, Luciferase reporter assays. Luciferase reporter arrays were purchased 
from SA Biosciences ® and were employed as a method to reveal pathways 
influenced by PDE4D7 activity in prostate signalling. The array relays on dual 
luciferase reporter technology to provide a pathway-focused, transcription 
factor responsive readout of transcription factor binding. 
Chapter 5: Exposing the role of PDE4D7 in Prostate Cancer Progression 
140 
 
   
Figure 5.8 Diagram demonstrating the layout and procedure for the use of luciferase 
reporter arrays (SA Biosciences®). 
 
As transcription factors play a central role in cellular processes and regulate 
gene expression, they can be used to provide readouts for the activation status 
of certain signalling pathways. The luciferase reporter arrays used in this study 
exploits this by combining a luciferase gene with a specific transcription factor 
binding site and basic promoter elements. Thus, when a signalling pathway is 
influenced, changing the activity of the downstream transcription factor, the 
level of expression of the luciferase gene is altered. Therefore, changes in 
luminescence intensity directly correlate with events that modulate 
transcription activity. The array contains 45 different firefly luciferase reporters 
each specific to a particular transcription factor. In addition, the array 
comprises a negative control, which is a non-inducible firefly luciferase, a 
positive control, which is a mixture of constitutively expressing GFP and a 
constitutively active firefly luciferase. Each well of the array also contains a 
constitutively expressing Renilla luciferase as an internal control. This acts to 
normalise for unwanted variability between wells by as Renilla utilise different 
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substrates when catalysing a luminescent reaction, and as a result does not 
interfere with the test, firefly luciferase luminescence (Figure 5.8).  
As with the RT-qPCR experiments, the arrays were carried out using VCaP cells 
under four transfection conditions; transfection reagent only, pcDNA3, PDE4D7 
VSV and DN PDE4D7 VSV. Unfortunately, no significant changes were show 
between the transfection control and test treatments across all of the 45 
reporters (Figure 5.9).  
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Figure 5.9 Luciferase reporter array results 
Each graph contains 9 different transcription factor reporters. VCaP cells were transfected 
with pcDNA3, PDE4D7VSV or DN PDE4D7 VSV constructs plus Luciferase and Renilla 
reporter constructs. Luciferase luminescence was normalised using Renilla luminescence.  
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Figure 5.10 Positive and negative controls for the Luciferase reporter arrays. 
 
The negative and positive controls of each array worked, indicating that changes 
in the test wells were not due to problems with the luciferase constructs, 
transfection of the constructs or the transfection reagent (Figure 5.10). By way 
of explanation as to why we failed to observe any significant changes, it is worth 
remembering that PDE4D7 is just one PDE in an array of compartmentalised 
micro-environments within the cell established by many different PDE isoforms 
(25 PDE4 isoforms in one family). Therefore, it is conservable that PDE4D7 
upregulation alone could have small effects on downstream transcription factors 
and thus these changes could be swallowed by the ‘noise’ of the system. In 
addition to this, the VCaP cells used in this experiment already convey 
overexpression of PDE4D7 endogenously. Any concurrent downstream signalling 
effects on transcription factors could therefore be saturated within the cells 
only and pcDNA transfection controls, thus any potential additional effects of 
PDE4D7 transfection would be small and undetectable by this technology. 
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However, both of these theories are conjecture and we have to consider that 
PDE4D7 expression may not affect the transcription factors within this array.  
5.2.6  RPPA 
As I have been unable to implicate any signalling pathway using the above 
molecular techniques, I decided to move to a novel proteomics technique that 
allows analysis of a “snapshot” of signalling changes caused by an alteration in 
the chemical environment or genetic make-up of cells. RPPA (Reverse Phase 
Protein Array) is a high-throughput proteomics technology that allows the 
analysis of protein expression levels of a large number of biological samples. The 
coverage of proteins can include native or modified species (e.g. 
Phosphorylated) and depends on the selection of primary antibodies used in the 
first detection step.  
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Figure 5.11 Diagram outlining the Reverse Phase Protein Array procedure  
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Cellular lysates were deposited as individual spots in an automated manner onto 
microarray slides. Proteins of interest were then detected using a large range of 
specific antibodies. Only small amounts of biological material are deposited per 
spot, and many samples can be analysed simultaneously on the same slide. 
Detection was carried out using a secondary antibody labelled with fluorescence. 
As this technology uses antibody technology, it shares the majority of the 
benefits and draw backs as western blotting techniques. With the foremost issue 
been antibody problems such as, cross-reactivity, sensitivity and specificity. To 
try to circumvent such issues, this screening was carried out by Dr Bryan Serrels 
(University of Edinburgh) who has a fully validated database of antibodies 
routinely used for this technique. VCaP cells were transfected with pcDNA3 
transfection control, PDE4D7 VSV, dominant negative PDE4D7 VSV and 
cells/transfection reagent only.  
 
 
 
 
Figure 5.12 PDE4D7 transfected VCaP RPPA protein expression profile 
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VCaP cells transfected with pcDNA3 transfection control, PDE4D7 VSV, dominant negative 
PDE4D7 VSV and cells/transfection reagent only, spotted onto microarray slides and 
overlaid with different antibodies. Values are net intensity of fluorescence relative to cells 
only. (Screen carried out by Dr Bryan Serrels- University of Edinburgh) 
Analysis for the RPPA experiment was conducted by Dr Bryan Serrels. Figure 5.12 
shows proteins identified by the analysis software as potentially noteworthy (For 
full screen see appendix). Unfortunately none of the proteins show 2 fold or over 
increase or decrease in protein expression levels compared to both controls. DN 
PDE4D7 control is constitutively inactive construct (as previously described) and 
so I would expect this construct to cause similar effects on protein expression as 
the cell only and transfection controls. However, in some cases (Figure 5.12) DN 
PDE4D7 transfection elicits a much larger change in protein expression compared 
to either control, I could hypothesize that this increase could be due to 
scaffolding effects of the protein but as this effects is not shown with the active 
construct also this is unlikely.  
Caspase 3 and PI3 kinase suggest that PDE4D7 transfection may have a small 
effect on these proteins. Caspase 3 was previously explored using RT-PCR (Figure 
5.4), however changes in this protein, due to PDE4D7 overexpression, couldn’t 
be validated (Figure 5.7). Validation of these proteins via western blot wasn’t 
undertaken due to time and money constraints.  
5.2.7 Celluspot arrays 
CelluspotsTM peptide array technology utilises arrays that are spotted with short 
peptide sequences. The individual peptides are covalently linked to cellulose 
and then spotted onto a membrane. This technology is able to form a 3D 
structure that is able to hold 1000 times more peptides than conventional 
peptide arrays, allowing low affinity protein-protein interactions to be detected. 
Here, pre-made arrays containing a variety of short, well documented kinase 
substrates, as well as consensus sequences for both, tyrosine and 
serine/threonine kinases were purchased from Intavis ®. The tyrosine kinase 
chip has 384 peptide substrates and the serine/threonine kinase substrates come 
as two chips with 768 peptides in total, each printed in duplicate.  
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Figure 5.13 Diagram outlining the Celluspot array procedure 
Lysates, transfected as previously discussed, were overlaid on the arrays with 
the appropriate kinase buffer and [γ-32P]ATP with the notion that a “snapshot” 
of kinase activation from the 4 cell treatment conditions (untreated, pcDNA3, 
PDE4D7 and DN PDE4D7) could be observed.  Phosphorylation was detected by 
autoradiography and analysed using image J software. As expected several 
peptides were phosphorylated in all test conditions (see Appendix). Therefore, 
phosphorylated peptides with a fold change above 2, between PDE4D7 and 
pcDNA3 transfection control, and low internal variability, were cross referenced 
with the autoradiograph images to identify the short list that is displayed in 
Figure 5.14 (For full screen see Appendix). This list also demonstrated similar 
phosphorylation levels for DN PDE4D7 overexpression as pcDNA3 transfection 
control, showing that all increased phosphorylation activity displayed with 
overexpression of PDE4D7 is due to the catalytic activity of the enzyme.  
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Figure 5.14 CelluSpot peptide array phosphorylation analyses with PDE4D7 transfected 
VCaP lysates 
CelluSpot peptide arrays overlaid with VCaP lysates transfected with; pcDNA3, PDE4D7 VSV 
or dominant negative PDE4D7 VSV. Lysates were mixed with the appropriate kinase buffer 
and [γ-32P]ATP. Detection was carried out via autoradiography. 
This short list of proteins potentially changed via PDE4D7 increase was then cross 
referenced with the literature. However, due to time constraints further analysis 
and validation was not carried out. 
5.2.7.1 APC 
Adenomatous polyposis coli or APC protein is a multifunctional protein that can 
contribute to a number of basic cellular processes, including cytoskeletal and 
transcriptional regulation. It is involved in Wnt-regulated degradation of β-
catenin and can also regulate cytoskeletal proteins, consequently effecting cell 
migration, cell adhesion, and mitosis. The best-characterized function of APC is 
as a scaffolding protein. It forms a multiprotein complex with a variety of 
proteins including GSK3β, β-catenin, axin, and numerous kinases and 
phosphatises. This signalling hub is essential for Wnt signalling. In the absence of 
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Wnt signals, GSK3β in the complex is able to phosphorylate all three other 
complex proteins, leading to an increase in their interaction and sequent 
destruction of β-catenin by the proteasome. In the presence of a Wnt signalling 
molecule, Dishevelled (Dsh),GSK3β activity ceases and thus, the kinase activity 
in the complex drops, leading to a build-up of β-catenin in the cell. In general, 
accumulation of β-catenin correlates with deregulation of target gene 
transcription and potential changes in the proliferation and differentiation state 
of cells [277, 278]. Truncations in the APC gene are found in >80% of sporadic 
colonic tumours and are also accountable for Familial Adenomatous Polyposis 
(FAP), an inherited form of colon cancer. APC has also been detected in other 
cancers such as breast cancer [277, 279]. In prostate cancer, changes in the 
Wnt/β-catenin signalling have been link to cancer progression. In mouse studies, 
deletion of APC leads to elevated levels of β-catenin. Tumours that are induced 
via this deletion are highly proliferative, fully penetrant and follow normal 
cancer progression patterns [280]. 
5.2.7.2 N-Myc 
N-Myc is a member of the Myc family. Myc family proteins function as 
transcription factors, and their broad transcriptional and biological activities 
regulate cell growth and proliferation, as well as activities such as stimulating 
angiogenesis and vasculogenesis, and blocking differentiation. Thus, this family 
of proteins is exploited and over-regulated in a range of cancers [281]. In human 
prostate cancer, an increased Myc gene copy number is often observed. MYC has 
also been shown to increase relevant to Gleason score, in protein and mRNA 
studies. The mechanism behind this increase in expression still remains elusive. 
However, some studies have shown that increased levels of MYC could be 
collected with its activation via increased levels of β-catenin [282]. 
5.2.7.3 Glutamate Receptor Subunit Zeta1 
Glutamate Receptor Subunit Zeta1 or NMDAR1/ GRIN1 is a ligand-gated ion 
channel that has a role in the control of synaptic plasticity and memory 
function. As a result, its effects have been widely studied in neuronal diseases, 
such as Alzheimer’s disease and neuroblastoma’s [283, 284].  Blockage of this 
channel has been reported to have many effects on calcium influx, kinase and 
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phosphatase regulation, translation and transcription, suggesting that NMDA 
receptor is coupled with many signalling pathways [285]. NMDAR1 like most 
cellular proteins can also phosphorylated, and this action has been shown to 
regulate discrete cellular processes. NMDAR1 can be phosphorylated by both PKC 
and PKA. It is phosphorylated by PKC on two residues (S890 and S896) and PKA 
on one (S897). Phosphorylation of S890 disrupts the clustering of the NR1 
subunit, whereas S896 phosphorylation alone has no effect on GRINR1 clustering. 
However, when phosphorylated together with PKA phosphorylation of S897, 
receptor surface expression is increased [286]. In our study, peptides containing 
S890, S896 were available for phosphorylation on the chip. 
In addition to neuronal malignancies, the channel subunit has been shown to be 
expressed in high-grade breast tumours, that, when treated with NMDAR1 
antagonists, showed significant decrease in tumour growth [287]. In terms of 
prostate cancer, very little is known, however an immunohistochemical study by 
Abdul et al [284] showed a higher percentage staining in prostate cancer 
samples. They also showed that upon treatment of prostate cells with NMDAR 
antagonist it reduced growth of all cancer cell lines tested.  
5.2.7.4 Ret 
RET is a proto-oncogene that encodes a receptor tyrosine kinase which is most 
expressed in neural, kidney and urogenital cells. Is it required for the maturation 
of many cells in the nervous system and spermatogenesis. RET acts as a 
signalling receptor of a complex that binds the growth factors of the glial cell 
line-derived neurotrophic factor (GDNF) family and GFRαs ligand-binding co-
receptors.  
RET can activate several intracellular signalling cascades, which regulate cell 
survival, differentiation, proliferation, migration, chemotaxis, branching 
morphogenesis, neurite outgrowth and synaptic plasticity [288] and thus can 
often be exploited in cancers. The catalytic and signalling activities of RET, are 
regulated by the autophosphorylation of tyrosine residues in the cytoplasmic 
region. Some studies have revealed possible autophosphorylation sites within 
this region [289]. In our celluSPOT experiment, Y806 and Y809 were available for 
phosphorylation. Mass spectrometry studies show that both the kinase activity 
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and transforming activity of RET was impaired in Y806F and Y809F mutants .In 
prostate cancer, RET is suggested to be overexpressed in both high-grade PIN 
and in carcinoma [290].  
5.2.7.5 CD136 
CD136 or MST1R/RON is a proto-oncogene tyrosine kinase receptor, that binds 
macrophage-stimulating protein (MSP). On binding of this protein, 
autophosphorylation occurs on the intracellular section of the receptor, 
Y1238/1239 which regulates the catalytic activity of the enzyme and 
Y1353/Y1360 which provides a docking site for downstream signalling molecules 
[291]. These phosphorylations allow CD136 to affect many physiological 
processes including cell survival, migration and differentiation. These functions 
can be exploited in cancer, and CD136 has been shown to respond to other 
growth factors to promote cell survival. CD136 expression has been found in 
many epithelial human tumours including colon, and exhibits increased 
expression in a significant number of human breast cancer tissues and 
established breast cancer cell lines. Further studies have shown that this 
overexpression correlates with poor prognosis and aggressive disease [292, 293]. 
Furthermore, in prostate cancer, CD136 has been shown to be highly expressed 
in cancer tissue, compared to normal prostate tissue, and is also highly 
expressed in androgen-insensitive cell lines. In vivo, mice lacking functional 
CD136 presented decreased prostate tumour size and prostate vasculature [294, 
295]. In this study, transfection of PDE4D7 increased the phosphorylation of 
Y1238/Y1239 phosphorylation site compared to pcDNA3 and DN controls, 
suggesting effects on CD136-tyrosine kinase catalytic activity. 
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5.3 Discussion 
This study was undertaken to find interacting pathways/proteins for PDE4D7 in 
order to gain a better understanding of the molecular function of PDE4D7 in 
developing prostate cancer. As previously mentioned, a large amount of 
evidence exists surrounding cAMP signalling and its effects on prostate cancer 
progression. In comparison, there is a paucity of information for putative roles 
for PDEs. Studies by Uckert et al, reported on RT-PCR analysis of PDE expression 
in various anatomical regions of the prostate gland and found PDE 1A, 1B, 2A, 
4A, 4B, 4C, 4D, 5A, 7A, 8A, 9A and 10A in each different histological region. In 
addition PDE4 and PDE5 hydrolytic activities were shown in the cytosolic fraction 
of the tissue, suggesting conversion of mRNA to active enzymes. Furthermore, 
immunostaining implied that the occurrence of these isoenzymes was not evenly 
distributed [239, 240]. These studies however, were of histological regions and 
lacked the precision of expression in differing cell types.  
To further the knowledge regarding PDE expression within prostate cancer and 
its changes within cancer progression, a study was conducted by former 
laboratory member [179]. This study described PDE expression in 19 different 
cell lines and xenographs and isolated PDE4D isoforms, specifically PDE4D7, to 
be significantly downregulated between AS and AI prostate cancer samples. In 
correlation with this finding, using FRET sensors, they also observed a decrease 
in the ability to hydrolyse cAMP in AI cell lines suggesting that this change in 
mRNA expression translates into comparable changes in protein levels. In 
addition they localised PDE4D7 expression to the plasma membrane in AS cell 
line, suggesting that PDE4D7 is important in controlling compartmentalisation of 
cAMP signalling at the sub-plasma membrane. 
However, this study failed to address why these changes in PDE4D7 regulation 
occur during prostate cancer progression and how these changes affect down-
stream signalling to execute cellular changes. We endeavoured to address this 
absence in knowledge by using several different high-through-put screens to try 
to expose interacting partners or downstream signalling effects of PDE4D7 over 
expression. 
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The RT2 ProfilerTM PCR arrays studies identified some interesting genes that are 
key in prostate cancer progression. Furthermore, these genes have been linked 
to cAMP signalling molecules in prostate, prostate cancer or cancer signalling.  
Unfortunately these changes in gene regulation could not be validated. ETV1 
shows possible trend towards downregulation when PDE4D7 is overexpressed, 
however as these genes are not highly expressed and thus, due to the low levels 
of transcript abundance they are more susceptible to fluctuations in expression, 
this causes an increase in variability within the experiment. In addition, 
unpublished work from the Baillie laboratory [179] showed that VCaPs shows the 
highest abundance of PDE4D7 isoform compared to other AS cell lines used in 
this study. As PDE4D7 is already highly expressed in this cell line, it has to be 
considered that this low level of transcript abundance could be a result of 
PDE4D7 endogenously causing dysregulation of these pathways and thus further 
overexpression is unable to cause much further downregulation of these genes. 
EVT1, as discussed, has been shown to be involved in chromosomal translocation 
with the TMPRSS2 gene which is highly expressed in prostate cancer. 
Downregulation of the ETV-1 gene can impair proliferation, invasion and tumour 
formation [270]. The TMPRSS2:ETS fusion proteins, however, are under 
androgenic control due to the TMPRSS2 gene promoter and subsequently is 
overexpressed in androgen sensitive cancerous tissues. As the AR has a pivotal 
role in prostate cancer, but few AR gene mutations have been shown, it could be 
hypothesised that other gene mutations could contribute to progression. 
The VCaP cell line, used in this study, is often used as a model for TMPRSS2:ERG 
gene fusion. Cases with ETS fusions are often grouped together for simplicity, 
however, although there is functional overlap among ETS family members, 
individual ETS genes have distinct roles and can vary through development and 
oncogensis. A recent study shows a difference in regulation between ETV1 fusion 
genes and ERG and their effects in cancer signalling. It was shown that ERG 
causes negative regulation of androgen receptor transcription, while ETV1 aids 
AR signalling by favouring the activation of AR transcription. Furthermore, they 
suggested that ETV1 expression, promotes autonomous testosterone production 
that is not shown with ERG [296]. ETV-1 transcriptional activity is increased 
following phosphorylation by PKA on the edge of the DNA-binding domain [270, 
297]. The DNA-binding domain is highly-conserved between family members and 
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thus, it can be extrapolated that PKA has the same effect on ERG activity. As 
PDE4D7 would decrease PKA activity, it could be suggested that PDE4D7 
overexpression could play a role in decreasing the transcriptional activity of ETS 
fusions. Given more time, I would have explored this novel signalling axis.   
ETV1 downregulation via PDE4D7 signalling could be the key to explain how 
PDE4D7 exhibits its protective effects over regulation and how dysregulation of 
this pathway could lead to aggressiveness in AI disease. However, we have to 
take into account that no PDE4D7 siRNA knockdown model or AI cell line has 
been used to compare changes in gene regulation to an environment with low 
PDE4D7 expression.  In addition, many other signalling events, such as 
phosphorylation, can affect protein function and thus trends in gene regulation 
by qPCR can’t be fully relayed upon. All in all, further work into ETV1 and cAMP 
signalling maybe warranted but no clear conclusions can be drawn from this 
study. 
As PDEs affect global cAMP levels and shape cAMP gradients in response to 
extracellular simulii, they also indirectly affect the function of many signalling 
kinases. In this light, Celluspot array studies were employed to examine the 
phosphorylation status of signalling molecules in relation to PDE4D7 over 
expression. PDE4D7 is a long cAMP specific PDE and so acts to degrade cAMP. 
This method has identified proteins which have a distinctive increase in 
phosphorylation status with an increase in PDE4D7 suggesting a downstream, and 
not direct effect, of cAMP signalling. However these results are yet to be 
verified and much more work has to be conducted to ascertain how PDE4D7 
over-expression contributes to this increase in phosphorylation and their effects 
in prostate cancer. 
Despite high-through-put screen being a powerful tool for systematic 
identification of transcription changes or protein-protein interactions, they do 
have limitations. They are costly and thus often can only be carried out once. 
Also, due to the systematic nature of the screening methods used, no set of 
screening substituents can be complete, hence there will always be a set of 
untested substrates/binding partners/signalling systems. While high-through-put 
screens are useful in screening large amounts of interacting pathways with low 
starting materials, the drawbacks discussed and lack of time hindered my 
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evaluation. Given more time, a thorough validation of all of the proposed “hits” 
would have been done as this may provide novel insight into the functional role 
of PDE4D7 in prostate cancer signalling.
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6 Discussion 
6.1 Aims 
cAMP signalling dynamics have often been implicated in prostate cancer 
signalling. In particular, the effects of increased cAMP on prostate cancer 
phenotype have attracted attention for over 40 years. This project looks at two 
major cAMP signalling molecules in the context of prostate cancer development 
and as such, the project was divided into two parts: 1) the profiling of PKA 
isoform expression in prostate progression and subsequent characterisation of 
the direct effects on AR; 2) the isolation of interacting pathways with PDE4D7 in 
advancing prostate cancer, to establish how changes in PDE4D7 regulation can 
effect prostate cancer signalling. 
6.2 cAMP Signalling Molecules and Prostate Cancer 
Cancers are no longer regarded as isolated masses but rather that their 
properties relay on the complex interactions of the surrounding micro-
environments. In prostate cancer, this involves complex interaction between the 
stromal and epithelial cellular compartments resulting in the drive of tumour 
progression  [298]. This ever changing complex environment of stimulatory and 
inhibitory factors, changes in secondary messenger molecules are paramount for 
cells to interpret this environment. PKA is the ‘classical’ effector molecule of 
cAMP and PDEs are the only known means which to degrade cAMP signal, thus 
these two signalling molecules together can underpin the majority of cAMP 
signalling and compartmentalisation in cells [9, 32]. 
6.2.1 PKA Sub-Unit Regulation Change 
6.2.1.1 Regulatory subunits  
In the first part of this study I have shown the expression pattern of PKA 
regulatory and catalytic isoforms within androgen sensitive and insensitive cells. 
Here, I showed that PKA RIIβ and RIα subunits are expressed inversely in prostate 
cancer cells and their ratio switch in AI cells vs AS cell lines. This is in keeping 
with other cancer studies [50, 160, 163, 169]. In addition, I have shown that RIIβ 
Chapter 6: General Discussion 
158 
 
expression diminishes in cells no longer under androgenic control, leading to the 
hypothesis that RIIβ may have a direct effect on AR signalling. Upon testing 
weather RIIβ exerts control on the AR via direct binding, I showed that this was 
improbable and another indirect mechanism was likely. Although I mainly 
focused on PKARIIβ isoform, I also examined the expression of all other PKA 
regulatory subunits. My study showed that, in addition to RIIβ, PKARIα and 
PKARIβ also significantly change in regulation as prostate cancer progresses. 
PKARIα has been shown extensively to be up-regulated as cancer progresses [163, 
171, 299]. This disruption in isoform balance is associated with tumorigenesis 
and tumour proliferation [160, 161, 163]. Furthermore, PKARIα has been isolated 
as a potential biomarker for prostate cancer progression and in recent years 
PKARIα antisense molecules in addition to androgen deprivation therapy, has 
shown an enhanced decrease in tumour volume and significant increase in 
tumour apoptosis [171, 299]. However, despite this significant research, the 
mechanism of how PKARIα isoform exerts its action has still not been fully 
investigated. As RIIβ and RIα ratio is obviously important in prostate cancer 
progression, if more time was allowed it may be prudent to further explore my 
hypothesis that RIIβ is effective in AR signalling, but in a less direct manner. This 
research may lead to an understanding of how the switch from RIIβ to RIα is 
important in prostate cancer progression and lead to the uncovering of the 
mechanism whereby RIα shows its effects in an AR free environment.   
6.2.1.2 Catalytic subunit 
Additionally, the first part of this study highlighted PKACβ as significantly down 
regulated in AI vs AS prostate cells. This initial data is concurrent with data 
expressed in a study by Kvissel et al, in which PKACβ2 is shown to be down 
regulated in AI tumour cells [169]. A proposed synergism between cAMP and 
steroid pathways or activation of AR via FSK treatment has been shown in studies 
[215, 229-231], thus I went onto show that PKACβ mRNA is downregulated upon 
androgen ablation and mRNA levels are again decreased in AI differentiated 
LNCaPs. This suggested that PKACβ protein regulation is directly linked to 
androgens and androgen receptor function. Using novel peptide array technology 
I was able to identify possible phosphorylation sites on the AR by PKACβ and 
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using phospho-antibodies produced to isolate the putative phosphorylation site 
as pS791. 
However, the kinetics of phosphorylation at S791 are slow following FSK/IBMX 
treatment. As PKA is rapidly dissociated from the R subunits upon cAMP binding 
and nuclear translocation of PKA catalytic unit can begin within 3–5 minutes, it is 
unclear why this is the case. This type of slow kinetics have also been shown in 
the progesterone receptor, and studies into androgen receptor phosphorylation 
have suggested that most phosphorylation sites show a delay in hormone 
dependant maximal phosphorylation [205, 235]. Furthermore, AR has been 
shown to destabilise upon phosphorylation of S791 by AKT and restored following 
treatment with the proteasome inhibitor MG132. These results suggest that 
phosphorylation of AR at S791 plays a role in the ubiquitination of AR and 
modulates its degradation via the proteasome [232]. PKA and AKT have been 
shown to share the same phosphorylation site due to their structural similarities 
[233, 234]. Thus I could hypothesize that the phosphosite maybe monopolised by 
both kinases. However, significant amounts of further research are required to 
delineate the function of this PKA phosphorylation site during early prostate 
cancer. A longer study with FSK/IBMX treatment may prove to be enlightening.  
 
Due to the obviously important enzymatic activity of PKACβ in prostate cancer, 
one may also postulate it may be a target for therapeutic intervention during 
the progression of prostate cancer. Certainly if my hypothesis is correct, and 
phosphorylation of this site causes de-stabilization of the AR, small molecules 
tailored to this site could be used to decrease androgen receptor function in 
prostate cancer thus leading to a less invasive therapeutic approach compared 
to conventional methods and could be worth investigating. However, the data 
presented in other studies suggest that FSK treatment and activation of PKA 
leads to the progression of prostate cancer and activation of PKA may actually 
be of detriment to prostate cancer patients  [76].   
In conclusion further study is required to delineate the function of the PKA 
isoforms in PC. However, this is an exciting area of research which, with more 
work, may help us better understand the progression of prostate cancer from AS 
to AI. 
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6.3 PKA RIIβ and PKACβ as Biomarkers 
In the context of using PKACβ and RIIβ isoforms as biomarkers, the expression of 
protein and mRNA in the initial screening does exhibit a significant change in 
transcript levels between AS and AI prostate cancer phenotypes.  However there 
is an inherent problem when using intracellular proteins as biomarkers: How are 
they measured? Without a biopsy of the tissue it is difficult to specifically 
measure expression of these proteins. Therefore if a biopsy is needed then what 
significance are these proteins as an initial diagnostic tool? Biopsies of patients is 
common practice, however at this stage immunohistological studies can be 
conducted which are very accurate at determining stage and prognosis of the 
prostate tumour. It could be plausible to use these proteins alongside 
conventional staging methods to assess the androgen sensitivity of the samples 
and potentially defining populations of AI cells, prior to clonal selection by 
androgen withdrawal therapy. 
Furthermore, if one takes into account that PKACβ and PKARIIβ are both 
upregulated between normal prostatic epithelial cell line, PNT1, and androgen 
sensitive cells (Chapter 3), which is further correlated in tumour studies by 
kvissel et al [169], thus although I first proposed these proteins as biomarkers 
due to their decrease into androgen independence, they’re potential for use as a 
diagnostic tool may actually be in determining their increased expression during 
tumourigenesis and use as a marker for prostate cancer progression.  For 
instance, they may be used as markers for remission or the development of AI 
disease in patients treated with androgen ablation therapy. 
To solve the problem of how to detect PKACβ and RIIβ in order to use them as a 
clinical biomarker a new method that has shown initial promise with PDEs could 
be tested and potentially implicated for use with these proteins also. This 
method involves the use of urine sediments; phosphodiesterases are also 
intracellular enzymes that are not secreted into the extracellular environment. 
However, urinary sediments contain dislodged cells from the urinary tract and 
the prostate [300]. Initial data by Researchers at Philips Research Centre 
(Eindhoven) has shown that PDE4D7 mRNA can be detected from these dislodged 
cells [179]. This could be a potentially interesting technique that could be 
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utilised to detect PKACβ or RIIβ in urine, rendering these molecules promising 
biomarkers.  
6.4 PDE4D7 Compartmentalised Signalling Dynamics and 
Interactive Pathways 
Continuing on from work previously carried out in the laboratory, the second 
section of my thesis (chapter 5) investigates the interacting pathways/proteins 
for PDE4D7 in order to gain a better understanding of the molecular function of 
PDE4D7 in developing prostate cancer.  
Previous work described PDE expression in 19 different cell lines and xenographs 
and isolated PDE4D7, to be the highest downregulated between AS and AI 
prostate cancer samples. In addition, it was shown that PDE4D7 expression was 
localised to the plasma membrane in AS VCaP cell line, suggesting that PDE4D7 is 
important in controlling compartmentalisation of cAMP signalling at the sub-
plasma membrane. However, this study failed address why these changes in 
PDE4D7 regulation occur during prostate cancer progression and how these 
changes affect down-stream signalling to execute cellular changes.   
In order to address these questions, I used a varied range of high-through put 
screens which look at the messenger, protein or activity levels of various 
proteins when PDE4D7 is overexpressed in VCaP prostate cancer cell line. 
Unfortunately changes in gene regulation shown could not be further validated, 
or due to time constraint, weren’t validated. One may want to consider that as 
VCaPs cells have the highest abundance of PDE4D7 compared to other AS cell 
lines used in this study [301], that PDE4D7 is already highly expressed in this cell 
line and so low level of transcript abundance or protein expression could be a 
result of PDE4D7 endogenously causing dysregulation of these pathways and thus 
further overexpression is unable to cause much further downregulation of these 
genes. Therefore siRNA knockdown model may be useful in further validations of 
potential ‘hits’.  
Despite high-through-put screen being a powerful tool for identification of 
transcription changes or protein-protein interactions, they do have limitations. 
Due to the systematic nature of the screening methods, not all of the potential 
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interacting proteins can be screened. In addition, the quality and variability of 
the screen itself is also a major limitation. While every effort was taken to 
overcome these draw backs (i.e. picking relevant proteins and buying in the 
high-through put kits), the sample size is still relatively small compared to the 
size of libraries screened by pharmaceutical companies which often constitutes 
millions of potential partners. Given more time, a thorough validation of all of 
the proposed “hits” would have been carried out, including a knockdown model 
for PDE4D7. This may potentially provide novel insight into the functional role of 
PDE4D7 in prostate cancer signalling. 
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Figure 7.1 Quantification of VCaP cells transfected with PDE4D7 constructs 
 
 
CAV1 CAV2 CASP3 BCL2 ETV1 IL6
pcDNA3 100% 100% 100% 100% 100% 100%
PDE 4D7 101% 105% 104% 95% 46% 103%
Dom Neg PDE4D7 91% 130% 131% 118% 79% 66%
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Figure 7.2 Validation of the genes isolated for potential interaction with PDE4D7 (18s HKG) 
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CAV1 CAV2 CASP3 BCL2 ETV1 IL6
pcDNA3 100% 100% 100% 100% 100% 100%
PDE 4D7 90% 108% 106% 90% 51% 100%
Dom Neg PDE4D7 76% 113% 113% 115% 71% 62%
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Figure 7.3 Validation of the genes isolated for potential interaction with PDE4D7 (β-actin HKG) 
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Figure 7.4 PDE4D7 transfected VCaP RPPA protein expression profile (Full Screen Part 1) 
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Figure 7.5 PDE4D7 transfected VCaP RPPA protein expression images (Full Screen Part 1) 
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Figure 7.6 PDE4D7 transfected VCaP RPPA protein expression profile (Full Screen Part 2) 
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Figure 7.7 PDE4D7 transfected VCaP RPPA protein expression images (Full Screen Part 2) 
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Figure 7.8 PDE4D7 transfected VCaP RPPA protein expression profile (Full Screen Part 3) 
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Figure 7.9 PDE4D7 transfected VCaP RPPA protein expression images (Full Screen Part 3) 
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